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Abstract 
Timothy James Merkel 
Biologically Inspired PRINT Particles:  
Design, Fabrication, in vitro and in vivo Evaluations of Extremely Soft Particles 
(Under the direction of Joseph M. DeSimone) 
 
 This work utilized PRINT (particle replication in non-wetting templates) technology 
to fabricate extremely soft, biologically inspired particles.  Using soft biological systems like 
cancer cells and red blood cells as an inspiration, hydrogels were designed with cell-like 
deformability.  Preliminary studies, which utilized porogens added to otherwise highly 
crosslinked hydrogels, resulted in deformable, but rapidly cleared particles due to insufficient 
particle flexibility.   
 A loosely crosslinked hydrogel system was developed and evaluated in bulk samples 
to determine the elastic modulus, and to closely match it to that of RBCs. Microfluidic 
models of vascular constriction were designed and fabricated in order to test in vitro the 
ability of particles to deform.  RBC-sized particles (RBCMs) were fabricated from hydrogels 
having a range of modulus similar to that of RBCs.  An intravital imaging technique allowed 
for direct observation of particles in the peripheral vasculature.  Pharmacokinetic analysis of 
particle elimination showed an 8-fold decrease in particle modulus resulted in an over 30-
fold increase in the elimination phase half-life for these particles.  More deformable particles 
bypassed filtration in the lungs and elsewhere, resulting in extended circulation times.   
Novel hydrogel monomers were synthesized and used to fabricate low modulus particles with 
varying sizes to further probe the role of modulus on in vivo behavior.  These particles 
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avoided physical filtration in the circulation as a result of their ability to deform. These 
results demonstrated the critical nature of modulus as a design parameter for microparticles.   
As an application for such porous and long-circulating microgels, low modulus 
cationic RBCMs were tested for their ability to bind to, and affect the triggered release of, 
small nucleic acids.  These particles may be able to capture and protect transiently available 
microRNA (miRNA) biomarkers for cancer from the circulation, potentiating the 
identification of novel biomarkers and early detection of the disease.  
  
v 
 
To my parents, family and friends for their continuing support 
  
vi 
 
Acknowledgements 
 There are so many people who have contributed to my work over the years in one 
way or another, and all deserve my heartfelt thanks.  First and foremost, I would like to thank 
my advisor, Joseph DeSimone, for guiding me and believing in me long enough to make it 
work.  Being a member of his research group has been a great experience full of 
opportunities.  Few grad students will likely be interviewed and filmed as much as I have, 
whether for an ACC commercial touting student athletes (as an extra) or to promote our work 
for the media, both domestic and foreign.  Serving as a teaching assistant for the 
entrepreneurship class with Joe and Dr. Lowry Caudill was a treat; thank you gentlemen, I 
will use the lessons I learned there for the rest of my life.   
I owe many thanks to my collaborators in the DeSimone lab, both current and former 
members:  Kai Chen has been a great help and will further these projects when I leave; I 
know he’ll be a superstar. To Dr. Kevin Herlihy; thank you for showing me how it’s done 
and supporting me in reviving our MRS chapter.  Dr. Farrell Kersey and Stephen Jones were 
integral to my research; thank you for your help.  I owe Dr. Mary Napier many thanks for her 
helpful discussions and crucial grant proposals!  For his hard work and for letting me help 
him with some of his brilliant ideas, I thank Dr. Yapei Wang.  I hope that we collaborate 
when we run our respective research labs! I thank Dr. Ji Guo, who helped me dive headfirst 
into the first long leg of my research and Dr. Stephanie Barrett, for providing guidance and 
conversation when I needed each of them.  To Ryan Orgel, thank you for putting up with me 
as your mentor, I hope to get some free medical care out of the deal.  To the rest of the lab –
vii 
 
 Dr. Janine Nunes, Dr. Stuart Williams, Dr. Elizabeth Enlow, Dr. Matthew Parrott, Dr. 
Hanjin Zhang, Dr. J. Christopher Luft, Dr. Rob Petros, James Byrne, Jing Xu, William 
Hinson, Dr. Merve Ertas, Stuart Dunn, Dr. Doug Betts, Dr. Andy Wang, Kevin Chu, Tammy 
Shen, Dr. Jin Wang, Bill Wagner and others - I thank you for your support, your patience and 
your help and hope that I haven’t forgotten anyone.   
I owe many thanks to my collaborators outside of the DeSimone lab as well.  I offer 
my thanks to Helen Zha for all of her questions.  Our technologies may have been 
incompatible, but I learned a lot in the process of making that discovery.  To Holger Mißlitz; 
thanks for your patience with us.  I hope you have the opportunity to finish what we started.  
I owe thanks to Dr. Adam Shields, who taught me about microfluidics.  Thanks to Jeremy 
Niskala for all the discussions about science; they really got my creative juices flowing.  
Thanks to Devin Barrett- it was a pleasure working with you.  Thanks to Lloyd Frick for 
pointing me in the right direction for pk analysis and to Huali Wu, Dr. Bill Zamboni 
continuing my education in this area.  Many thanks to Charlene Ross and the UNC animal 
handling core for enabling our research.  To the officers of the UNC chapter of the materials 
research society; thank you all for your support and help in setting up a great organization.  
My thanks to Dr. Wei You for selecting me to help with the 2010 NGRP conference; it was 
an honor.   
Finally, I would like to thank my family and friends for their support through this 
journey.  Particular thanks go to Jeremy Niskala, Dale Wilger, Austin Smith, Jason Johnson, 
and Kevin Lilley.  Thanks to Sam Price and Tim Martin for occasionally reminding me of the 
location of the SRC.  I would also like to thank my brothers Andy and Ben for keeping me 
grounded and inspired and my sisters Cherie and Sue for joining the family.  Thanks to my 
viii 
 
parents, Ed and Carol, for their support and understanding.  Thanks to Lucy, for making us 
laugh.  Lastly and most importantly, I thank my fiancé and best-friend, Jennifer McGinnis, 
for her love and support.   
  
ix 
 
Table of Contents 
List of Tables…………………….…….…………………………………….…………...…xiv 
List of Figures…………………….….…………………………………………...……...…xvi 
 
List of Abbreviations and symbols………………………………………………...……....xxiii 
Chapter 1 The Biomechanics of Soft Tissues…..….……………………………………….…1 
1.1 The Mechanics of Biology…………….…………………………………………..2 
1.2 Cellular Response to Environment………………………………………………..2 
1.3 Mechanics of Disease……………………………………………………………..4 
1.4 Methods for Measuring Elasticity…………………………………………………6 
1.5 Conclusions……………………...…….…………...…………………………….8 
1.6 Figures……………………………………………………………………………..8 
1.7 References………...……………………………………………………………..10 
Chapter 2 Towards Synthetic Red Blood Cells: Using Mechano-biological  
Mimicry to Extend Circulation Times of Hydrogel Microparticles………..…....14 
 
2.1 Introduction…………...…………………………………...……………………15 
2.2 Results and Discussion…………………………………………………………..19 
2.2.1 Early Designs of Deformable PRINT RBC Mimic Particles………….19 
2.2.2 HEA-Based Red Blood Cell Mimics…………………………………..26 
2.2.3 Conclusions and Future Work…………………………………………37
x 
 
 
2.3 Materials and Methods…………………………………………………………..40 
 2.3.1 Materials……………………………………………………………….40 
2.3.2 Fabrication of Master Templates………………………………………42 
2.3.3 Fabrication of Thick PRINT Molds……………………………………44 
2.3.4 Fabrication of “Thin” PRINT Molds…………………………………..44 
2.3.5 Particle Fabrication……………………………………….……………45 
2.3.6 Ice Harvesting of Particles……………………………………………..46 
2.3.7 Particle Purification………………………………………….………...47 
2.3.8 Particle Characterization……………………………………………….47 
2.3.9. Surface modification of particles……………………………………...48 
2.3.10 Humidity Control……………………………………….…………….48 
2.3.11 Modulus Testing……………………………………………………...49 
2.3.12 Radiolabeling of Particles with I125………………..……….…………50 
2.3.13 Measuring Particle Filtration Times………………………….………51 
2.3.14 Microfluidics………………………………………………….………51 
2.3.15 Intravital Microscopy…………………………………………..……..52 
  2.3.16 Compartmental Analysis……………….……………………………..53 
  2.3.17 Biodistribution………………………………………………………..56 
  2.3.18 Evaluation of 1% RBCMs at Long Times……………………………56 
  2.3.19 Histology……………………………………………………………...57 
  2.3.20 Assessment of Biocompatibility and Interaction  
with Endothelial Cells………………………………………………..58 
xi 
 
 
2.4 Figures……………………………………………………………………………61 
2.5 References………………………………………………………………………..80 
 
Chapter 3 Pharmacokinetics and Biodistribution of Low Modulus 
        Hydrogel Particles……………………………………………………………….84 
 3.1 Introduction………………………………………………………….………...…85 
 3.2 Results and Discussion…………………………………………………………..88 
  3.2.1 Hydroxy PEG Acrylate Monomers…………...………………………..88 
  3.2.2 Low Modulus HP3A Hydrogels…………………………………….…. 90 
  3.2.3 Fabrication and Characterization of HP3A Hydrogel  
           PRINT particles………………………………………………………..91 
  3.2.4 In vivo Studies……………………………………………….…………92 
  3.2.5 Pharmacokinetics of Particle Clearance from Blood…………………..94 
 3.3 Conclusions and Future Work…………………………………………………...96 
 3.4 Materials and Methods…………………………………………………………..98 
  3.4.1 Materials……………………………………………………………….98 
  3.4.2 Synthesis of Hydroxy PEG Acrylate Monomers………………………98 
  3.4.3 Purification of HPA Monomers………………………………………..99 
  3.4.4 Modulus Testing……………………………………………………...100 
  3.4.5 Particle Fabrication…………………………………………………...101 
  3.4.6 Particle Harvesting and Purification………………………………….102 
  3.4.7 Particle Characterization……………………………………………...103 
  3.4.8 In vivo Studies………………………………………………………...104 
  3.4.9 Biodistribution………………………………………………………..104 
xii 
 
  3.4.10 Pharmacokinetics of Particle Clearance from Blood………………..105 
 3.5 Figures…………………………………………………………………………..106 
 3.6 References………………………………………………………………………112 
Chapter 4 Cationic Microgel Particles for Identification of Cancer Biomarkers……….….115 
 4.1 Introduction to miRNA as Cancer Biomarkers…………………………………116 
 4.2 Results and Discussion…………………………………………………………117 
4.2.1 Low Modulus Cationic Hydrogels………………………………....…117 
  4.2.2 Fabrication of Cationic Red Blood Cell  
         Mimicking PRINT Particles………………………………………….118 
4.2.3 Binding Capacity……………………………………………………..119 
4.2.4 Binding and Release of miRNA from Cationic Microgels…………...120 
4.3 Conclusions and Future Work………………………………………………….121 
4.4 Materials and Methods……………………………………………………….…123 
4.4.1 Materials……………………………………………………………...123 
4.4.2 Modulus Testing……………………………………………………...123 
4.4.2 Particle Fabrication…………………………………………………...124 
4.4.3 Particle Purification…………………………………………………..125 
4.4.4 Surface Modification…………………………………………………125 
4.4.4 Surface Modification…………………………………………………125 
4.4.6 Binding and Release of miRNA……………………………………...126 
4.5 Figures……...…………………………………………………………………..127 
4.6 References………………………………………………………………………129 
Chapter 5 Summary and Future Directions…..…………………………………………….131 
xiii 
 
 5.1 Summary………………………………………………………………………..132 
  5.1.1 Mechano-biological Mimicry of Red Blood Cells…………………....133 
 
  5.1.2 Pharmacokinetics and Biodistribution of  
         Low Modulus Hydrogel Particles………………………………….....135 
5.1.3 Cationic Microgel Particles for Identification  
of Cancer Biomarkers………………………………………………135 
5.2 Future Directions…………………………………………….…………………136 
5.2.1 Biodistribution Maps of Soft Particles…………….………………….136 
5.2.2 Methods for Determination of Particle Modulus….………………….137 
5.2.3 Hemoglobin Carriers for Oxygen Transport………………………….139 
5.2.4 Membranous Particles………………………………………………...142 
5.3 Figures…………………………………………………………………………..146 
5.4 References………………………………………………………………………151 
 
 
 
 
 
  
xiv 
 
List of Tables 
Table 1.1   Young’s modulus values for various cells, viral  
particles, tissues and soft materials, with source  
and testing method listed where available…………………………………….3   
Table 2.1   The composition of 7 µm disc PRINT particles  
used for preliminary in vivo studies………………………………………….22   
Table 2.2 Modulus values for bulk samples of the materials  
used for the particles in the mouse study………………………….…………24   
Table 2.3 Mechanical properties of 2-hydroxyethyl acrylate 
hydrogels with varying length and weight  
percentage of poly (ethylene glycol) diacrylate 
(PEG-DA) crosslinker.  Hydrogels were prepared 
in two cases as 25% solutions in water, increasing  
the flexibility of the gels.  Swelling percentage  
represents the % increase in area of the coupons  
after 24 hours of soaking in water.  Error represents  
one standard deviation, with n=3…………………………………………….28 
Table 2.4 The composition of HEA hydrogels intended for in  
vivo use as RBCMs.  The polymerizable dye for  
bulk samples was fluorescein-o-acrylate; for RBCM  
particles, the fluorescein-o-acrylate was replaced by  
Dylight 680 maleimide………………………………………………………..29   
Table 2.5 Modulus values and compartmental analysis of  
RBCM particles from intravital microscopy  
experiments.  Ranges given represent one standard  
deviation.  Values were derived from scans of three mice………….……….29 
 
Table 2.6 Physical characteristics of RBCM particles and  
mouse RBCs.  Error represents one standard deviation  
from the mean with n=50 for particle diameters, and n=16  
for zeta potential measurements……………………………………………...30 
 
Table 2.7 Pharmacokinetic parameters for 1% crosslinked  
RBCMs calculated from blood draws taken out to  
5 days post-injection…………………………………………………………35 
 
 
 
 
 
xv 
 
Table 3.1 Properties of lightly crosslinked hydrogels composed  
of different acrylic monomers containing 1% of a  
4,000 g/mol PEG diacrylate crosslinker and 1% of  
HCPK photoinitiator, hydrated for 12 hours in  
deionized water at room temperature.  Monomers are  
shown with increasing PEG chain length……………………………………89 
 
Table 3.2 Mechanical properties of hydroxyl PEG3 Acrylate  
(HP3A) hydrogels with varying amounts of  
PEG4000diacrylate crosslinker and 10% of 2-carboxyethyl 
acrylate.  Swelling ratios were determined from one 
bulk sample hydrated for 24 hours in PBS.  Modulus  
and strain at break represent an average value determined  
from three samples cut from the bulk gel, with error  
representing one standard deviation………………………………………….91 
 
Table 3.3 The composition of hydrogel particles fabricated for in vivo work………….91 
 
Table 3.4 Characterization of particles fabricated for in vivo  
studies.  Particle diameters were determined by microscopy.   
Error represents one standard deviation from the mean  
with n=50 for particle diameters………………………………………….….92 
 
Table 3.5 Pharacokinetic parameters for low modulus hydrogel  
PRINT particles with increasing diameters.  Parameters  
were determined from particle concentration in whole  
blood at times 0.2 -104 hours post-dose using a standard  
two-compartment model according to the equation  
C= Ae-αt +Be-βt where C is the concentration of particles  
in blood and t is time post-dose….…………………………………………..95 
 
Table 4.1 Young’s modulus values for cationic hydrogels with  
varied crosslink density, charge density, and amount  
of porogen added……………………………………………………………118 
 
Table 4.2 Zeta potential of cationic red blood cell mimicking  
microgels with varying PEG chain length used for  
surface modification………………………………………………………...119 
 
 
 
 
 
 
 
 
xvi 
 
List of Figures 
 
Figure 1.1 Schematic representations of different techniques used to  
measure the mechanical properties of cells.  (A) Atomic  
force microscopy (AFM) and (B) magnetic twisting cytometry  
(MTC) are methods that probe local areas of cells at a force  
resolution of 10−10 and 10−12 N, respectively, and a displacement 
 resolution of at least 1 nm. (C) Micropipette aspiration (MA)  
and (D) optical trapping deform an entire cell at a force  
resolution of 10−10 and 10−11, respectively.  This figure was  
adapted from reference 45………………………….…………………………9 
 
Figure 2.1 Scanning electron microscope images of 7 µm disc PRINT  
particles made from (A) 89% PEG 428 triacrylate, 10% mPEG1000  
methacrylate and 1% DEAP photoinitiator and (B) 89% PEG428 
triacrylate, 10% mPEG 1000 methacrylate and 1% DEAP  
photoinitiator mixed 1:1, by weight, with PEG 550 dimethyl ether 
as a porogen.  The addition of porogen increases particle flexibility…….….61 
 
Figure 2.2 SEM images of 7 µm diameter, discoid PRINT particles with 
varying amounts of 550 g/mol molecular weight poly (ethylene  
glycol) added to the pre-particle solution as a porogen.  The  
particles appear increasingly flexible, porous, and fragile as  
porogen content increases as follows: (A) 0 %, (B) 50 %, (C)  
60 %, (D) 75 % and (E,F) 90 % porogen…………………………………….62 
 
Figure 2.3 Measuring particle deformability by filtration times through a  
track-etched membrane.  (A) A graphic showing the filtration  
set-up, with one port directed towards mild vacuum and a second  
port directed to the membrane apparatus.  The cut-away depicts  
particles passing through the membrane.  (B) A bright field  
microscope image of rigid particles (“No porogen”) on the  
membrane after filtration.  Particles are along the sides and  
bottom of the image, with the membrane and some of the 5 µm  
pores visible in the center of the image.  The scale bar is 20 µm.   
(C) Filtration times for 5 mL of particle or control solutions through  
a 5 µm nucleopore track etch membrane.  Each plot represents n=4  
with error bars as one standard deviation……………………………………63 
 
Figure 2.4 SEM images of 7 µm diameter, discoid PRINT particles with 
varying deformability used in preliminary in vivo studies.  Rigid  
particles (A) contain no porogen while moderately deformable  
ones (B) were made with 50% (by weight) of a non reactive  
PEG porogen.  The most deformable particles (C) were made  
primarily with a PEG diacrylate monomer in lieu of the triacrylate  
used in A and B, and included 50% porogen as in B………………………...64 
xvii 
 
 
Figure 2.5 Biodistribution of 7 µm diameter RBC mimic PRINT  
particles in mice as a function of % injected dose.   
Deformability of the hydrogel particles increases from A  
to C with the addition of a porogen in series B and replacement  
of triacrylate monomer with diacrylate in addition to porogen  
for series C.  Particle accumulation in the tail is typical of tail  
vein injection procedures.  Major accumulation occurred in the  
lungs in all cases along with poor persistence in the blood,  
suggesting that no formulation was deformable enough to  
navigate the narrow capillaries found in this organ………………………….65   
 
Figure 2.6 RBCM particles.  (A) A graphical depiction of the  
PRINT process used to fabricate RBCMs.  Briefly, from  
top to bottom, an elastomeric fluoropolymer mold (green)  
with disc shaped wells was covered by an aliquot of the  
pre-polymer mixture (red).  The mold was passed through  
a pressured nip (black) covered by a high energy sheet (grey),  
wicking away excess liquid from the mold surface while filling  
the wells of the mold.  The filled mold was cured photochemically 
, yielding cross-linked hydrogel particles, which were harvested  
from the mold by freezing onto a thin film of 1% poly (vinyl  
alcohol) in water (blue) and peeling away the mold.  Melting  
of this layer resulted in a suspension of red blood cell mimic  
(RBCM) hydrogel particles.  (B-E)  Fluorescent images of hydrated  
RBCMs with varying % crosslinker (B) 10% crosslinked (C) 5%  
crosslinked (D) 2% crosslinked and (E) 1% crosslinked.  Scale 
 bars are 20 µm…………………………………………...…………………..66 
 
Figure 2.7 Modulus of hydrated samples of hydrogel as % crosslinker was  
varied from 1-10%.  Additional dye (1% fluorescein-o-acrylate)  
was included to show the effect the addition of a near-IR  
dye to the composition for in vivo imaging applications…………………….67 
 
Figure 2.8 Discoid master templates fabricated in SU-8 on six inch silicon 
   wafers.  Discs with diameters of (A) 1.5 µm, (B) 2 µm, (C) 
   3 µm, (D) 4 µm, (E) 5 µm, and (F) 6 µm were prepared with  
an aspect ratio of 0.3.  The scanning electron microscope  
images are shown at approximately the same scale and  
represent embossed films of cyanoacrylate cast from  
PRINT molds made using the appropriate masters…………………………..68 
 
Figure 2.9 The dose dependant cell viability of HUVEC (endothelial) 
   cells when dosed with HEA-based RBCMs with varied  
crosslink density (1-10%) after 72 hours of incubation  
with the particles as determined by MTS (A) and ATP/luciferase  
xviii 
 
(B) assays as a percent of saline-dosed control……………………………...69 
 
Figure 2.10 Uptake of 1, 2, 5, and 10% crosslinked RBCMs in HUVEC 
   cells after dosing times from 15 minutes to 24 hours based  
on flow cytometry.  Results are expressed in terms of the  
percentage of cells which had taken up RBCMs (internalized)  
and which were free of RBCMs (unassociated).……………...……………..70 
 
Figure 2.11 Microfluidic evaluation of RBCM deformability. (A)  
A schematic of the microfluidic devices.  The channel  
has a repeating pattern of 50 µm long pores which are  
3 µm  wide and 3.5 µm tall, forcing particles passed  
through the device to deform. Flow was driven by a syringe  
pump. (B) An image sequence showing a 1% crosslinked  
RBCM (6.0 µm diameter) deforming to pass through a  
3 x 3.5 µm channel (25 ms between frames).  (C) 10%  
crosslinked RBCMs stuck in the entrance of the 3 µm pores  
in a microfluidic device.  Scale bars are 30 µm……………………………...71 
 
Figure 2.12 Intravital microscopy data and compartmental analysis.   
(A) Vasculature highlighted with rhodamine B labeled  
dextran prior to injection of RBCMs.  (B) Dylight 680  
labeled 1% cross-linked RBCMs flowing through this  
stretch of vasculature 20 minutes after dosing, with ROI  
outlined in yellow.  (C) Colored overlay of A and B, with  
dextran in blue and particles shown in red.  Scale bars are 100  
um.  (D) Two-compartment model schematic and governing  
equations for the model applied to the data. (E) Decrease in  
fluorescent signal in the ROI for the 2 hour scan in this mouse.   
The semi-log plot shows calculated fit for the two compartment  
pharmacokinetic models…………………………………………………..…72 
 
Figure 2.13 A standard curve which correlates fluorescent efficiency (signal  
intensity) and concentration of 1% crosslinked RBCMs in 
whole blood.  Deviation from linearity defines the lower  
limit of quantification for fluorescent signal.  Data collected  
for the blood draw experiments fell within the linear range of 
this plot.  Scale bars represent one standard deviation, with n=3……….…...73 
 
Figure 2.14 A plot of particle concentration in whole blood over time 
for 1% crosslinked RBCMs where n=4 for each data point.   
A two compartment pharmacokinetic model with elimination  
from the central compartment was fit to the data (red) by  
nonlinear regression analysis.  The fit was used to calculate  
pharmacokinetic parameters for these particles.  Scale  
bars represent one standard deviation, with n=3…………………..…………74 
xix 
 
Figure 2.15 Biodistribution of RBCMs.  (A) Distribution of RBCMs into  
various tissues 2 hours post dosing by percent recovered  
fluorescence normalized for tissue weight.  Error bars represent  
one standard deviation, with n=3 for each case. (B)  Lung tissue  
from a mouse dosed with 10% cross-linked RBCMs.   Particles  
are shown in red, with cell nuclei in purple and cytoskeleton  
(F-actin) stained green.  (C) Lung tissue from a mouse dosed with  
1% cross-linked RBCMs, with tissue stained as in (B).   
Very few RBCMs were in this tissue compared to mice dosed with  
more rigid particles, consistent with the tissue distribution data.    
Scale bars are 50 µm…………………………………………………………75 
 
Figure 2.16 A plot showing the biodistribution of 1% crosslinked RBCMs in  
mice over a 2-120 hour time course in the liver, lung, spleen  
and kidneys.  Data is presented as fluorescent efficiency per  
gram of tissue weight.  Error bars represent one standard  
deviation, with n=3 for each case……………………………………………76   
 
Figure 2.17 Histological analysis of spleen tissue from RBCM dosed mice.   
(A) Overlaid image of immunostained spleen tissue from a  
mouse dosed with 2% cross-linked RBCMs.  The particles  
(red) are primarily sequestered in the red pulp, an area of tissue  
which is rich in macrophages (green).  Cell nuclei are shown  
in purple.  (B) An enlarged view of the area indicated in (A)  
by a grey square……………………………………………………………...77 
 
Figure 2.18 Left:  A chrome on quartz reticle designed for fabrication of  
master templates with micron sized discoid features.   
Right:  Bright field microscopy images of the patterned sections  
of the reticle at 100x magnification (scale bar is 20 µm)…………………....78 
 
Figure 2.19 A plot showing SU-8 film thickness as a function of weight  
percent solids of SU-8 2010 when diluted from the original  
58% solids with SU-8 thinner.  Film were spin coated at  
3000 rpm for 30 seconds.  Thickness measurements were made  
based on post-exposure feature heights……………………………………...79 
 
Figure 3.1 Synthetic scheme for hydroxyl PEG acrylates (HPAs).  The  
structure of the monoacrylated products are shown below  
the reaction scheme, along with the naming  convention.………………….106 
 
 
Figure 3.2 Fluorescent images of the particles used for the in vivo  
studies.  The particles have hydrated diameters of (A)  
3.79 ± 0.17 µm, (B) 6.39 ± 0.56 µm, and  
(C) 8.88 ± 0.47 µm …………………………………………………………107 
xx 
 
 
 
Figure 3.4 Biodistribution of extremely deformable particles of different  
sizes in mice over the course of several days.  These semi-log  
plots show the percent of fluorescent signal normalized per  
gram of tissue weight.  Four mice were examined per time-point,  
with error bars representing one standard deviation………………………..108 
 
Figure 3.5 Biodistribution of low modulus hydrogel particles of different  
sizes in mice in terms of total fluorescence signal (fluorescence  
efficiency) in each tissue.  Fluorescence in blood was measured  
in 100 µL aliquots and adjusted to account for the total blood  
volume of each mouse.  Four mice were measured per time point.   
Error bars represent one standard deviation…………………...……………109 
 
Figure 3.6 A plot showing the change in particle concentration in blood  
over time for particles of different sizes.  Particles with a  
diameter of 6.4 µm, similar to that of mouse red blood  
cells, were cleared more slowly than both larger and smaller  
particles with identical mechanical properties and composition.   
The concentration of the largest particles, with a diameter of 8.8  
µm, fell to below the lower limits of quantification after  
7 hours post-injection………………………………………………………110 
 
Figure 3.7 SEM images of 200 nm particles made from 1% PEG4000DA  
crosslinked HP3A.  The particles are on a harvesting film  
after transfer from the mold.  A scratch in the harvesting film  
(top right corner of both images) illuminates the deformability  
of these particles where they were disturbed as the scratch  
was made……………………………………………………………………111 
 
Figure 4.1 Cationic hydrogel particles (A) Particles fluoresce in the green  
channel due to matrix bound fluorescein dye.  (B) Fluorescence  
in the red channel from adsorbed Cy3 dye-conjugated DNA  
20mer.  Particles were incubated at 37 ºC for one hour with 1  
µM DNA, then washed 3 times to remove unassociated DNA.   
Scale bars are 20 µm………………………………………………………..127 
 
 
 
 
 
 
 
 
 
xxi 
 
Figure 4.2 Analysis of miRNAs bound to and released from  
CRBCM particles.  Lanes 1-3 are miRNA 96 in increasing  
amounts (100, 200 and 300 ng).  Lane 4 is miRNA 96  
desorbed from CRBCs in high salt concentration, causing  
band broadening.  Lane 5 was loaded with miRNA 96 after  
degradation with and RNase cocktail.  Ethidium bromide was  
not sufficient to stain the degraded RNA.  Lanes 6-10 were  
identical to 1-5, respectively, but with miRNA 100 in place  
of miRNA 96………………………………………………………………..128   
 
Figure 5.1 A plot showing the diameter and modulus of low  
aspect ratio particles examined in this dissertation.  The  
grey oval indicates the particles which demonstrated  
longer circulation times as a result of avoidance of  
physical filtration mechanisms in the circulation.  The  
green box indicates the combination of particle diameters  
and moduli which should be the target of future studies…………………...146 
 
Figure 5.2 A schematic representation of atomic force microscopy  
(AFM) being used to probe the mechanical properties of  
a PRINT particle.  A known force is applied by the  
AFM to the particle, causing a deformation in the particle.   
The movement of the cantilever is tracked by the movement  
of a laser on a photodiode detector as it reflects from the  
top of the cantilever.   Deformations must be small relative  
to the thickness of the particle to avoid interference from  
the substrate………………………………………………………………...147 
 
Figure 5.3 A schematic of the initial attempts at the fabrication of  
micron sized, self assembled HA/PA membranes.  (A) A  
PRINT mold (green) is filled with HA solution (red)  
and frozen before bringing into contact with a layer of  
PA solution (brown).  (B) The assembly is frozen on dry  
ice and, (C) the mold is peeled away, leaving the frozen  
HA particles on the PA ice surface.  (D) The solutions thaw  
and the HA drops into the PA solution where membrane  
self-assembly occurs, yielding hollow sacs………………………………...148 
 
Figure 5.4 Membranes assembled from HA particles cast in 7x7 µm  
cylinder PRINT molds and harvested to a solution of PA.   
(A) The particles appeared to assemble into fully formed  
sacs which were reminiscent of red blood cells.  (B)  
Inspection with a confocal microscope showed that the sacs  
did not fully close, likely due to incomplete immersion of HA  
particles into the PA solution.  Scale bars are 20 µm………………………149 
 
xxii 
 
Figure 5.5 An image of sacs formed from assembly of HA and  
PA with a connecting scum layer resulting from incomplete  
de-wetting of the PRINT mold surface.  The bottom left of  
the image contains collapsed sacs trapped in this scum layer,  
while the upper right side has more holes in this membrane.   
The scale bar represents 20 µm……………………………………………..150 
 
   
 
 
xxiii 
 
   
List of Abbreviations and Symbols 
% v/v Volume percent 
°C Degrees C 
µm Micrometer 
µM  Micromolar 
125I Iodine 125 
AEM 2-aminoethyl methacrylate hydrochloride salt 
AFM Atomic Force Microscope 
AR Aspect ratio 
ATP Adenosine triphosphate 
AUC Area under the curve 
BALB/c A strain of mouse 
CD 47 A human "marker of self" protein 
CEA 2-carboxyethyl acrylate 
CLT Total body clearance 
CO2 Carbon dioxide 
Cp Concentration of particles in plasma 
CRBCM Cationic red blood cell mimicks 
Cy3 Cyanine dye 3 
DEAP 2,2-diethoxyacetophenone 
DMF Dimethylformamide 
DNA Deoxyribose nucleic acid 
xxiv 
 
DPBS Dulbecco's phosphate buffered saline 
EGDA Ethyleneglycol diacrylate 
EtOH Ethanol 
FBS Fetal bovine serum 
g/mol Grams per mole 
GEM Genetically engineered mouse 
GPa Gigapascal 
HA Hyaluronic acid 
Hb Hemoglobin 
HBOC Hemoglobin based oxygen carrier 
HCl Hydrochloric acid 
HCPK 1-hydroxycyclohexyl phenyl ketone 
HEA 2-hydroxyethylacrylate 
HIV Human immunodeficiency virus 
HPA HydroxyPEG acrylate 
ICP-MS Inductively coupled plasma mass spectrometry 
ipa Isopropanol 
IR Infrared 
kCl Potassium chloride 
kDa Kilodalton 
kPa Kilopascal 
LbL Layer-by-layer 
MA Micropipette aspiration 
xxv 
 
mCi/mL Millicurie per milliliter 
MgSO4 Magnesium sulfate 
miRNA Micro ribose nucleic acids 
MPa Megapascal 
mPEG Methoxy terminated poly(ethylene glycol) 
MS Microplate stretching 
MTC Magnetic twisting cytometry 
mV Millivolt 
N Newton 
NaCl Sodium chloride 
nm Nanometer 
OT Optical tweezers 
PA Peptide amphiphile 
PBS Phosphate buffered saline 
PEG Poly(ethylene glycol) 
PEGDA Poly(ethylene glycol) diacrylate 
PET Poly(ethylene terapthalate) 
PFPE Perfluoropolyether 
PRINT Particle replication in non-wetting templates 
psi Pounds per square inch 
PVOH Poly(vinyl alcohol) 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RBC Red blood cell 
xxvi 
 
RBCM Red blood cell mimic 
RNA Ribose nucleic acid 
RNase Ribonuclease 
rpm Rotations per minute 
SEM Scanning electron microscopy 
SU-8 A negative photoresist 
t1/2 Half-life 
TB Trypan blue 
TBS Tris buffered Saline 
Tff Tangential flow filtration 
TGA Thermogravimetric analysis  
UV Ultraviolet 
V3A3K3 A polypeptide with 3 valine, 3 Alanine, and 3 Lysine  
amino acids 
Vc Volume of the central compartment 
Vdβ Volume of distribution in the beta phase 
α Alpha 
β Beta 
 
  
Chapter 1 
 
 
The Biomechanics of Soft Tissues
 2 
 
1.1 The Mechanics of Biology  
 Biomechanics seeks to understand the workings of biological systems through the 
mechanical properties of the component materials.  Natural materials display a wealth of 
structures and structure dependant properties which are essential to their specific functions.  
Tissues in the body possess a range of mechanical properties (Table 1.1); with elastic moduli 
ranging from stiff calcified bone (5-13 GPa)1,2 to softer materials like pre-calcified bone (> 
30 kPa)3,4, red blood cells (26 kPa)5, skin and muscle cells (around 10 kPa) and extremely 
soft brain tissue (about 0.5 kPa)4.  With advances in nanotechnology allowing for closer 
scrutiny of the structure and properties at the cellular and sub-cellular levels, the links 
between biomechanics and human disease has developed as a subject of intense scrutiny.  
Indeed, as we grow more advanced and versatile in our ability to design and fabricate new 
materials for biological applications, we are increasingly looking towards the soft materials 
found in nature for inspiration and guidance.   
1.2 Cellular Response to Environment  
 An essential consideration in designing materials for biological applications lies in 
understanding how the mechanical properties of a biomaterial will enable a desired biological 
response.  Circulating cells are extremely soft; the mechanical flexibility of red blood cells 
allows them to avoid filtration in the spleen, one of several factors resulting in long 
circulation times for these abundant cells4.  The mechanical properties of a local environment 
may influence the biological response of cells as much or more than chemical stimuli.  The 
differentiation of stem cells6, the proliferation of fibroblasts7, and cell death8 are highly 
influenced by the geometry of the cellular microenvironment.   Similarly, substrate 
mechanical properties can influence cell and tissue behavior3.  For example, mesenchymal  
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stem cells cultured on polyacrylamide substrates of different stiffness developed distinctly 
different morphologies and lineage28.  Cells cultured on soft (0.1–1 kPa) substrates developed 
neuronal cytoskeletal markers while a moderately stiff substrate (8–17 kPa) resembling 
muscle resulted in the expression of myogenic markers and a stiffer substrate (25–40 kPa) 
 Source Testing method Elastic modulus 
(kPa) 
Ref 
Bone Human Nanoindentation 13.5 x 109 2 
Tobacco mosaic virus Virus AFM 6 x 106 9 
HIV (immature) Virus AFM 9.3 x 105 10 
Achilles’ tendon Rat Tension 3.1 x 105 11 
HIV (mature) Virus AFM 1.2 x 105 10 
E. coli DH5 alpha Bacteria AFM 1.9 - 3.0 x 103 12 
Articular cartilage Bovine Compression 9.5  x 102 13 
Skeletal muscle Rat Tension 1.0 x 102 14 
Carotid artery Mouse Perfusion 90 15 
Spinal cord Human Tension 89 16 
Thyroid cancera Human Compression 45 16 
Pre-mineralized bone - - 30 3 
Poly(dimethyl siloxane) Synthetic - 10-1000 3 
Polyacrylamide Synthetic - 0.1-100 3 
Spinal cord Rat Tension 27 17 
Red blood cells Human AFM 26 5 
Cardiac muscle Mouse Tension 20–150 18 
Skeletal muscle Mouse AFM 12 19 
Thyroid Human Compression 9 20 
Lung Guinea pig Tension 5–6 21 
Breast tumor b Human Compression 4 22 
Alginate Algae - 0.1-150 3 
Hyaluronic acid Various - 0.1-150 3 
Collagen Various - 0.001-1 3 
Fibronectin Various - 0.001-1 3 
Matrigel Mouse - <1 3 
Lung cells (normal) Human AFM 2.1 23 
Lung cancer cell c Human AFM 0.56 23 
Kidney Swine Rheology 2.5 24 
Premalignant breast Human Indentation 2.2 16 
Fibrotic liver Human Compression 1.6 25 
Liver Human Compression 0.640 25 
Lymph containing metastases Human Vibrational resonance 0.330 26 
Brain Swine Indentation 0.260–0.490 27 
Lymph node Human Vibrational resonance 0.120 26 
a Thyroid papillary adenocarcinoma.  b Mammary ductal carcinoma.  c Non-small cell carcinoma 
Table 1.1.  Young’s modulus values for various cells, viral particles, tissues and soft 
materials, with source and testing method listed where available.   
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resembling pre-calcified bone proved osteogenic.  In order to differentiate based on the 
elasticity of a substrate, the stem cells must be able to pull on the matrix and judge the force 
necessary for a deformation.  Because these stem cells egress from their origin in the marrow 
and engraft in different environments through the body, they must be capable of 
differentiation based on microenvironmental clues.  In light of this issue, it may not be 
surprising that sensing of the microenvironment was found to be more selective than soluble 
induction factors in directing stem cell differentiation28.   
1.3 Mechanics of Disease 
 In addition to cellular behavior and differentiation on substrates, the elasticity of 
individual cells has been given increasing attention due in large part to the increase in the 
elasticity of cancer cells compared to benign cells of the same type and the possibility that 
this difference may be translated to better screening methods for the disease23,29,30.  This 
increase in deformability may have several biological consequences which promote the 
survival and proliferation of these cells.  A decrease in cell stiffness may result in reduced 
recognition by phagocytic cells.  Bacteria are much stiffer than most tissues in the body, with 
elastic moduli from 1.9-3.0 MPa, about 100 times that of red blood cells12.  Virus particles 
are also orders of magnitude less flexible, with the tobacco mosaic virus (6,000 MPa)9 and 
HIV virus particles (115-930 MPa)10 extremely stiff compared to commonly circulating cells. 
Phagocytotic pathways may have evolved to preferentially act on recognition of bacterial 
shape31; it stands to reason that the dramatically increased stiffness of bacterial cells and viral 
particles may also cause a recognition phenomenon. Phagocytosis of soft, polyacrylamide 
microparticles was significantly reduced compared to more rigid counterparts32.  These softer 
beads were unable to stimulate the assembly of actin filaments required for the formation and 
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closure of phagosomes.  The addition of a lysophosphatidic acid, an activator of several 
signaling pathways, resulted in an increase in phagocytosis of soft beads to levels similar to 
those for the rigid beads.  Rigid beads were unaffected by the addition of lyophosphatidic 
acid, suggesting that the acid activated a pathway usually initiated by rigid substrates.  These 
results suggest that macrophages use substrate rigidity and force input from a surface-bound 
particle as cues to determine whether the target should be ingested.     
 The elasticity of cancer cells may enable their proliferation throughout the body.  
Metastasis describes the process by which cancer cells spread from one organ or tissue to a 
different part of the body.  For metastasis to occur, a cancer cells must first invade a 
lymphatic or blood vessel by a process called intravasation.  Transport through the 
circulatory system results in lodging of the cancer cells in small blood vessels and subsequent 
extravasation to the parenchymal tissue lining the vessel wall.  Greater elasticity, which has 
been identified as an indication of disease33, may allow cancer cells to more readily escape 
tumor beds and infiltrate the bloodstream in a metastatic process.  A decrease in the stiffness 
of the cell can be directly attributed to changes in the cellular cytoskeleton from which 
mechanical rigidity is derived.  The cytoskeletal components of actin, microtubules, and 
intermediate filaments work in concert with their accessory proteins to facilitate tasks such as 
cell motility, mitosis, ribosomal and vehicle transport and mechano-transduction34.  The 
order and structure of these cellular components in the cytoskeleton devolves to a more 
irregular and compliant state as cells progress from normal to cancerous35.  Cancer cells have 
high motility and replication, both of which are facilitated by a less rigid cytoskeleton. In 
addition to the decrease in stiffness of cancer cells versus normal cells, several studies have 
correlated increased metastatic efficiency in multiple cancer cell lines with decreased cell 
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stiffness29,35,36.   Metastatic cancer cells from patients with non-small cell carcinomas of the 
lungs and breast ductal adenocarcinoma were found to be more than 70% softer than benign 
cells of the same type using AFM analysis, with elastic moduli on the order of 0.5 kPa23.   
   
1.4 Methods for Measuring Elasticity  
 The measurement of elasticity on a cellular level can be difficult due to the low forces 
and short length scales involved, but a variety of techniques have been developed to probe 
the mechanical properties of cells (Figure 1.1).  These techniques can be broadly separated 
into several categories according to the length scale across which they act on the cell.  
Atomic force microscopy (AFM) and magnetic twisting cytometry (MTC) mechanically 
probe the cell surface with forces on the order of 10-12 – 10-6 N and displacements smaller 
than 1 nm29.  In AFM methods, the deformation is localized, induced by the sharp tip at the 
end of an AFM cantilever, though rounded spherical tips can be used to broaden the 
deformation area37.  The applied force is calculated by calibration of the deflection of the 
cantilever by reflection of a laser to a photodiode detector.  In MTC, a magnetic bead is 
attached covalently to the cell surface and rotated via the application of a magnetic field.  
Analysis of the membrane deformation yields information about the elastic and viscoelastic 
properties of the cell membrane38.   
 Deformations of large portions of the cell with sub micron displacements are possible 
using the optical tweezers (OT)39 and micropipette aspiration (MA)40 techniques shown in 
Figure 1.1 as well as other techniques like mechanical microplate stretching (MS)29.  For 
these techniques, forces on the order of 10-12 – 10-7 N are applied and the deformation tracked 
using optical microscopy.  Optical tweezers feature beads covalently attached to a cell 
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membrane; cells picked for analysis will feature two beads attached to a single cell at 
opposite sides of the membrane.  A laser is aimed at the beads, which are made from a high-
refractive index dielectric material.  The beads, focused on by individual lasers, are attracted 
towards the focal point of each laser trap, inducing displacement between them.  In MA 
techniques, suction aspirates a portion of a cell, or the entire cell through a micropipette tip.  
Analysis of the geometry change then provides the elastic and viscoelastic response of the 
cell, though adhesion to a substrate and friction between the cell surface and the walls of the 
micropipette are typically ignored41.   In MS experiments, a cell is covalently bound to two 
functionalized glass surfaces which are moved or sheared apart with force control and 
measured displacement determining the mechanical properties of the cell30.   
 In addition to the above methods for probing the mechanical properties of cells, a 
wide variety of methods are employed which provide a qualitative measure of deformability 
rather than quantitatively measuring forces and cellular response.  Measurements of the time 
required populations of cells to pass through micropore filters with distinct pore sizes offers a 
facile simulation of cell motility through the microvasculature 42,43.   Microfluidic systems 
offer more sophisticated models of the vasculature, and can be sized to model flow through 
restrictions in blood vessels or tissue42,44.  These channels are typically fabricated from 
poly(dimethyl siloxane), glass or silicon with dimensions in the range of 10-100 µm.  The 
device design can vary from narrowing channels to multiple branches designed to replicate 
the branching of blood vessels to capillaries.  Assays can be designed to put a fixed pressure 
over a channel, or to measure flow characteristics, cell velocity, and cell count passing 
through such a restricted space, providing insight into the relative flexibility of the cells 
examined. 
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1.5 Conclusions 
 As our ability to measure the stiffness of materials on the length scale of cells has 
advanced, so too our understanding of the role played by mechanical rigidity and flexibility 
in biological materials.  The picture emerging from these studies describes mechanical 
flexibility as a component of biology that is equally essential to biological function as 
chemical factors like molecular signaling, ligand-receptor interactions and protein structure.  
While our understanding of the interplay between material properties and biological 
functions is growing, the field remains in an early stage of development, with many questions 
still unanswered4.  However, it is clear that the design of biomaterials can be enhanced by 
consideration of material stiffness.    
   
  
 9 
 
1.6 Figures 
 
 
Figure 1.1.  Schematic representations of different techniques used to measure the 
mechanical properties of cells.  (A) Atomic force microscopy (AFM) and (B) magnetic 
twisting cytometry (MTC) are methods that probe local areas of cells at a force resolution 
of 10−10 and 10−12 N, respectively, and a displacement resolution of at least 1 nm. (C) 
Micropipette aspiration (MA) and (D) optical trapping deform an entire cell at a force 
resolution of 10−10 and 10−11, respectively.  This figure was adapted from reference 45.   
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Towards Synthetic Red Blood Cells: Using Mechano-biological Mimicry to Extend 
Circulation Times of Hydrogel Microparticles 
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2.1 Introduction 
 The effect of changes in the physical and mechanical properties of nano- and 
microparticles on their in vivo behavior in the circulation has become an area of growing 
interest, with increasing attention directed to the design of particles for use in the fields of 
drug delivery and medical imaging1-5.  Many basic design parameters have relevance on the 
behavior of synthetic particles once introduced to the circulation, including particle shape, 
size, aspect ratio, charge, surface chemistry and deformability.  While the precise nature of 
the body’s response to changes in each of these parameters remains a focus of intense study, 
some guidelines have been determined.  
Size has been, perhaps, the most well explored parameter for particles in the field of 
drug delivery and has long been considered the dominant factor in the determination of in 
vivo behaviors such as circulation time, biodistribution profile, and mechanism and rate of 
cellular internalization3,6,7.  For example, microparticles are generally regarded as unsuitable 
for intravenous application due to their rapid clearance times, while the ideal nanoparticle 
design gives diameters below 100 nm1.  The interaction of cells with particles can be 
determined, to some extent, by tuning parameters like particle size and shape; the rates and 
mechanisms of cellular internalization for micro- and nanoparticles are influenced by both 
particle shape 6,8 and deformability9.   Filamentous particles were found to have increased 
circulation times with respect to their spherical counterparts, though this effect may be a 
factor of both the shape and deformability of these particles or their tendency to fragment to 
avoid uptake 5.  Particles with negative surface charge are less likely to undergo cellular 
internalization than those with positive charges due to electrostatic repulsion with negatively 
charged cell membranes 6 
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  Though particle size has long been considered dominant in determining in vivo 
behaviors such as circulation time and biodistribution profile, it stands to reason that physical 
filtration barriers in the body could be navigated by larger, but more deformable particles 7,10. 
Deformable particles which resembled RBCs in size and shape have been shown to deform in 
restricted channels 11 or capillaries 12 which were smaller than the particle diameter, though 
the modulus of these particles was not characterized 11 or was poorly matched to RBCs12 and 
was restricted to in vitro testing in both cases. In one case, Haghgooie et al. fabricated 
discoid particles with 8 µm diameter by stop flow lithography from solutions of 700 g/mol 
molecular weight PEG diacrylate in 200 g/mol PEG with the polymerizable monomer 
between 10 and 40% v/v11.  The deformability of these particles was tested by passing them 
through microfluidic channels which were 4 µm in diameter and 4 µm tall at low pressures.  
This allowed for a qualitative examination of particle deformability as the pressure in the 
channels could be changed to obtain a threshold pressure for pushing the particles through 
the small channels as the crosslink density was varied.  An interesting result of this study was 
that the particles deformed to navigate the channels primarily by folding, rather than 
stretching, as is more typical for RBCs.  
To replicate the hollow membrane structure of natural RBCs, Doshi, et al. used 
spherical particles as a template for layer-by-layer assembly of complementary 
polyelectrolytes 12.  Dissolution of the spherical template resulted in a biconcave collapsed 
structure which was similar in shape to mature red blood cells.  The authors determined the 
elastic modulus of their particles from force-indentation curves obtained by AFM, and found 
their particles to be over 6 times stiffer than similarly evaluated RBCs (92.8 kPa and 15 kPa 
respectively).  The particles were able to deform when passed through a circular capillary 
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(5µm diameter) which was smaller than their diameter (6 µm). These particles were not 
evaluated in vivo. 
In a simulation of renal filtration of soft particles, microgels translocated through 
pores that were 1/10th of the particle diameter under physiologically relevant pressures13.   In 
this study, Hendrickson, et al. applied 0.5 psi of hydrostatic pressure on track etch 
membranes with 100 nm pores to drive hydrogel particles as large as 1 µm in hydrated 
diameter through the pores.  In the kidneys, renal filtration occurs by passage through 
endothelial gaps which are approximately 8 nm in diameter with a pressure differential of 
0.7-1.5 psi13.  Particles with hydrated diameters of 116 nm were passed through membranes 
with 10 nm pores with 0.5 psi in a more realistic simulation of renal filtration conditions.  
Two flexible gels, with different crosslink densities correlating to bulk modulus values of 8 
and 13 kPa, were examined in these studies, though the particles made from these materials 
showed a similar ability to traverse the pores.  These gels may not have direct biological 
relevance, as they were fabricated from crosslinked poly(N-isopropylacrylamide), which 
would collapse at physiological temperatures (37 ºC) above the lower critical solution 
temperature of the hydrogel (32 ºC), rendering them less deformable.    
Filamentous worm-like micelles (filomicelles) were found to have increased 
circulation times with respect to their spherical counterparts, though this effect was attributed 
to the size and shape of these particles as well as the deformability 5.  These filomicelles were 
observed to decrease in length with increasing time in vivo; a factor which may be crucial to 
their extended circulation times.  Initiation of a phagocytotic event results in a fragmentation 
of the filament, leaving behind a fragment but with the bulk of the filament avoiding uptake. 
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Inspired by nature’s example of long-circulating microparticles, we sought to mimic 
the size and shape of RBCs while varying the modulus across a physiologically relevant 
range to probe the physical barriers encountered in vivo by soft microparticles.  The 
mammalian red blood cell (RBC) presents a fascinating example of a biological particle for 
which deformability is essential to function.  Once mature, mammalian RBCs eject their 
nucleus and all of their organelles, and so neither self-replicate through mitosis nor 
synthesize any RNA or proteins to effect cellular repairs 14.  The extraordinary flexibility of 
mammalian red blood cells (RBCs) enables them to deform many thousands of times during 
their long lives in the circulation with up to 100% strain 15 as they  pass through restrictions 
in the vasculature which are smaller than their diameter.    During their 120 day lifetime, 
RBCs experience chemical changes to their membrane structure, rendering them less 
flexible, and leading to their removal from the circulation via splenic filtration 16.  Instead, 
RBCs remain in the circulation for a finite time, approximately 120 days, before a gradual 
decrease in their flexibility results in their clearance. The extreme flexibility of RBCs is such 
that, when young, they routinely deform to pass through capillaries throughout the body and 
the slit-like sinusoids in the spleen which are much smaller than their diameter.    During 
their lifetime they experience gradual chemical changes to their membrane structure, 
rendering them less flexible, and which cause their removal from the circulation via splenic 
filtration at the end of this lifecycle16.  Beyond RBCs, cancer cells, especially metastatic 
cancer cells, are elastically softer than healthy cells, a characteristic that is believed integral 
to their ability to spread to new locations 17,18.   
Here we show that increasing the deformability of RBC sized particles to biologically 
relevant levels increased their circulation times beyond that of conventional microparticles 
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and significantly altered their biodistributions.  Particle deformability was inferred from the 
measured properties of the bulk materials, and evaluated by multiple in vitro methods, 
including microscopy-based inspection, measuring filtration times through a track etched 
membrane, and by passing the particles through microfluidic devices with narrow channels.  
We found that, as a consequence of their low modulus, these discoid microparticles bypassed 
several in vivo filtration mechanisms, illustrated by animal survival and dramatic increases in 
elimination half-lives of particles with decreasing modulus.  Such deformable and long-
circulating particles may find utility in the fields of drug delivery and medical imaging, 
where long circulation times and varied biodistributions are often desirable characteristics 1-3.  
Further, we expect these results will stand as an introduction for particle deformability as a 
vital design parameter that can affect the behavior of particles on both the micro and nano 
scales.  
 
2.2 Results and Discussion 
2.2.1 Early Designs of Deformable PRINT RBC Mimic Particles 
2.2.1.1 Design of Deformable Particles 
 Our initial efforts to design deformable RBC mimicking PRINT particles were based 
on the addition of a porogen to previously established particle matrices.  Previously, Gratton 
et al. used PEG triacrylate and 2-aminoethyl methacrylate (AEM) as primary components of 
their particle matrix for multiple in vitro and in vivo studies19.   Here, a non-reactive porogen, 
PEG550dimethyl ether (PEG550), was added in varying percentages to a particle matrix in 
order to decrease crosslink density and increase the deformability of the particles. As a 
qualitative measure of deformability, scanning electron microscopy (SEM) was used to 
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examine deformable PRINT particles.  Particles were made from a formulation consisting of 
89% PEG 428 triacrylate, 10% mPEG 1000 methacrylate and 1% DEAP photoinitiator.  As seen 
in Figure 2.1, particles made from this formulation, mixed 1:1 (by weight) with a porogen 
appeared to be much more deformable, with a striking resemblance to actual red blood cells.   
An amine functional monomer, AEM, was incorporated into the particles to allow for 
facile surface functionalization.  Surface coatings of PEG or other hydrophilic polymers on 
particles creates a hydrophilic steric barrier, which has been shown to prevent aggregation 
and to provide colloidal stability to particle dispersions 20,21.  Particles fabricated with a 7 µm 
PRINT disc PRINT mold were composed of 50% AEM, 48% PEG 428 triacrylate, and 2% 
HCPK (photoinitiator), with porogen (PEG550) added to this preparticle solution.  After 
washing the particles to remove the porogen, SEM examination revealed that particles 
fabricated with 50% porogen appeared flexible and were largely unbroken.  Greater amounts 
of porogen made the particles too fragile to survive the fabrication and purification process, 
possibly as a result of phase separation.  As seen in Figure 2.2, particles with 75% and 90% 
porogen have large pores visible, and were easily broken by the purification process.   
These experiments provided an initial insight into the interplay between increasing 
deformability and decreasing toughness.  It was concluded that the addition of greater than 
50-60% of a porogen could result in an undesired loss of particle durability.  As such, the 
addition of porogen was limited to 60% or less to maintain particle integrity. 
 
2.2.1.2 Evaluating Deformability by Filtration Times 
 To evaluate the deformability of these porogen added 7 µm disc particles, we initially 
measured time for filtration through a Nucleopore polycarbonate membrane with 5 µm pores 
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(Whatman, Ltd.).  This method of measuring filtration times through membranes has been 
used extensively to evaluate the relative deformability of RBCs, with stiffer cells taking 
longer times to pass through the filter22.    Particles for the filtration studies were composed 
of 28% AEM, 60% PEG428 triacrylate, 10% PEG1000 methacrylate, 1% Fluorescein-o-
acrylate, and 1% HCPK.  In this work, filtration was driven by an aspirator generated 
pressure differential (Figure 2.3).  Particles were prepared without added porogen (PEG550), 
or with 25%, 50% or 60% porogen.  As the concentration of particles was measured by 
weight, an adjustment was necessary to produce solutions with approximately equal numbers 
of particles.  Particles made with porogen were adjusted to account for the theoretical 
difference in particle density.  For example, 5 mL of a 0.01 mg/mL solution of 0% porogen 
particles should have approximately the same number of particles as 5 mL of a 0.005 mg/mL 
solution of 50% porogen particles because the particle density is approximately 50% of the 
non-porous particle.   
The times observed for filtration of 5 mL of these particle solutions followed the 
expected trend, with higher amounts of porogen resulting in more rapid filtration (Figure 
2.3).  Imaging of the filtrate revealed that a small number of particles had successfully passed 
through the membrane in the case of the particles with added porogen, though the number of 
particles in the filtrate was not quantified.  Examination of the polycarbonate membranes 
after filtration showed large amount of particles remaining on the membrane in all cases, 
likely as a result of poor fluid flow through areas of the membrane which were in contact 
with a supportive backing.  In contrast, a solution of human red blood cells in isotonic saline 
rapidly traversed the membrane while leaving no residual cells on the membrane.  While 
some particles traversed the pores in these membranes, the difference in filtration times may 
 22 
 
have been a result of the different porosity of the particles used in each case and the ease of 
passing fluid through them, rather than passing the particles through the pores.  This method 
of measuring deformability may be best relegated to the examination of cells or non-porous 
particles in order to avoid this complication.     
 
2.2.1.3 Preliminary in vivo Evaluation of Porous 7 µm RBC mimicking PRINT Particles 
 Preliminary in vivo evaluations of deformable RBC-like PRINT particles were 
conducted to determine the effect of modulus on particle circulation times.  A series of 7 µm 
disc particles with decreasing crosslink density were prepared with compositions described in 
Table 2.1.  For the most rigid particle (A) the matrix consisted primarily of a trifunctional 
PEG acrylate (PEG912triacrylate, 70%).  A moderately deformable composition (B) included 
the addition of 50 weight percent of a non-functional porogen (PEG550).  The most 
deformable particle (C) replaced much of the trifunctional PEG acrylate with a difunctional 
PEG acrylate (PEG330diacrylate) in addition to the inclusion of 50% porogen.  The increase 
in deformability was evident in the SEM images of the particles taken after purification 
(Figure 2.4). 
    
Monomer A (%) B (%) C (%) 
PEG912 triacrylate 70 35 5 
2-aminoethyl methacrylate 28 14 14 
Fluorescein o-acrylate 1 0.5 0.5 
HCPK 1 0.5 0.5 
PEG330 diacrylate 0 0 30 
PEG550dimethylether 0 50 50 
Table 2.1.  The composition of 7 µm disc PRINT particles used for 
preliminary in vivo studies.   
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In this study, 7 µm disc PRINT particles were PEGylated and radiolabeled with 125I to 
track their biodistribution.    Particles were administered into healthy BALB/c mice via bolus 
tail vein injection at a dose of 20 mg/kg. The particles were radiolabeled using Iodogen® 
following the procedure recommended by the supplier (Pierce). Mice were sacrificed at time 
points 1, 3, 8, and 24 hours after dosing and tissues harvested.  The tissue distribution was 
monitored using a gamma counter, and the percent recovery of injected dose was calculated 
from the measured radioactivity.  The biodistribution of the particles is shown in Figure 2.5.     
The particles examined in this study primarily distributed into the lungs, with the bulk 
of the recovered dose accumulating in this tissue.  This was likely a first-pass filtration with 
the particle becoming entrapped in the capillary beds of the lungs directly after tail-vein 
injection, as this organ is almost immediately down-stream from the tail vein in the mouse 
circulatory system.  All three groups showed similar behavior with regards to this filtration in 
the lungs, demonstrating that the decrease in modulus was insufficient to overcome this 
initial biological barrier for large particles in the circulation.   
A modest amount of the injected dose remained at the injection site in the tail.   This 
may be due to the rupture of blood vessels upon rapid injection of a large number of particles 
in a short period of time (< 5 seconds), creating endothelial gaps for particle retention.  Very 
little (less than 1%) of the dose was detected in the kidneys, heart, spleen, bladder, brain or in 
the blood.   A low, but significant amount of radioactivity was observed in thyroid gland, 
possibly indicating the biodegradation of particles, yielding radioactive I2. Production of 
iodine from biochemical degradation of iodinated proteins or peptides is not uncommon and 
is also consistent with the observation that signal in the thyroid, while remaining low overall, 
increased over the 24 hour period studied 23.  
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Interestingly, the most deformable of the particles showed enhanced, though still low, 
accumulation in the liver which increased over the course of the study.  This may have been 
due to mechanical fragmentation of these particles due to the stresses experienced in the 
circulation.  Fragments of particles may have been sequestered in the sinusoidal walls of the 
liver, which is lined with discontinuous endothelium that allows for passive entrapment of 
foreign particulates or nanoparticles 19.  Particle fragmentation in the circulation was 
undesirable for this study; fragmentation of the particles would serve to complicate the 
analysis of the distribution since smaller fragments could distribute differently than intact 
particles.   Fragmentation and deformation seem to have been competing processes.  Further, 
fragmentation would expose unPEGylated, positively charged surfaces, possibly leading to a 
more rapid uptake of fragments versus intact particles.   
 
2.2.1.4 Evaluation of Bulk Mechanical Properties  
To determine the modulus of the hydrogels used in the above studies, bulk samples of 
the materials were prepared.  The samples were evaluated in both a dry state and after 24 
hours of soaking in water to hydrate the gels (Table 2.2).  While we were able to decrease  
 
A B C 
Modulus – dry (MPa) 8.61 5.23 0.87 
Modulus – hydrated (MPa) 2.45 1.57 0.76 
 
Table 2.2.  Modulus values for bulk samples of the materials used for the particles in the 
mouse study.   
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the modulus of the particles by decreasing the crosslink density of the matrix material, the 
Young’s modulus of the materials remained much greater than that of red blood cells (15-26 
kPa)12,24.  Indeed, even the most deformable particles, with a modulus of 760 kPa, were over 
an order of magnitude stiffer than RBCs.   
 
2.2.1.5 Conclusions from Initial Studies 
This work represented an initial effort to determine the effect of particle modulus on 
in vivo behavior.  While neither of the particle formulations included in the studies showed 
significant differences from the “rigid” control particle, several important lessons were 
learned.  The lack of difference in the in vivo profiles of the particles demonstrated that the 
changes in the modulus of the particles were biologically insignificant.  That is, while the 
particles were made to be softer, they remained too rigid to navigate the first filtration barrier 
encountered in the circulation; the narrow capillaries in the lungs. The accumulation of the 
softest particle, C, in the liver, implies particle fragmentation in vivo and indicates that these 
materials may not be ideal for this application due to insufficient toughness.  Further 
decreases in crosslink density for these, or similar, PEG di- or triacrylates, would yield a 
lower modulus material; however, a corresponding decrease in the material toughness would 
likely result in the advent of greater fragmentation.   
More studies with these materials would be required to determine the nature of the 
material failure leading to fragmentation.  There may have been phase separation of the 
different monomers leading to an inhomogeneity in crosslink density and, possibly the 
creation of fracture points at the phase boundaries or in the less-tough phase.  The reaction 
rate of acrylates (such as the PEG di- and tri-acrylates) and methacrylates (AEM) should 
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differ to some extent, leading to blocky polymer chains, encouraging phase separation and 
reducing toughness.  Uneven surface PEGylation may have led to particle aggregation in 
solution, which would have added to the initial sequestration of particles in the lungs.  
While different hydrophilic polymers may be better suited for the fabrication of 
particles with RBC-like modulus, future work with PEG acrylate systems could avoid many 
of the above pitfalls with the advent of several changes to the particle matrix material.  First, 
longer chain PEG diacrylates may be a better material choice than either the PEG triacrylates 
or shorter PEG diacrylates.  These materials should decrease crosslink density while 
increasing the PEG character of the particles.  Such an increase in PEG character may reduce 
the need for surface PEGylation, and therefore, inclusion of AEM in the particle matrix.  
Inclusion of the methacrylate component (AEM) may have resulted in phase separation in the 
particles and diminished the toughness of the particles; exclusion of this component may 
eliminate these issues.      Inclusion of a solvent, such as water or a higher molecular weight 
organic, may serve to minimize any phase separation, resulting in greater particle 
homogeneity and better mechanical properties.     
 
2.2.2 HEA-Based Red Blood Cell Mimics 
2.2.2.1 Fabrication of HEA-Based Red Blood Cell Mimics 
 The particle replication in non-wetting templates (PRINT®) technique that has been 
developed in our laboratory allows for the fabrication of non-spherical, shape-specific 
particles through use of elastomeric fluoropolymer molds 4,25.  Using PRINT, HEA-based 
particles were fabricated with similar size, shape, and deformability characteristics as RBCs 
(Figure 2.6).   In these studies we chose to model the 6 µm diameter mouse RBC 26 and 
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observe the in vivo behavior of the RBC mimics (RBCMs).  While the distinctive biconcave 
discoidal shape of mature RBCs is generally conserved throughout the animal kingdom, 
mouse RBCs (6 µm diameter) are slightly smaller than their human counterparts (8µm 
diameter) 26.           
 
2.2.2.2 Determination of Modulus of Bulk HEA Hydrogels 
 To evaluate the suitability of HEA hydrogels for RBCM particles, we hydrated 
macroscopic coupons of hydrogels with varying percentage of PEGDA cross-linkers with 
different molecular weights in water and tested their mechanical properties with an Instron 
5556 Universal Testing Machine (Instron) with a strain rate of 5 mm/min.  Many hydrogels 
exhibit excellent biocompatibility 27, with their swelling and deformability controllable by 
varying the amount of cross-linking in the gel 28.  PEGDA crosslinkers with molecular 
weight of 700 and 4,000 g/mol were used, with longer PEG chains resulting in lower 
modulus gels.   In addition to lower modulus compared to the shorter crosslinker 
(PEG700DA), hydrogels made with PEG4000 DA had reduced swelling and were capable of 
greater strains without failure with comparable weight percentages of monomer.  Generally, 
HEA hydrogels with low crosslink density were able to undergo high strains before breaking 
(>100%) and had a suitably low modulus for comparison with RBCs.   Two compositions 
were fabricated “pre-swollen” as 25% solutions of monomers in water.  While this had the 
intended effect of reducing the swelling that accompanied hydration of the gels, it served to 
decrease the strength of the materials (Table 2.3).   
For the in vivo studies, several changes were made to the above hydrogel 
composition. To mimic the negatively charged RBC membrane, we added 2-carboxyethyl  
 28 
 
 
acrylate (10%).  Fluorescent dyes were needed to facilitate tracking of the particles in vivo.  
Hydrogels composed primarily of 2-hydroxyethyl acrylate (HEA) that were lightly (1-10%, 
by weight) cross-linked with poly (ethylene glycol) diacrylate (PEGDA, MW=4,000g/mol) 
with a photoinitiator (1-hydroxycyclohexyl phenyl ketone), 10% CEA, and polymerizable 
fluorescent dyes (1%) were fabricated for modulus testing (Table 2.4).  Fluorescein-o-
acrylate was used as the polymerized dye for these bulk studies, and to improve depth of 
tissue penetration and avoid tissue autofluorescence, a near IR dye (Dylight680maleimide) 
was used for in vivo applications.  The addition of the bulky dye molecules to the polymer 
samples caused an increase in the hydrogel stiffness at higher crosslink densities (at 10%  
 
Crosslinker  
%  PEG-DA 
(crosslinker) 
% water in 
monomer 
solution 
Modulus 
(kPa) 
Stress at 
Yield (kPa) 
% Strain at 
Yield 
% 
Swelling 
with 
hydration 
PEG700 DA 10 0 621 ± 25 82.3 ± 18.7 8.2 ± 1.8 240 
PEG700 DA 1 0 89 ± 14 61.7 ± 6.1 91.9 ± 8.4  420 
PEG700 DA 0.5 0 21 ± 4 15.4 ± 1.2 161.0 ± 1.0 1020 
PEG700 DA 0.5 75 3.3 ± 0.4 5.3 ± 0.8 151.3 ± 28.2 314 
PEG4000DA 5 0 28 ± 2.5 15.0 ± 2.4 79.0 ± 33.8 262 
PEG4000DA 5 75 4.0 ±  2.6 5.1 ± 0.7 84.5 ± 12.8 128 
PEG4000DA 1 0 14 ± 0.6 16.0 ± 1.8 132.0 ± 59.9  345 
PEG4000DA 0.5 0 12 ± 2.5 8.0 ± 2.6 229.7 ± 58.4 360 
Table 2.3.  Mechanical properties of 2-hydroxyethyl acrylate hydrogels with varying 
length and weight percentage of poly (ethylene glycol) diacrylate (PEG-DA) crosslinker.  
Hydrogels were prepared in two cases as 25% solutions in water, increasing the 
flexibility of the gels.  Swelling percentage represents the % increase in area of the 
coupons after 24 hours of soaking in water.  Error represents one standard deviation, 
with n=3.   
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Monomer (%) 
PEG4000diacrylate 1-10 
2-Carboxyethyl Acrylate 10 
1-Hydroxycyclohexyl Phenyl Ketone 1 
Methacryloxyethyl Thiocarbonyl Rhodamine B  0.1 
2-Hydroxyethylacrylate Remainder 
Polymerizable Dye 0-1 
Total 100 
Table 2.4.  The composition of HEA hydrogels intended for in vivo use as RBCMs.  The 
polymerizable dye for bulk samples was fluorescein-o-acrylate; for RBCM particles, the 
fluorescein-o-acrylate was replaced by Dylight 680 maleimide.   
 
 
 
crosslinker,  modulus equal to 63.9 ± 15.7 and 53.2 ± 19.1 kPa for hydrogels with, and 
without added dye, respectively).  For samples with lower amounts of crosslinker (1 and 
2%), there was little change in modulus of hydrated samples with and without dye, though 
we observed a decrease in the amount of water taken up by the samples which included dye 
(Figure 2.7).  By lowering the amount of cross-linker from 10% to 1% in samples including 
dye, we tuned the modulus of the resultant hydrated polymer from  63.9  to 7.8  kPa, 
respectively (Table 2.5); overlapping the range of the reported modulus for RBCs (26+ 7 
kPa)24.  The above formulations were targeted for use in further studies. 
% 
Crosslinker  
Modulus of 
Bulk 
Material 
(kPa)  
Distribution 
Half-life 
(hours)  
Elimination 
Half-life 
(hours)  
AUC   
(fluorescence*hour)  
Average 
R
2
 
10%  63.9 ± 15.7  0.04 ± 0.001  2.9 ± 0.9  
  
0.6  ± 0.1 0.8966  
5%  39.6 ± 10.4  0.07 ± 0.04 5.1 ± 2.2 
 
0.8 ± 0.6 0.9029 
2%  16.9 ± 1.7  0.2 ± 0.02  
 
7.1 ± 0.8  
 
1.4  ± 0.3 0.9468 
1%  7.8 ± 1.0  0.3 ± 0.1 93.3± 31.1  
 
15. 4  ± 15.6 0.9330  
Table 2.5 Modulus values and compartmental analysis of RBCM particles from 
intravital microscopy experiments.  Ranges given represent one standard deviation.  
Values were derived from scans of three mice. 
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2.2.2.3 RBCM characterization 
 Due to the swelling observed in the bulk hydrogel samples, we designed master 
templates and molds for these studies.  Master templates with disc features were fabricated 
on 6 inch silicon wafers with features cast in SU-8 photoresist (Figure 2.8).  To account for 
hydrogels with different swelling ratios when hydrated, masters were made with feature 
diameters between 1 and 6 microns.  For the in vivo studies, the features of the masters were 
scaled-down from the desired hydrated particle diameter, to 2 or 3 µm, allowing the RBCMs 
to swell to the desired dimensions upon hydration.  The RBCMs fabricated from these 
masters were discs that were 5.2- 5.9 µm in diameter and 1.22-1.54 µm tall, with the feature 
size and final RBCM dimensions dependent upon the percent of cross-linker and the mold 
used (Table 2.6).  Filling the molds resulted in a meniscus, leaving the particles thinner in 
the middle and thicker at the edges (Figure 2.6). This effect, which is not uncommon for the 
PRINT method 6, yielded RBCMs that were reminiscent of the biconcave shape of RBCs. 
 
 
 1% cross-
linker 
2% cross-
linker 
5% cross-
linker 
10% cross-
linker 
Mouse red 
blood cell 
Particle 
Diameter 
(µm) 
5.96 ± 0.27 5.68 ± 0.32 5.66 ± 0.34 5.18 ± 0.30 6.0 26 
 
Zeta 
Potential 
(mV) 
-24.2 ± 5.4 -23.6 ± 3.4 -19.9 ± 6.6 -17.2 ± 3.4 -46.6 ± 4.84 
 
Table 2.6.  Physical characteristics of RBCM particles and mouse RBCs.  Error represents 
one standard deviation from the mean with n=50 for particle diameters, and n=16 for zeta 
potential measurements.   
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2.2.2.4 Biocompatibility of RBCMs 
 To assess the biocompatibility of the RBCMs, we performed in vitro cytotoxicity 
assays on HUVEC (endothelial) cells.  We dosed cells with varied concentrations of RBCMs 
(1.5-200 µg/mL) and incubated for 72 hours (Figure 2.9) before performing both MTS and 
ATP-luciferase assays to assess cell life.  Particles were well tolerated at all dosages tested by 
both assays, demonstrating a high level of biocompatibility.  To examine the interaction of 
RBCMs with endothelial cells, we performed a flow cytometry-based cell uptake 
experiment29.  RBCMs were dosed to HUVEC cells at a concentration of 15 µg/mL and 
incubated for 15 minutes, 1, 2, 4, and 24 hours then evaluated to determine the percentage of 
cells which had internalized the RBCM particles.  Interaction between the RBCMs and cells 
were minimal, with less than 10% of cells having internalized particles after 24 hours of 
incubation time (Figure 2.10). 
 
2.2.2.5 Microfluidic Examination of Particle Deformability 
 To demonstrate the ability of RBCMs to deform in flow conditions such as they 
might experience in traversing the microvasculature, we utilized a microfluidic device with 
constricted pores (Figure 2.11).  Microfluidic models of vascular constriction have been 
explored to evaluate the behavior of natural and diseased RBCs 30 and synthetic mimics of 
RBCs 11.  We designed a 3 µm tall channel with square pores that were 3 µm wide and 50 
µm long and repeated many times over the length of the device. The height of the channels 
was too short for the RBCMs to orient vertically to pass through the restrictions, forcing the 
particles to deform in order to traverse the pores. The device design (Figure 2.11 A) included 
over 100 repetitions of 3 um restricted pores over the length of the channel, as well as an 
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unrestricted 15 um path on each side of the restrictions, running the length of the channel.  
This architecture tested the ability of the particles to deform repeatedly while providing an 
unobstructed path for fluid flow to maintain reasonably low pressures through the constricted 
pathways. While the smallest capillaries in the body have diameters of around 5 µm, RBCs 
routinely deform to traverse splenic sinusoids that are much smaller 31.  When dilute 
suspensions of RBCMs were flowed through the device at a constant flow rate (0.06 
mL/min) the lower modulus RBCMs (1 and 2% crosslinked) navigated these pores while 
more rigid RBCMs rapidly clogged them.  In flow, the 1% crosslinked RBCMs stretched in 
the 3 um wide channels, increasing in length 239% ± 26% (n=15) while flowing through the 
restricted channels, followed by a relaxation back to their original discoid shape in the 
absence of flow. This behavior is similar to that of natural RBCs, which deform under flow 
conditions and only fully resume their characteristic discoid shape once flow is halted 32.   
While RBCMs have similar size, shape and deformability to RBCs, they differ in 
fundamental structure: RBCs are fluid filled sacs contained by a complex membrane that has 
extreme flexibility originating from the membrane structure 33,34, while the RBCMs are 
uninterrupted hydrogel discs.  These two disparate structures should have different behaviors 
and mechanisms of deformation in constricted flow11 though further studies are needed to 
elucidate these details for the RBCMs.   
 
2.2.2.6 Intravital Microscopy  
 We used an intravital imaging method to examine the behavior of RBCMs when 
intravenously injected into mice.  For intravital approaches, the microcirculation is directly 
observed with high spatial and temporal resolution, often through the use of surgical 
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techniques to expose tissues of interest 35,36.  In our approach, we observed the peripheral 
vasculature through the skin of an anesthetized mouse’s ear.  We directly observed the 
RBCMs via the near-IR fluorescence of the particles by imaging every 2 seconds for 2 hours 
as the particles traversed this portion of the vasculature.  Elimination curves were generated 
by tracking the change in fluorescent signal from the particles over time (Figure 2.12), 
normalizing each scan to the maximum intensity slice and plotting decay as a function of this 
maximum intensity.   
 
2.2.2.7 Pharmacokinetic Analysis 
 Several pharmacokinetic models were investigated using a standard pharmacokinetic 
modeling program (WinNonlin (version 5.2.1; Pharsight Corp., Mountain View, Calif.)) to 
describe the plasma concentration versus time profiles to determine the best model.  One- 
and two-compartment models with elimination from the central compartment, from the 
software’s library, were investigated, as was a two-compartment model with elimination 
from both the central and peripheral compartments, which was built by our group.  The 
evaluation of the goodness of fit was based on the Akaike information criterion, the 
variability (CV) of the parameter estimates, and the absence of a significant correlation 
between independent model parameters (<0.95).  The two compartment model with one 
elimination step from the central compartment provided the best fit for all of the data sets 
examined.   
To evaluate the kinetics of RBCM clearance, we used this two compartment 
pharmacokinetic model, characterized by a bi-exponential decrease in particle concentration 
over time 37, with parameters fit by non-linear regression analysis 38. This model describes an 
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initial (distribution) phase where the particles distribute from the plasma into various tissues, 
followed by a late (elimination) phase that describes the ultimate clearance of particles from 
the plasma (Figure 2.12).  For small molecules and nanoparticles the distribution is 
attributed to extravasation into tissue; because of their size, the distribution of RBCMs may 
be due to physical entrapment in constricted capillaries or tissues with low blood flow rather 
than by an extravasation process. While we only observed the RBCMs for the initial 2 hours 
in vivo, the uncertainty associated with the mathematical fitting was minimized due to the 
large number of data points used to fit each curve (over 350).  Calculated distribution and 
elimination half-lives (t1/2(α) and t1/2(β), respectively) trended to longer times with decreased 
modulus (Table 2.5).  While the least flexible RBCMs were cleared quite rapidly, circulation 
times increased with increasing particle elasticity, with the most deformable RBCMs 
eliminated over 30 times more slowly than their most rigid counterparts (t1/2(β)= 3.9 days).   
 Intravital microscopy provided a method for direct observation of RBCM particles in 
the peripheral vasculature of mice, and allowed us to make a close and thorough examination 
of the initial clearance profiles of these particles.  Our analysis provided curves with 
approximately 350 data points illustrating the elimination of these particles from the 
circulation over each two hour scan.  Non-linear regression analysis yielded excellent fits, 
with the large number of data points adding a measure of certainty to the shape defined by 
these elimination curves.  With a method of directly observing the particles, we expect that 
our detection limits should be quite low as we are able to discern individual particles in the 
scans.  However, this method was not without limitations.     Direct correlation of the 
intensity of the fluorescent signal of the particles to a particle concentration was difficult due 
to several factors, including variabilities in the depth, volume and flow rates in observed 
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portions of vasculature and the relatively fast movement of particles relative to the scanning 
speed of the microscope.   Lacking the correlation to particle concentration, we were unable 
to perform a full pharmacokinetic analysis on the RBCMs examined, though much was 
learned through an analysis of the shape of these curves. 
 
2.2.2.8 Evaluation of 1% RBCMs at Long Times 
To verify the long-circulating behavior of 1% crosslinked RBCMs, we tracked 
particle concentration in blood at time points out to 5 days post-injection via a more 
traditional blood-draw method.  We examined 3 mice per time-point, including 2, 8, 24, 72, 
and 120 hours post injection.  At each time point examined, we sacrificed the mice, collected 
blood via cardiac puncture and measured the fluorescent signal from the particles in the 
whole blood, which was correlated to concentration through the generation of a standard 
curve (Figures 2.13 and 2.14).    Pharmacokinetic analysis of this data by the two-
compartment model discussed above was in good agreement with the data obtained from the 
intravital technique; both techniques showed a fairly rapid distribution of the majority of the 
dose to various tissues, with 10-15% remaining in the blood after 2 hours, resulting in an 
elimination half life of 3.6 days, with 5% of the injected dose remaining in the blood after 5 
days (Table 2.7).    
 
A 
(mg/mL) 
B 
(mg/mL) 
α (hr-1) β (hr-1) αt1/2 
(hr) 
βt1/2 
(hr) 
VC (mL) AUC 
(mg*hr/mL) 
CL
T
 
(mL/hr) 
Vd
β
 
(mL) 
0.19 0.048 0.24 0.0077 2.886 90.24 2.93 7.07 0.099 12.89 
Table 2.7.  Pharmacokinetic parameters for 1% crosslinked RBCMs calculated from blood 
draws taken out to 5 days post-injection. 
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2.2.2.9 Biodistribution of RBCM particles after Intravenous Injection 
 To examine the biodistribution of RBCMs with changing deformability, we sacrificed 
the mice two hours post-injection and harvested tissue and blood samples for further analysis. 
Tissue samples were not perfused prior to analysis.  Five and 10 % crosslinked RBCMs 
distributed primarily into the capillary beds in the lungs (Figure 2.15). This behavior is 
typical for intravenously injected microparticles, with the bulk of the dose most likely 
sequestered immediately post-injection as this is the first downstream tissue with 
microvasculature. These stiffer RBCMs were poorly tolerated, with significant distress 
requiring sacrifice of some mice prior to scan completion; presumably due to the stiff 
particles contributing to pulmonary embolism.  More flexible RBCMs (1 and 2% cross-
linker) were very well tolerated, presumably due to the avoidance of filtration in the lungs.  
Mice which were sacrificed early were not included in any data sets presented here, as the 
time post-injection was incongruent with the bulk of the data analyzed.  The most deformable 
RBCMs (1% crosslinked) were primarily sequestered in the spleen (67% RD/g), having 
largely avoided filtration in the lungs.   Lung filtration was largely avoided by particles with 
2% or less cross-linker (< 16.9 kPa, bulk material), suggesting that the modulus of these 
materials may indicate a threshold value for avoidance of filtration by the lungs.     Uptake in 
the kidneys was significant for all but the 1% crosslinked RBCMs, though further studies 
will be required to elucidate the mechanism of this clearance.   
 Distribution of 1% crosslinked RBCMs in liver, lung, spleen and kidneys was tracked 
for 2, 8, 24, 72, and 120 hours post-injection (Figure 2.16).  Saturation of tissues occurred at 
different times, indicating a redistribution of particles after some initial distribution at the 
time of dosing.   While splenic accumulation peaked at 24 hours, signal in the lungs 
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decreased over the time course of the experiment; suggesting a delayed release of the 
physically entrapped particles back into the circulation. 
 With approximately 5% of the cardiac output flowing through the spleen 16 and the 
total blood volume of the mouse circulating 7-8 times per minute 39, the whole blood volume 
was passed through the mouse spleen some 42-48 times over the course of our two hour 
scans.  The continued persistence of 1% cross linked RBCMs in the circulation after this time 
suggests that splenic accumulation may be due in part to long residence time rather than 
permanent filtration, as is the case for RBCs, where filtration occurs first as an effect of slow 
blood flow through the macrophage-containing red pulp, followed by physical filtration when 
passing through the sinusoids or transmural apertures 16. 
 
2.2.3 Conclusions and Future Work 
The above studies have clearly demonstrated the importance of particle deformability 
on in vivo behavior over a physiologically relevant range of mechanical properties.  The most 
deformable particles, 1% crosslinked RBCMs, avoided filtration in the capillary beds in the 
lungs, leading to much slower clearance compared to particles which were stiffer.  A 30 fold 
increase in the elimination half-life of the 1% RBCMs resulted from an approximately 8 fold 
decrease in elastic modulus.  Interestingly, the modulus of the stiffer particles was higher 
than that of normal RBCs, but similar to that of pathological RBCs as evaluated by AFM 24, 
with normal blood cells (26 kPa) coming in softer than those with hereditary spherecytosis 
(43 kPa), anisocytosis (40 kPa) or G6PD deficiency (90 kPa).  A comparison of 10% 
crosslinked RBCMs (70 kPa) with G6PD deficient RBCs or 5% crosslinked RBCMs (40kPa) 
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with spherocytosis or anisocytosis RBCs may provide insights on the role of RBC modulus 
in these diseases.  
The method of the accumulation and retention of the RBCMs in the spleen may be of 
significant interest in future studies (Figure 2.17).  The pharmacokinetic analysis suggests 
that accumulation in this tissue may be, in part, reversible.  This makes sense physiologically, 
with low blood flow in the red pulp of the spleen causing a pooling of the RBCMs in this 
tissue over time.  However, it is possible that the accumulation is due primarily to uptake of 
RBCMs by splenic macrophages in this tissue.  The use of spleenectomized mice for a study 
tracking the clearance of RBCMs over time may shed some light on this issue.  Lacking this 
filtration mechanism, it is possible that RBCM pharmacokinetics would change dramatically, 
possibly following a one compartment model or with greatly extended circulation times.   
Use of RES depleted mice represents an alternate strategy to probe the interaction of 
RBCMs with macrophages in the spleen and elsewhere.  The intravenous application of 
clodronate liposomes has been demonstrated to specifically and temporarily deplete 
macrophages in the reticuloendothelial system 40.  Once phagocytosed by macrophages, the 
lipisomes accumulate inside the cells and cause cell apoptosis.  This strategy has been 
employed to study the role played by the RES in tumor uptake41 and biodistribution42 of 
quantum dots.  Changes in biodistribution and circulation profile of the RBCMs should 
indicate the role played by physical sequestration in the spleen versus cellular internalization.   
 Another interesting system for probing the interaction of RBCMs with macrophages 
is the integrin associated protein CD47, which acts as a “marker of self” on red blood cells 
and leukocytes 43.  This protein binds to signal regulatory protein alpha on macrophages and 
serves to downregulate phagocytotic pathways.  Expression of CD47 analogs provide 
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smallpox and vaccina viruses some protection from macrophage clearance 44, while 
overexpression of CD47 has a similar function in leukemia and hematopoietic stem cells 45.  
Recently, CD47 was shown to inhibit macrophage uptake when conjugated to polystyrene 
beads in cell culture 46.  RBCMs appear to be a promising substrate for application of these 
“markers of self”, which may allow for even longer circulation times.  The low blood flow 
conditions in the splenic red pulp assure proximity of RBCMs to splenic macrophages at this 
point in the circulation and inhibition of phagocytosis by recognition of “self” would most 
likely greatly extend circulation times.   
Further studies will be required to illuminate the capability of these particles to carry 
and deliver therapeutic payloads, however, extremely low modulus RBCMs could have 
therapeutic applications for splenic disorders due to their preferential accumulation in this 
tissue, and have potential for drug delivery applications due to their long-circulation times 
and low accumulation in the liver. Drug dosing can be limited by toxicity to a clearance 
organ such as the liver47,48.  The apparent splenic clearance of RBCMs affords the possibility 
of different dosing restrictions if these particles were to be used as drug carriers because of 
the low concentrations found in the liver, as well as the possibility for direct treatment or 
imaging of the spleen.   
In addition to carrying therapeutics, RBCMs should be evaluated for their capacity to 
carry hemoglobin (Hb) and transport oxygen throughout the body.  Previous work by Kelly, 
et al. has demonstrated that the PRINT process is well tolerated by proteins 49.  To modify 
RBCMs to carry and deliver oxygen, Hb can be included in the pre-particle formulation.   
The primary anticipated challenges include the possible denaturation of some of the 
encapsulated Hb by the particle making process, difficulty in encapsulating erythrocyte like 
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amounts of Hb (up to 33% by weight) while retaining hydrogel strength and deformability, 
and leakage of Hb from the particles leading to renal toxicity.  While some amount of 
denaturation may be inevitable due to the UV curing process and the free radicals generated 
therein, it may be possible to shorten the exposure time or decrease the temperature of the 
UV oven to increase Hb stability.  Cargo encapsulation at high weight percentages may 
significantly alter the physical properties of the particle matrix material, requiring 
reexamination of the relative component ratios to obtain suitable modulii for long circulation 
times.   
The most deformable of the RBCMs tested here successfully navigated regions of 
constricted blood flow, resulting in extended circulation times and illuminating a critical 
design parameter for microparticles.  Further experimentation with extremely deformable 
materials on different size scales – from tens of nanometers to the 6 µm diameter particles 
used in this study, should cast light on the role played by deformability in enhancing the 
circulation times of biologically relevant particles. 
 
2.3. Materials and Methods  
2.3.1. Materials  
Fluorocur®, the perfluoropolyether (PFPE) used as the molding material in the 
PRINT process, was purchased from Liquidia Technologies (Product # 2M-140).  
Trimethylolpropane ethoxylate triacrylates (PEG triacrylates) and PEG diacrylates (Aldrich), 
were passed through short plugs of alumina prior to use to remove inhibitors.  Photoinitiators 
2,2-diethoxyacetophenone (DEAP), and 1-hydroxyl-cyclohexyl phenyl ketone (HCPK) were 
purchased from Aldrich and used as received.   
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Commercially available 2-hydroxyethylacrylate (HEA, 96%, Aldrich) contains 
impurities such as acrylic acid, ethylene glycol and ethyleneglycol diacrylate (EGDA), and 
was purified prior to use according to the procedure set forth by Elif, et al 50.  Briefly, HEA 
was dissolved in water (25% by volume) and the solution extracted 10 times with hexanes.  
Salt (200 g of NaCl/L) was added to the aqueous phase and the monomer extracted by 
washing with ether (4 times).  The solution was dried with MgSO4 (3 wt %), and ether 
removed by rotary evaporator.  The purified monomer was distilled under vacuum prior to 
use.   The purification of the HEA monomer and subsequent storage conditions were crucial 
to the reproducibility of the properties of hydrogels composed of this monomer. HEA was 
stored in aliquots at -20 ºC to prevent degradation.  It became apparent that, over time, the 
short-chain crosslinker (EGDA) was regenerating in solution.  This was most readily 
apparent in particles made from older or improperly stored HEA, where the hydrated 
diameters were smaller than expected.  We attributed this to the presence of some EGDA in 
the HEA monomer, which reformed over time. Proper storage of the monomer for up to 3 
months (at -20 ºC in aliquots to prevent repeated exposure to the atmospheric moisture) 
resulted in reproducible particle diameters.   
Poly(ethylene glycol)4000diacrylate (PEG4000DA, Polysciences, Inc.), 2-carboxyethyl 
acrylate (Aldrich), fluorescein-o-acrylate (97%, Aldrich), Dylight680maleimide (Thermo 
Scientific), Fluorescein-o-acrylate (97%, Aldrich), PEG5000N-hydroxysuccinimidyl ester 
(PEG5000NHS) (polysciences, inc.) and methacryloxyethyl thiocarbamoyl rhodamine B 
(PolyFluor 570, Polysciences, Inc.) were used as received.  Iodogen® pre-coated tubes were 
purchased from Pierce Biotechnology, Inc., and radioactive iodine (Na125I) was purchased 
from Perkin Elmer Life and Analytical Sciences, Inc. as 100 mCi/mL in 10-5 M NaOH.  All 
 42 
 
other chemicals were purchased from Fisher Scientific, and were used as received unless 
otherwise noted.  
 
2.3.2 Fabrication of Master Templates 
 Master templates were fabricated at the North Carolina State University 
Nanofabrication Facility (NCSU NNF) using traditional photolithographic techniques.    
Photolithography is a process in which a film of photoresist on a silicon wafer is exposed to 
light that has passed through a patterned mask or reticle. The light induces a change in 
solubility in the photoresist, typically due to the presence of photoacid generators in the 
resist.  In a positive resist, the exposed area becomes soluble. In negative photoresists, the 
light exposure causes a crosslinking reaction which renders the exposed regions insoluble. 
After exposure the soluble portion of the photoresist is removed with a developing solution. 
The resist pattern can then be used as part of a final device (more typical for negative resists) 
or as mask for etching the silicon wafer. In the case of etching of silicon, cleaning steps are 
used to remove residual resist from the wafer.  Achievable feature sizes for each technique 
are largely dictated by the wavelength of light that is used to expose the photoresist.   
Silicon wafers (6 inch) were purchased from Silicon Quest International and were 
used as received.  Chrome on quartz reticles (6” x 6” x 0.250”) were purchased from 
Benchmark technologies for use on the GCA 8500DSW stepper at the NCSU NNF with a 
negative resist.  The reticles had clear circles with diameters five times the intended diameter 
of the features on the master templates due to the 5x reduction lens of the GCA stepper 
(Figure 2.18).   
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The wafers were coated with SU-8 photoresist at the desired thickness by diluting 
SU-8 2010 (58% solids, Microchem) with SU-8 thinner (Microchem).  Due to the viscosity 
of the SU-8 resists, proper mixing was essential.   Mixtures of SU-8 and the SU-8 thinner 
were covered in foil and mixed on a shaker for 6 hours prior to the spin coating procedure.  
Film thicknesses were determined by the % solids in the diluted SU-8 and were designed to 
obtain the desired feature heights (Figure 2.19).  Obtaining uniform films across the 
diameter of the 6 inch wafers required special attention to several details.  First, the spin 
coater had to be exhaustively cleaned prior to use, as the excess SU-8 caused any residual 
resist on the sides or top of the spin coater to drip onto the wafer, ruining the uniformity of 
the coating. This effect may have been due to the SU-8 thinner acting as a solvent for 
residues of other photoresists used in this shared equipment.   Static dispensing of SU-8 (7.5 
mL) was required, with an extended slow spin (300 rmp for 15 seconds) to coat the wafer, 
after which the spinning was allowed to stop completely (5 seconds) before the next step of 
the program spun the resist to the desired thickness (3000 rpm by 133 rpm/sec for 30 
seconds).    It was important to seal the top port of the spin coater lid to avoid bull’s eye 
defects.  The coated wafers were soft-baked at 95 ºC for 90 seconds.  Wafers with SU-8 films 
were prepared at UNC’s cleanroom facility and transported in this state to NCSU in a light-
proof wafer boat for exposure.   
Features were exposed using the GCA 8500DSW i-line (365 nm laser) wafer stepper 
with a 5 x reduction lens at the NCSU NNF.  Exposure times were 1 second per step.  The 
wafers placed on a 95 ºC hot plate for 2 minutes as a post-exposure bake.  The resist was 
developed for 2 minutes in SU-8 developer, after which the wafers were hard baked at 165 ºC 
for 30 minutes to increase feature durability.  Feature heights were verified with a KLA 
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Tencor P-6 profiler, and by SEM of 99% PEG 428 triacrylate, 1% DEAP PRINT particles 
fabricated from the masters.  Feature fidelity was confirmed by SEM examination of 
embossed cyanoacrylate (Zap CA PT-08, Pacer Technologies) film cast from PRINT molds 
prepared from these master templates (Figure 2.8).    
 
2.3.3 Fabrication of Thick PRINT Molds 
The 7 µm RBC particles were made from “thick” PRINT molds fabricated as follows:  
10-12 mL of fluorocur® resin (Liquidia technologies) was placed onto a 6 inch silicon wafer 
etched with the desired pattern (raised discs with diameter of 7 µm and aspect ratio of 0.25).  
The resin was allowed to spread and completely wet the wafer for 3-5 minutes under a 
nitrogen purge in a UV oven, followed by 2 minutes of exposure to UV irradiation (λ = 365 
nm, power > 20 mW/cm2) to cure the resin.  The elastomeric mold was removed from the 
surface by gently peeling it away. This method describes the fabrication of a “thick mold”.   
 
2.3.4 Fabrication of “Thin” PRINT Molds 
 Thin molds were fabricated by drop casting approximately 500 µL of Fluorocur resin 
onto a master template.  The resin was spread out using a sheet of poly(ethylene terapthalate) 
(PET) that had been specially treated for adhesion with the Fluorocur resin.  The master was 
coated evenly with Fluorocur by laying the sheet onto the resin on the master, allowing it to 
spread, then peeling the sheet off and rotating it slightly before touching it back down to the 
master. This process was repeated multiple times until the entire master template was coated 
with PFPE resin.  Air bubbles were removed from between the master template and the PET 
by peeling the PET all the way off of the PFPE-wetted master surface and slowly and gently 
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rolling the PET back over the master using a soft, rubberized roller which was longer than 
the width of the master. The master/PFPE/PET sandwich was placed in a UV oven. The oven 
was purged with nitrogen for 2 minutes, then exposed to UV light (λ=365nm) for 3 minutes 
to cure the resin. The PET with the cured resin was then peeled off the master template, 
yielding a thin mold consisting of a thin, patterned layer of PFPE bound to a PET backing 
sheet.   
 
2.3.5 Particle Fabrication 
 For the PRINT technique4,6, low surface energy molds are filled with a liquid pre-
particle mixture using a variety of techniques so that the wells of the mold are filled while the 
area of the mold between the wells remains clean.  For particles composed primarily of PEG 
triacrylates or PEG diacrylates, the particles were fabricated by spraying a 10% (w/v) 
solution of the monomers in isopropanol onto the mold to wet it evenly.  The molds were 
allowed to dry for 5 minutes in air to allow the isopropanol to evaporate.  The mold surface 
was covered with a sheet of PET and this assembly sent through a laminator with a heated 
nip at a slow rate while the PET was peeled back at a steady angle.  A slow peel rate and 
steady peeling angle are essential for fabrication of large, low aspect-ratio particles to avoid 
filling defects or scum formation.  Following this, the mold was placed in a UV oven, purged 
with nitrogen for 2 minutes and UV irradiation was applied (λ = 365 nm, power > 20 
mW/cm2) for 2 minutes to cure the particles.    
The master templates and molds used to make HEA-based RBC particle had discoid 
features with 2 and 3 µm diameters and heights of 0.6 and 0.9 µm, respectively and produced 
particles with 5-6 µm diameters due to swelling of the particle hydrogel material.  For the 
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fabrication of the particles, the pre-polymer mixture was spread onto a mold which was taped 
to a silicon wafer and chilled to 2-5°C on a custom built laminator platform.   The reduced 
temperature prevented evaporation of the pre-polymer solution prior to photo-curing.  A PET 
sheet was laminated to the top of the mold and pre-polymer solution, wetting the total mold 
area.  The sheet was peeled away at the nip point of the laminator, leaving the wells of the 
mold filled while wicking away excess solution.  The filled mold was immediately 
transferred into a chilled (~5°C), nitrogen purged UV oven and cured with UV light 
(λ=365nm, 3 minutes, power ~ 20 mW/cm2).   
 
2.3.6 Ice-harvesting of Particles 
Particles were harvested from the mold by freezing to a thin layer of ice, called “ice 
harvesting”.  For this method, 1 mL of millipore water or 0.1% 2 x103 g/mol poly(vinyl 
alcohol) (PVOH, Acros) in water was placed onto a substrate.  The substrates used included 
clean, 6 inch silicon wafers, or PET sheets.  The mold was placed face-down onto the 
substrate so that the water spread out evenly, forming a uniform layer between the substrate 
and the mold surface.  This assembly was placed into a in a -80°C cooler (dry ice), but was 
not brought into direct contact with the ice.  The assembly was allowed to freeze for at least 
30 minutes; shorter freeze times resulted in poor harvest yields. The mold was peeled rapidly 
away from the substrate at a steep angle, leaving particles stuck to the layer of ice frozen to 
the substrate.  Upon melting of the ice, particles were collected by pooling the solution on the 
wafer with a cell scraper, and collecting it with a pipette.  This procedure was generally 
repeated two times per mold to harvest nearly 100% of the particles from the molds.   
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2.3.7 Particle Purification 
PEG-acrylate particles were purified by washing up to 6 times with water or acetone 
via centrifugation, removal of supernatant and resuspension of the particle pellet with 
sonication and vortex mixing.  The HEA based particles were washed and concentrated via 
tangential flow filtration with a MicroKros hollow fiber filter (500 kDa, Spectrum 
Laboratories, Inc.) to remove any sol fraction from solution.  Particles were then suspended 
in 0.1% 2 x103  g/mol PVOH in PBS, pH 7.4 for subsequent experiments.   
 
2.3.8 Particle Characterization 
HEA based particle dimensions were determined by analysis of images from a 
microscope mounted camera (Zeiss AxioCam MRm) using a 100x objective (Zeiss Axio 
Imager D.1M).  Over 50 fully hydrated particles in pH 7.4 PBS buffer were measured for 
each case.   Mouse red blood cells (RBCs) used for zeta potential measurements were 
pelleted and washed three times with cold PBS prior to crosslinking with 1% glutaraldehyde 
for 5 minutes.  The mouse RBCs were washed with PBS and diluted 1000 fold with cold DI 
water for zeta potential measurements.  Zeta potentials for HEA particles and RBCs were 
measured on a nano ZS zetasizer (Malvern Instruments) in water.  The zeta potential of PEG-
acrylate particles was measured using a ZetaPlus Zeta Potential Analyzer (Brookhaven 
Instruments Corporation) in water at a concentration of 0.3 mg/mL.  
To obtain particle mass, the particles were transferred to a previously weighed 
eppendorf tube, centrifuged to pellet and the supernatant removed.  This pellet was dried 
overnight in a vacuum oven to remove residual solvent, massed, and dispersed in saline to 
the appropriate concentration.  The concentration of HEA based particles was determined 
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using thermogravimetric analysis (TGA) to determine the mass of particles in a small sample 
(20 µL) of particle solution.   
 
2.3.9 Surface modification of particles 
To modify the surface of amine-containing particles with PEG, the particles were 
transferred to dry DMF and placed into a flame-dried vial.  Freshly distilled triethylamine 
was added to the reaction mix, followed by addition of a solution of excess (2.5 molar 
equivalents compared to amines) PEG5000 NHS in DMF.  The mixture was incubated at room 
temperature overnight with mixing.  Acetic anhydride (excess) was added to quench any 
unreacted amines.  Solvent was removed by applying vacuum with slight heating.  Particles 
were resuspended in 1 M HCl and mixed for 5 minutes.  Particles were then washed with 
water by centrifugation and resuspension, until the supernatant pH was neutral.  The 
PEGylation reaction was monitored by the change in zeta potential of the particles from 
positive to negative values, with typical values of -25 to -45 mV for particles after 
PEGylation.  
 
2.3.10 Humidity Control 
 Because of the low temperatures used during the particle fabrication process for 
HEA-based particles, a low level of relative humidity was required, beyond the typical 
ambient conditions in the laboratory.  However, particle fabrication using PRINT requires a 
fair amount of manual dexterity and specialized equipment and proved impractical in a glove 
box environment.  Subsequently, a small, single person enclosure was designed to maintain 
low humidity for this process using inexpensive and readily available equipment.  A portable 
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greenhouse with polyethylene panels and a 6’ x 6’ footprint was used for the body of the 
enclosure.  This was large enough to accommodate a table holding the chilled laminator and 
UV oven with some additional work space.  The chiller unit for the chilled laminator and UV 
oven generates a fair amount of heat, and was placed outside of the enclosure with chilled 
fluid lines piped to the equipment inside.  A small home dehumidifier was placed inside the 
enclosure to remove moisture from the air.  Additionally, a compressed air line runs into the 
room through a drierite dessicator (Drierite Co. Ltd.) to put a positive pressure on the room 
with arid air.  A heat-exchanger after the desiccator, consisting of 50 feet of coiled copper 
tubing in a dry ice/ipa bath, serves to cool the incoming air, offsetting the heat generated by 
the equipment and personnel.   
 Humidity in the room can be maintained at 20-30% at temperatures of 70-75 ºF, 
which is sufficient to prevent condensation on the chilled laminator (the limiting factor).  In 
the higher temperature months, when the relative humidity in the building soared to 50-60% 
at 72-74 ºF, low humidity conditions became more difficult to maintain as the dehumidifier 
worked harder to dry the air, causing it to generate more heat.  In this case, it was necessary 
to leave the enclosure for 15 minutes out of every hour to allow the temperature and humidity 
to drop back to acceptable levels.    
 
2.3.11 Modulus Testing   
To measure the mechanical properties of crosslinked hydrogels, macroscopic coupons 
of the prepolymer mixtures were polymerized via UV light in a Teflon mold.  Approximately 
650 µL of prepolymer mixture was pipette into a 2.5 x 2.5 x 0.5 cm square mold.  The mold 
was placed in a low-intensity UV oven, and nitrogen purged for 3 minutes prior to curing.  
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The low intensity oven was used to minimize the heat generated from the UV light.  The 
coupons were cured for 5 minutes, allowed to cool for 3 minutes, then cured for an additional 
3 minutes.  The cross-linked hydrogels were removed from the mold, weighed, and placed in 
pH 7.4 PBS buffer for 24 hours to fully hydrate.  The coupons were patted dry with paper 
towels and weighed again prior to testing with an Instron 5556 Universal Testing Machine 
(Instron) with a strain rate of 5 mm/min. 
 
2.3.12 Radiolabeling of Particles with I125 
Radiolabeled particles were surface functionalized with Bolton-Hunter reagent  
(BHR, Sulfosuccinimidyl-3-[4-hydroxyphenyl]propionate) to provide a facile iodination site.  
Briefly, prior to the addition of PEG-NHS, BHR in DMF was added in a ratio of 
approximately 600,000 BHR/particle along with excess triethylamine.  The reaction was 
allowed to proceed for 2 hours at room temperature, followed by the addition of PEG-NHS.  
Reaction proceeded as above.  PRINT particles were radiolabeled using IodogenTM solid 
phase oxidant in the presence of Na125I. Briefly, 10 mg of PRINT particles in 1 mL of H2O, 
53 μL of phosphate buffered saline, and 1 mCi of Na125I in  10 μL o f 10-5 M NaOH were 
added to an Iodogen pre-coated tube (50 μg of Iodogen reagent) and the tube was swirled 
every other minute for 15 minutes. The radiolabeled particle solution was then transferred to 
a pre-weighed 1.5 mL Eppendorf tube. The original reaction tube was rinsed with one 20 μL 
portion of 1 mM KI and with two 100 μL portions of water and the rinsing solutions were 
added to the tube containing radiolabeled particles followed by the addition of NaHSO3 (1 
μmol/10 μL). The particle dispersion was then centrifuged for 10 minutes at 15,000 x g using 
an Eppendorf centrifuge 5415 D (Eppendorf). The supernatant was removed and the particles 
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were washed with four 500 μL portions of water (until the radiation in the supernatant was no 
greater than the background, ensuring complete removal of non-specifically bound 125I) and 
evaporated to dryness in a SpeedVac SC100 (Savant Instruments). The total mass recovered 
was 9.45 mg. The specific activity was measured with a Beckman Gamma 5500B gamma 
counter (Laboratory Technologies) and found to be 5.5 μCi/mg PRINT particles.  
 
2.3.13 Measuring Particle Filtration Times 
 To evaluate the deformability of 7 µm disc particles with added porogen, we 
measured the filtration time through a Nucleopore polycarbonate membrane with 5 µm pores 
(Whatman, Ltd.).  The set up, seen in Figure 2.3, featured an Erlenmeyer flask topped with a 
rubber septum.  The septum had two ports, one was directed to a water aspirator to generate 
vacuum to drive the filtration, the other port led to the filter assembly.  The filter assembly 
(Whatman, Ltd.) held the membrane and was attached to a 10 mL syringe held upright 
without a plunger, acting as a reservoir for particle solutions to be filtered.  A solution of 
particles (5 mL) was added to the open syringe, and the aspirator (held at constant flow for 
all experiments) connected.  Filtration time was measured with a stopwatch.  Solutions for 
this study were prepared to have approximately equal numbers of particles as a 0.01 mg/mL 
solution of 0% porogen particles.  Particle density was assumed to fall linearly with the 
addition of porogen to adjust solution concentrations for equal numbers of particles/mL.   
2.3.14 Microfluidics 
Microfluidic masters were fabricated in the Chapel Hill analytical and 
nanofabrication laboratory (CHANL) cleanroom.  Chrome on quartz masks were ordered 
from Benchmark Technologies.   SU-8 was coated onto 6 inch wafers with film thickness 
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equal to the desired feature height.  The wafers were soft baked at 95 ºC for 90 seconds.  A 
Karl Suss MA6/BA6 mask aligner was used to bring the mask into contact with the wafer, 
followed by 10 second exposure time.  Post-exposure bake at 95 ºC for 2 minutes was 
followed by soaking in SU-8 developer for 3 minutes to remove unexposed resist.  The 
masters were hard baked at 165 ºC for 30 minutes prior to fabrication of devices.  Feature 
heights were analyzed using a P-6 profilimeter (KLA Tencor).   
Microfluidic devices were fabricated from silicone (Sylgard 184, Dow Corning) 
sealed to glass after treatment with oxygen plasma.  Flow in the devices was driven by a 
syringe pump at a fixed rate (0.06 µL/min).  Dilute solutions of 1% crosslinked RBCMs (1-5 
µg/mL in PBS with 0.1% poly (vinyl alcohol)) were pumped through the channel and 
observed with a fluorescence microscope (Nikon TE2000).  Videos were taken with a with a 
Photometrics Cascade II:512 camera.  Particle stretching was analyzed with ImageJ software 
(NIH).  
 
2.3.15 Intravital Microscopy 
Intravital microscopy experiments were performed using an IV 100 laser scanning 
microscope (Olympus) on female BALB/c mice of 22-26 g body weight (Harlan Sprague 
Dawley).  Hair was removed from the ear and a tail vein catheter was applied.  The mice 
were anesthetized with isofluorane and placed onto a heated stage (37 °C) in a prone 
position, with an ear immobilized by taping to an aluminum block which was warm from 
contact with the heated stage.  Vasculature was located by injection with a solution of 20 
mg/mL rhodamine B labeled 70kDa dextran (Invitrogen) in PBS and visualized by excitation 
with a 568nm laser.  A suspension of RBCMs, 33 mg particles/kg mouse weight via a 3.5 
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mg/mL solution of RBCMs in PBS with 0.1% poly (vinyl alcohol), was then injected and 
visualized using a 633nm laser.   Controls were injected with the dextran solution followed 
by 200 µL of PBS with 0.1% poly (vinyl alcohol).  Imaging scans proceeded for 2 hours, 
with an image taken every 2 seconds.   
For analysis of the circulation persistence of the particles, the image files from each 
scan were exported to imageJ.  For ease of analysis, we followed the example of Tong, et 
al.51 and stacked the images in groups of ten.  We analyzed the ROI containing vasculature 
for fluorescent signal in each scan and corrected for variation in laser intensity or 
autofluorescence by background correcting each image with the signal from a region of the 
scan which was free of vasculature.  For comparison, we normalized each scan to the 
maximum intensity slice for that scan, providing curves which measured the clearance of 
particles from the peripheral vasculature over time as a percentage of the maximum signal.   
 
2.3.16 Compartmental Analysis 
Several pharmacokinetic models were investigated to determine the best model to 
describe the plasma concentration over time profiles collected with intravital microscopy, as 
well as the longer time point data collected via blood-draws.  PK analysis was performed 
separately on each mouse using WinNonlin (version 5.2.1; Pharsight Corp., Mountain View, 
Calif.) software.  Both one- and two-compartment models with elimination from the central 
compartment were investigated using models from the WinNonlin model library. To 
determine if the RBCMs followed a dual elimination mechanism, a two-compartment model 
with elimination from central and peripheral compartments built by our group was also 
investigated.  The data were weighted according to the equation 1/Ci, where Ci denotes the 
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predicted concentration or normalized fluorescent signal. All iterations were conducted using 
the Gauss-Newton algorithm 52. The evaluation of the goodness of fit was based on the 
Akaike information criterion, the variability (CV) of the parameter estimates, and the absence 
of a significant correlation between independent model parameters (<0.95).  Secondary PK 
parameters (t1/2(α), t1/2(β), CLs, CLd, Vp, and AUC) were calculated from the estimated 
pharmacokinetic parameters for the long time point scans.  The two compartment model from 
the WinNonlin library was found to best describe the data in all cases.   
For determination of alpha and beta half-lives from the intravital microscopy scans, 
we applied the best-fit model from the WinNonlin analysis.   The two compartment model 
assumes that particles are transported between the central and peripheral compartments with 
first-order kinetics and that particles are eliminated from the central compartment with first-
order kinetics.  The data was analyzed with equation 2.1, where Cp is the concentration of 
the particle in the plasma, and α and β are rate constants for the distribution and elimination 
processes, respectively.    
                
t tCp Ae Be β−α −= +                                           Equation 2.1 
The fit was calculated by nonlinear regression, maximizing the R2 value for the fit and 
producing best fit values for the coefficients and rate constants38.  Half lives for the 
distribution and elimination process were calculated by equations 2.2 and 2.3, respectively. 
       
1
2
ln 0.5
tα α
=
                                                      Equation 2.2 
       
1
2
ln 0.5
tβ β
=
                                                      Equation 2.3 
AUC (area under the curve) was determined by integrating equation 4.1, which describes the 
plasma concentration/time profile (Equation 2.4).   
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A BAUC
α β
= +
                                                                
Equation 2.4 
The volume of the central compartment, Vc, relates the dose administered and the initial 
particle concentration (equation 2.5).   
                                                  
c
DoseV
A B
=
+                                                       Equation 2.5 
Total body clearance, CLT, describes the volume of blood cleared of particles over time, and 
is calculated from the dose administered and the AUC (equation 2.6). 
                                      
T
DoseCL
AUC
=
                                                     Equation 2.6 
The volume of distribution in the elimination phase, Vdβ, describes the volume in which the 
particles would need to be disbursed to provide the observed concentration in blood for the 
elimination phase (equation 2.7). 
                                         
TCLVdβ β
=
                                                    Equation 2.7 
 
While exact values for particle concentrations in the plasma could not be calculated 
from the 2 hour intravital scans, the well defined shape of the elimination curves (350 points 
over 2 hours) allowed for determination of the half-life values, which are not dependant on 
absolute concentration.   
Each elimination curve was analyzed individually for the above values, with the 
averages representing 3-4 mice per particle modulus.  
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2.3.17 Biodistribution 
Controls and dosed mice were sacrificed 2 hours after injections, and blood and 
tissues harvested for imaging.  Harvested tissues including liver, lung, spleen, kidneys, heart, 
and intestines were weighed, then imaged using an IVIS Kinetic fluorescence imaging 
system (Caliper Life Sciences) with excitation at 675 nm and emission measured at 720 nm.  
Blood was harvested via cardiac puncture, and pipetted in 100µL aliquots to black 96 well 
plates for analysis on the imager.  The fluorescent signal for each tissue sample was 
background corrected by subtracting the signal from control tissues.    Biodistribution 
profiles for the RBCMs at two hours post-dose were determined by percent of recovered 
fluorescence in the above tissues.  Fluorescent signal in the blood was calculated by 
measuring the fluorescent signal from several aliquots of blood and extrapolating to account 
for the total blood volume in the mice (approximately 1.7 mL/20 g of body weight) 19.  
 
2.3.18 Evaluation of 1% RBCMs at Long Times   
Fluorescent signal from harvested blood was measured as above, with concentrations 
determined from a standard curve resulting from serial dilutions of particles in mouse blood.    
To verify the long circulating behavior of the 1% crosslinked RBCMs, 33 mg particles/kg 
mouse weight was administered with a 3.5 mg/mL solution of RBCMs in PBS with 0.1% 
poly (vinyl alcohol) via tail-vein injection to female Balb/c mice of 20-22g body weight.  
Three mice per time-point were examined, including 2, 8, 24, 72, and 120 hours post 
injection.  At each time point examined, the mice were sacrificed and the lung, liver, kidney 
and spleen tissues were harvested and blood collected via cardiac puncture. The fluorescent 
signal from the particles was measured using an IVIS Kinetic fluorescent imager (Caliper 
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Life Sciences) with excitation at 675 nm and emission measured at 720 nm.    Blood was 
pipetted in 100µL aliquots to black 96 well plates for analysis on the IVIS Kinetic imager, 
with blood measured in triplicate for each mouse.   To track biodistribution of 1% RBCMs in 
lung, liver, kidney and spleen tissues over time, tissues were imaged as above and plotted as 
fluorescence efficiency per gram of tissue weight. 
 
2.3.19 Hisology   
 Lung tissues were frozen on dry ice shortly after harvesting and 10 µm frozen 
sections prepared for staining.  Microscope slides with frozen tissue sections were allowed to 
thaw at room temperature for 20-30 min, at which point they were washed briefly with TBS.  
The sections were fixed with 2.5% paraformaldehyde in TBS for 5 min, followed by two 5 
minute washes with TBS.  The excess paraformaldehyde was quenched with 10 mM 
ethanolamine in PBS for 5 min, followed by washing twice with TBS for 2 minutes.  The 
sections were permeablized with 0.1% Triton X-100 (Alpha Aesar) in TBS for 5 min, and 
then washed with TBS twice for 5 min.  The sections were incubated overnight at 4°C with 
33 nM AlexaFluor488 conjugated phalloidin (Invitrogen) and 1 µM To-Pro-3 iodide 
(Invitrogen), both solutions having been prepared using 0.025% Tween 20 (Fisher Scientific) 
in TBS.  Following incubation, the sections were washed 4 times for 5 minutes prior to 
mounting with ProLong Gold antifade reagent (Invitrogen).  
 Spleen tissues were frozen on dry ice shortly after harvesting and 10 µm frozen 
sections prepared for staining.  Microscope slides with frozen tissue sections were allowed to 
thaw at room temperature for 20-30 minutes, at which point they were washed briefly with 
TBS to remove media compounds.  The sections were fixed with 2.5% paraformaldehyde in 
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TBS for 5 min, followed by subsequent washing with TBS twice for 5 minutes.  Excess 
paraformaldehyde was quenched with 10 mM ethanolamine in PBS for 5 min, followed again 
by subsequent washing with TBS twice for 5 min.  The sections were then incubated with 
10% rat serum in TBS for 1 hr in a humidity chamber.  After incubation, the sections were 
washed in TBS twice for 5 min.  Following this, the sections were permeabilized with 0.1% 
Triton X-100 in TBS for 5 min, and then washed with TBS twice for 5 min.  The sections 
were incubated overnight at 4°C with 0.2 µg/mL rat anti-mouse F4/80 antibody conjugated 
with AlexaFluor488 dye (Invitrogen), as well as with 1 µM To-Pro-3 iodide, both of which 
were prepared using 0.025% Tween 20 in TBS containing 1% rat serum.  Following 
incubation, the sections were washed 4 times for 5 min prior to mounting with ProLong Gold 
antifade reagent.    
 All samples were imaged with an Olympus FV 500 confocal laser scanning 
microscope with filters optimized for the different fluorescent probes, including the 
rhodamine B dye in the RBCMs.  Images were taken with a 40x objective lens.  
 
2.3.20 Assessment of Biocompatibility and Interaction with Endothelial Cells 
 HUVEC cells were seeded in 200 μL of media [HuMEC containing HuMEC 
supplement and bovine pituitary extract or Minimum Essential Medium (MEM) containing 
Earle’s salts and both supplemented with 10% fetal bovine serum] at a density of 5,000 cells 
per cm2 into a 96-well microtiter plate. Cells were allowed to adhere for 24 h and 
subsequently incubated with PRINT particles at concentrations ranging from 200 μg/mL to 
1.56 μg/mL for 72 h at 37 °C in a humidified 5% CO2 atmosphere. After the incubation 
period, all medium/particles were aspirated off cells. The ATP-luciferase assay requires 100 
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μL fresh medium, which was added back to cells, followed by the addition of 100 μL 
CellTiter-Glo® Luminescent Cell Viability Assay reagent (Promega). Plates were placed on a 
microplate shaker for 2 min, then incubated at room temperature for 10 minutes to stabilize 
luminescent signal. The luminescent signal was recorded on a SpectraMax M5 plate reader 
(Molecular Dynamics). The MTS viability assay utilizes 20μl of CellTiter 96® AQueous 
One Solution Reagent (Promega) into each well of the 96-well assay plate containing the 
samples in 100μl of culture medium. Plates were incubated at 37°C for 1–4 hours in a 
humidified, 5% CO2 atmosphere. The absorbance at 490nm was recorded using a 
SpectraMax M5 plate reader (Molecular Dynamics). The viability of the cells exposed to 
PRINT particles was expressed as a percentage of the viability of cells grown in the absence 
of particles. 
 The HUVEC cell line was used to investigate the uptake of RBCMs with 1, 2, 5, or 
10% crosslinker and which contained 1% fluorescein-o-acrylate as the covalently bound 
fluorescent dye. Cells were plated into 24 well tissue culture flat bottom plates 
(Corning/Costar 3526) and allowed to incubate overnight at 37°C, 5% CO2. The following 
day, particles were diluted in complete medium to obtain a final assay concentration of 
15µg/ml. 300µl of particles were then incubated with cells over a time course comprised of 
15m, 1h, 2h,4h, and 24h (37°C, 5% CO2). After cell/particle incubation, the cells were 
washed with 1X Dulbecco’s Phosphate Buffers Saline (DPBS) and detached by 
trypsinization (300µl/well). Cells were resuspended in a 1:1 solution of 0.4% trypan blue 
(TB) solution in 1X DPBS containing 10% FBS (500µl/well; total sample volume 800µl) and 
transferred to a 5 ml Falcon (352063) polypropylene round-bottom tube. This assay is based 
on the observation that, for non-internalized particles, the vital dye TB acts to quench the 
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fluorescence emission of the fluorescein bound to the particles, shifting the emission to red 
while an internalized particle will fluoresce green29. Cells were analyzed by flow cytometry 
(CyAn ADP, Dako) for green and red fluorescence. There were 10,000 cells measured in 
each sample. 
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2.4 Figures 
 
Figure 2.1.  Scanning electron microscope images of 7 µm disc PRINT particles made from 
(A) 89% PEG 428 triacrylate, 10% mPEG 1000 methacrylate and 1% DEAP photoinitiator and 
(B) 89% PEG 428 triacrylate, 10% mPEG 1000 methacrylate and 1% DEAP photoinitiator 
mixed 1:1, by weight, with PEG 550 dimethyl ether as a porogen.  The addition of porogen 
increases particle flexibility. 
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Figure 2.2.  SEM images of 7 µm diameter, discoid PRINT particles with varying amounts 
of 550 g/mol molecular weight poly (ethylene glycol) added to the pre-particle solution as a 
porogen.  The particles appear increasingly flexible, porous, and fragile as porogen content 
increases as follows: (A) 0 %, (B) 50 %, (C) 60 %, (D) 75 % and (E,F) 90 % porogen.   
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Figure 2.3.  Measuring particle deformability by filtration times through a track-etched 
membrane.  (A) A graphic showing the filtration set-up, with one port directed towards mild 
vacuum and a second port directed to the membrane apparatus.  The cut-away depicts 
particles passing through the membrane.  (B) A bright field microscope image of rigid 
particles (“No porogen”) on the membrane after filtration.  Particles are along the sides and 
bottom of the image, with the membrane and some of the 5 µm pores visible in the center of 
the image.  The scale bar is 20 µm.  (C) Filtration times for 5 mL of particle or control 
solutions through a 5 µm nucleopore track etch membrane.  Each plot represents n=4 with 
error bars as one standard deviation.   
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Figure 2.4.  SEM images of 7 µm diameter, discoid PRINT particles with varying 
deformability used in preliminary in vivo studies.  Rigid particles (A) contain no porogen 
while moderately deformable ones (B) were made with 50% (by weight) of a non reactive 
PEG porogen.  The most deformable particles (C) were made primarily with a PEG 
diacrylate monomer in lieu of the triacrylate used in A and B, and included 50% porogen as 
in B.    
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Figure 2.5.  Biodistribution of 7 µm diameter RBC mimic PRINT particles in mice as a 
function of % injected dose.  Deformability of the hydrogel particles increases from A to C 
with the addition of a porogen in series B and replacement of triacrylate monomer with 
diacrylate in addition to porogen for series C.  Particle accumulation in the tail is typical of 
tail vein injection procedures.  Major accumulation occurred in the lungs in all cases along 
with poor persistence in the blood, suggesting that no formulation was deformable enough to 
navigate the narrow capillaries found in this organ.   
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Figure 2.6.  RBCM particles.  (A) A graphical depiction of the PRINT process used to 
fabricate RBCMs.  Briefly, from top to bottom, an elastomeric fluoropolymer mold (green) 
with disc shaped wells was covered by an aliquot of the pre-polymer mixture (red).  The 
mold was passed through a pressured nip (black) covered by a high energy sheet (grey), 
wicking away excess liquid from the mold surface while filling the wells of the mold.  The 
filled mold was cured photochemically, yielding cross-linked hydrogel particles, which were 
harvested from the mold by freezing onto a thin film of 1% poly (vinyl alcohol) in water 
(blue) and peeling away the mold.  Melting of this layer resulted in a suspension of red blood 
cell mimic (RBCM) hydrogel particles.  (B-E)  Fluorescent images of hydrated RBCMs with 
varying % crosslinker (B) 10% crosslinked (C) 5% crosslinked (D) 2% crosslinked and (E) 
1% crosslinked.  Scale bars are 20µm. 
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Figure 2.7.  Modulus of hydrated samples of hydrogel as % crosslinker was varied from 1-
10%.  Additional dye (1% fluorescein-o-acrylate) was included to show the effect the 
addition of a near-IR dye to the composition for in vivo imaging applications.   
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Figure 2.8.  Discoid master templates fabricated in SU-8 on six inch silicon wafers.  Discs 
with diameters of (A) 1.5 µm, (B) 2 µm, (C) 3 µm, (D) 4 µm, (E) 5 µm, and (F) 6 µm were 
prepared with an aspect ratio of 0.3.  The scanning electron microscope images are shown at 
approximately the same scale and represent embossed films of cyanoacrylate cast from 
PRINT molds made using the appropriate masters.   
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Figure 2.9.  The dose dependant cell viability of HUVEC (endothelial) cells when dosed 
with HEA-based RBCMs with varied crosslink density (1-10%) after 72 hours of incubation 
with the particles as determined by MTS (A) and ATP/luciferase (B) assays as a percent of 
saline-dosed control. 
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Figure 2.10.  Uptake of 1, 2, 5, and 10% crosslinked RBCMs in HUVEC cells after dosing 
times from 15 minutes to 24 hours based on flow cytometry.  Results are expressed in terms 
of the percentage of cells which had taken up RBCMs (internalized) and which were free of 
RBCMs (unassociated).   
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Figure 2.11.  Microfluidic evaluation of RBCM deformability. (A) A schematic of the 
microfluidic devices.  The channel has a repeating pattern of 50 µm long pores which are 3 
µm  wide and 3.5 µm tall, forcing particles passed through the device to deform. Flow was 
driven by a syringe pump.  (B) An image sequence showing a 1% crosslinked RBCM (6.0 
µm diameter) deforming to pass through a 3 x 3.5 µm channel (25 ms between frames).  (C) 
10% crosslinked RBCMs stuck in the entrance of the 3 µm pores in a microfluidic device.  
Scale bars are 30 µm. 
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Figure 2.12.  Intravital microscopy data and compartmental analysis.  (A)  Vasculature 
highlighted with rhodamine B labeled dextran prior to injection of RBCMs.  (B) Dylight 680 
labeled 1% cross-linked RBCMs flowing through this stretch of vasculature 20 minutes after 
dosing, with ROI outlined in yellow.  (C) Colored overlay of A and B, with dextran in blue 
and particles shown in red.  Scale bars are 100 um.  (D) Two-compartment model schematic 
and governing equations for the model applied to the data. (E) Decrease in fluorescent signal 
in the ROI for the 2 hour scan in this mouse.  The semi-log plot shows calculated fit for the 
two compartment pharmacokinetic models. 
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Figure 2.13.  A standard curve which correlates fluorescent efficiency (signal intensity) and 
concentration of 1% crosslinked RBCMs in whole blood.  Deviation from linearity defines 
the lower limit of quantification for fluorescent signal.  Data collected for the blood draw 
experiments fell within the linear range of this plot.  Scale bars represent one standard 
deviation, with n=3. 
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Figure 2.14.  A plot of particle concentration in whole blood over time for 1% crosslinked 
RBCMs where n=4 for each data point.  A two compartment pharmacokinetic model with 
elimination from the central compartment was fit to the data (red) by nonlinear regression 
analysis.  The fit was used to calculate pharmacokinetic parameters for these particles.   Scale 
bars represent one standard deviation, with n=3.  
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Figure 2.15.  Biodistribution of RBCMs.  (A) Distribution of RBCMs into various tissues 2 
hours post dosing by percent recovered fluorescence normalized for tissue weight.  Error bars 
represent one standard deviation, with n=3 for each case. (B)  Lung tissue from a mouse 
dosed with 10% cross-linked RBCMs.   Particles are shown in red, with cell nuclei in purple 
and cytoskeleton (F-actin) stained green.  (C) Lung tissue from a mouse dosed with 1% 
cross-linked RBCMs, with tissue stained as in (B).  Very few RBCMs were in this tissue 
compared to mice dosed with more rigid particles, consistent with the tissue distribution data.   
Scale bars are 50 µm. 
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Figure 2.16.  A plot showing the biodistribution of 1% crosslinked RBCMs in mice over a 2-
120 hour time course in the liver, lung, spleen and kidneys.  Data is presented as fluorescent 
efficiency per gram of tissue weight.  Error bars represent one standard deviation, with n=3 
for each case.   
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Figure 2.17.  Histological analysis of spleen tissue from RBCM dosed mice.  (A) Overlaid 
image of immunostained spleen tissue from a mouse dosed with 2% cross-linked RBCMs.  
The particles (red) are primarily sequestered in the red pulp, an area of tissue which is rich in 
macrophages (green).  Cell nuclei are shown in purple.  (B) An enlarged view of the area 
indicated in (A) by a grey square. 
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Figure 2.18.  Left:  A chrome on quartz reticle designed for fabrication of master templates 
with micron sized discoid features.  Right:  Bright field microscopy images of the patterned 
sections of the reticle at 100x magnification (scale bar is 20 µm). 
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Figure 2.19.  A plot showing SU-8 film thickness as a function of weight percent solids of 
SU-8 2010 when diluted from the original 58% solids with SU-8 thinner.  Film were spin 
coated at 3000 rpm for 30 seconds.  Thickness measurements were made based on post-
exposure feature heights. 
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Pharmacokinetics and Biodistribution of Low Modulus Hydrogel Particles 
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3.1 Introduction 
Crosslinked hydrophilic polymers called hydrogels possess a number of properties 
which make them an important class of biomaterials for use in biotechnology and medicine.  
The presence of chemical crosslinks in these polymer networks render the hydrophilic 
polymer components insoluble in water, providing structure and physical integrity to the 
gels1.   Because of the hydrophilic nature of their constituent polymers, hydrogels can swell 
to encompass large amounts of water without dissolution 2.  The high water content of 
hydrogels makes them soft and rubbery; physical characteristics similar to those of soft 
tissues 3.  Many hydrogels exhibit excellent biocompatibility, likely as a result of their high 
water content, causing minimal inflammatory responses, thrombosis, and tissue damage1,4-6.  
The swollen structure and porous nature of hydrogels gives them high permeability to 
oxygen and water soluble metabolites - appealing attributes for use in contact lenses, and 
other membrane-related applications 7.  Hydrogels have several advantageous properties 
which are being exploited for medical applications to direct behavior of the gel in vivo.  
Many hydrogel properties are controlled to a large extent by the crosslink density of the gels, 
including the swelling, cargo release profile and stiffness of the gels 2,8.  Because of these 
properties and their facile control, hydrogels of a range of structures have found use in 
medical applications ranging from biosensor coatings 9,10, drug delivery agents 2,8, and tissue 
engineering 11.   
 Recently, increasing attention has been given to the fabrication and characterization 
of extremely deformable hydrogel particles, with many studies demonstrating the role played 
by particle deformability in the interaction of particles and biological systems.  In a study 
using poly acrylamide microparticles crosslinked with either 0.2 % (rigid) or 0.05 % (soft) 
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bisacrylamide, macrophages showed a strong preference for phagocytosis of rigid particles 
versus soft ones, suggesting that macrophages may use the rigidity of a particle as an 
indicator to initiate phagocytosis12.  A study comparing hydrogel particles with their 
elasticity (Young’s modulus) varied by changing crosslink density found that the endocytotic 
mechanism was dependant on the elasticity of the nanoparticle, with softer particles 
internalized preferentially by macropinocytosis while hard-sphere uptake involves clathrin-
mediated routes13.   Low modulus microgel particles were able to traverse pores which were 
1/10 their diameters under pressures relevant to renal filtration, suggesting a clearance 
mechanism for deformable nanoparticles14. Microparticles resembling red blood cells were 
more readily able to traverse microfluidic channels which mimicked the constrictions of 
capillaries when crosslink density was lowered15,16.   
Our previous work demonstrated that hydrogel particles based on lightly crosslinked 
2-hydroxyethyl acrylate (HEA) which resembled red blood cells in size and shape with 
decreasing crosslink density had dramatically altered behavior in vivo in a mouse model.  
Particles made from this hydrogel material with a Young’s modulus of 7.8 kPa were 
eliminated from the circulation over 30 times slower than particles which were only 
moderately (approximately 8x) stiffer (63.9 kPa), presumably due to avoidance of filtration 
in the capillary beds of the lungs, and to some extent, the spleen16.  The most elastically soft 
particles demonstrated the ability to deform to bypass physical barriers encountered in the 
circulation.  Because even slightly less elastic particles (modulus of 16.9 kPa) had greatly 
reduced circulation times, a modulus-based threshold for 6 µm diameter particles to avoid 
filtration in vivo was inferred.  
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While flexible particles have been shown to have some advantageous in vivo 
properties, relatively few studies have focused on the in vivo behavior of very deformable 
particles.  The rigidity of hydrogels is typically tuned by adjusting the amount of crosslinker.  
While this method provides fairly facile control of hydrogel modulus, increased swelling 
with decreasing crosslink density results in difficulty in maintaining identical particle size 
and size distribution with changing crosslink density for most particle fabrication methods3.  
However, with the PRINT® (particle replication in non-wetting templates) method, the size 
and/or shape of the elastomeric molds can be varied to maintain the size of hydrated particles 
made with varying compositions. In this study, the behavior of monodisperse populations of 
extremely soft hydrogel particles was probed as particle size was varied in the micron range 
while composition and modulus were maintained as constants.  
Herein the in vivo behavior of lightly crosslinked hydrogel particles with identically 
low modulus were examined as particle size varies.  A series of acrylic monomers with short 
PEG side chains were fabricated to facilitate particle making with the PRINT process and for 
the fabrication of low modulus hydrogels.  It was determined that a PEG chain length of 
three repeat units, derived from triethyleneglycol, yielded crosslinked hydrogels with optimal 
properties.  This monomer was used to fabricate PRINT particles from 1, 2 and 3 µm 
diameter molds.  Using the mechanical properties of the longest circulating, HEA-based 
hydrogels from Chapter 2 as a target (elastic modulus ~8 kPa), hydrogel particles were 
fabricated via the PRINT® method with a similarly low modulus.  The in vivo circulation 
profile and biodistribution of these extremely deformable particles was examined.   
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3.2 Results and Discussion 
3.2.1 Hydroxy PEG Acrylate Monomers 
   While previous work focused on low modulus (<10 kPa) hydrogels based on HEA, 
this monomer was less than ideal for the PRINT process when translated to smaller sized 
molds.  Small molecule monomers have the potential to interfere with the efficacy of particle 
molding methods like PRINT in two main ways.  Solvent absorption into the mold material 
may cause a change in the size of the mold due to swelling of the mold material, and may 
also cause significant underfilling prior to the curing step.  However, due to the fluorinated 
nature of the mold material used in the PRINT process, HEA is not absorbed to a significant 
extent, and this mechanism was unlikely to have an effect17.  When particle size decreases, 
the surface area to volume ratio of the mold features increases, allowing evaporation to 
become a factor.  Evaporation of the monomer would lead to underfilled molds and an 
increase in non-volatile components in the preparticle mixture (such as the PEGDA 
crosslinker).  Thus, particles consisting primarily of HEA were only successfully molded 
with diameters of 2 µm or greater while using chilled equipment to mediate evaporative 
effects16.  An increase in the molecular mass of the monomer serves to decrease this 
evaporative effect through a reduction of the vapor pressure of the monomer.  
 To increase the molecular weight of the monomer, PEG modified acrylics (HPAs) 
were synthesized with varying short-chain (n= 2, 3, or 4) PEG groups, essentially extending 
the side-chain of a HEA-like acrylic (Figure 3.1).  Rigorous purification of the HPA 
monomers was necessary to remove all of the diacrylate crosslinker, and cold storage ensured 
that the transesterified diacrylate did not reform in situ.  The properties of crosslinked 
hydrogels derive not just from the crosslink density of the gels, but also from the properties 
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of the main-chain polymer and the amount of water uptake or swelling2.  As the PEG side-
chain grows in length, the steric bulk should begin to hinder the rotation of the polymer, 
rendering it stiffer.  In terms of water uptake, as the PEG character of a gel increases, the 
hydrophilicity of the gel should increase as well.   
To determine the mechanical properties of the bulk hydrogels, bulk samples were 
hydrated in deionized water overnight.  The mechanical properties of the hydrated hydrogels 
were determined using an Instron 5556 Universal Testing Machine (Instron) with a strain rate 
of 5 mm/min.  Bulk samples of hydrogels made with 1% PEG4000Diacrylate crosslinker 
(PEG4000DA) and the HPA derived from triethylene glycol (HP3A) provided the lowest 
modulus HPA hydrogels (Table 3.1).  Though HP4A hydrogels should have a greater 
hydrophilic character than HP3A hydrogels, the longer PEG chain resulted in decreased water  
Monomer  E (kPa) 
% 
strain at 
break 
Swelling 
ratio, 
weight 
Swelling 
ratio, 
length 
HEA  
 
10 ± 1.6 270 13.6 2.9 
HP2A  
 
103 ± 8.6 60 5.8 1.9 
HP3A  
 
20 ± 1.7 83 10.9 2.4 
HP4A  
 
36 ± 4.8 52 8.8 2.2 
Table 3.1.  Properties of lightly crosslinked hydrogels composed of different acrylic 
monomers containing 1% of a 4,000 g/mol PEG diacrylate crosslinker and 1% of HCPK 
photoinitiator, hydrated for 12 hours in deionized water at room temperature.  Monomers 
are shown with increasing PEG chain length. 
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uptake.  This may be an effect of increased stiffness of the main chain making 
unentanglement, and greater swelling, difficult.  Interestingly, HEA hydrogels, though 
incompatable with PRINT at smaller particle sizes, had the most desirable properties, with 
lower modulus and greater elasticity than the HPA hydrogels.     
 
3.2.2 Low Modulus HP3A Hydrogels 
  Based on previous work with low modulus hydrogels16, an elastic modulus of < 10 
kPa was targeted for HP3A based hydrogels, requiring a drop in crosslink density compared 
to the hydrogels used to evaluate the effect of PEG side-chain length.  With deformability 
similar to that of red blood cells (15-26 kPa)18,19, a modulus in the  
target range should be sufficient to show a large effect on particle circulation with 6 µm 
diameter particles.  An acid containing monomer (2-carboxyethyl acrylate, CEA) was 
included in the hydrogel monomer mixture at 10 % (by weight) to give the particles a 
negative charge, thereby decreasing non-specific particle uptake20.  Bulk samples of HP3A 
hydrogels containing 10% CEA monomer, 1% 1-hydroxycyclohexyl phenyl ketone 
photoinitiator and crosslinked with PEG4000DA were hydrated in pH 7.4 PBS to simulate 
physiological conditions and tested with the Instron tensometer (Table 3.2).  Hydrogels with 
0.05% PEG4000DA crosslinker had the desired properties, with a Young’s modulus of 6.5 ± 
1.3 kPa.    
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% crosslinker (weight) 1 0.5 0.05 
E (kPa) 17 ± 2.2 13 ± 1.6 6.5 ± 1.3 
% strain at break 53 ± 19 46 ± 7 43 ± 7.5 
Swelling ratio (wt) 11.9 12.8 30.0 
Swelling ratio (length) 2.4 2.6 3.5 
Table 3.2. Mechanical properties of hydroxyl PEG3 Acrylate (HP3A) hydrogels with 
varying amounts of PEG4000diacrylate crosslinker and 10% of 2-carboxyethyl 
acrylate.  Swelling ratios were determined from one bulk sample hydrated for 24 
hours in PBS.  Modulus and strain at break represent an average value determined 
from three samples cut from the bulk gel, with error representing one standard 
deviation.     
 
3.2.3 Fabrication and Characterization of HP3A Hydrogel PRINT Particles 
  HP3A hydrogels containing 10% CEA monomer, 1% 1-hydroxycyclohexyl phenyl 
ketone (HCPK) photoinitiator, 0.05% PEG4000DA crosslinker, and fluorescent dyes, 
including 1% Dylight 680 maleimide for in vivo imaging, and 0.1% methacryloxyethyl 
thiocarbonyl rhodamine B for ease of particle analysis (Table 3.3). Particles were fabricated 
using PRINT molds with feature diameters of 1, 2 and 3 µm, resulting in hydrated diameters 
of 3.79 ± 0.17, 6.39 ± 0.56, and 8.88 ± 0.47 µm in PBS, respectively (Table 3.4).   
Monomer (%) 
HP3A 87.85 
2-carboxyethyl acrylate 10 
PEG 4000 Diacrylate 0.05 
1-hydroxycyclohexyl phenyl ketone 1 
methacryloxyethyl thiocarbonyl rhodamine B 0.1 
Dylight 680 maleimide 1 
 
Table 3.3. The composition of hydrogel particles fabricated for in vivo work.   
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Fluorescent microscopy was used to measure the diameter of hydrated particles (n=50).   The 
zeta potential of the particles was approximately -20 mV in all cases.  The particles were 
suspended in 0.1% 2,000 g/mol poly (vinyl alcohol) in PBS for in vivo applications.  
Fluorescent images of the particles can be seen in Figure 3.3. 
Mold diameter Particle Diameter Zeta Potential 
1 µm 3.79 ± 0.17 µm -22.1 ± 5.7 mV 
2 µm 6.39 ± 0.56 µm -17.6 ± 10.8 mV 
3 µm 8.88 ± 0.47 µm -22.9 ± 7.47 mV 
Table 3.4.  Characterization of particles fabricated for in vivo studies.  Particle 
diameters were determined by microscopy.  Error represents one standard deviation 
from the mean with n=50 for particle diameters. 
 
3.2.4 In vivo Studies 
To examine the distribution and clearance profile of the particles, female Balb/c mice 
were injected intravenously at a dose of 20 mg particles/kg of body weight.   The mice were 
sacrificed at time points of 0.2, 0.5, 1, 3, 7, 25, 56, and 104 hours post-dose and the tissues 
analyzed for fluorescent signal from the particles (Figures 3.4 and 3.5).  The tissues were 
not perfused prior to analysis. 
The smallest particles (hydrated diameter 3.8 µm) distributed primarily into the 
spleen and lungs immediately after injection.  While signal in the lungs decreased after 
injection, signal in the spleen increased, peaking at 3 hours and staying fairly constant or 
slightly decreasing over the next 101 hours.   These particles accumulated to some extent in 
the liver over the course of the study, with signal peaking 24 hours after injection and 
decreasing slightly thereafter. Liver accumulation was minor when viewed on a per gram 
basis (Figure 3.4).  Accumulation in the kidneys, heart, and muscle tissue remained low at 
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all times, decreasing over the course of the scan, possibly due to the small amount of blood 
remaining in these tissues.  Particles were cleared to low, but still measurable, levels in the 
blood by the final time-point examined, with 2.9% of the injected dose in the blood at 104 
hours.   
Particles with 6.4 µm diameters distributed primarily into the spleen and lungs 
immediately after injection with a profile similar to what we observed in previous studies 
with low modulus particles of this size16.  Signal in the lungs decreased after injection to low 
levels.  Signal in the spleen and liver increased after injection, with signal in the spleen 
peaking at 3 hours and the signal in the liver peaking later, 7 hours after injection. Signal in 
the spleen dipped at the 24 hour time-point, correlating to an increase in signal in the blood.  
This effect may have been due to the release of particles from the spleen back into the 
circulation.  Accumulation in the kidneys, heart, and muscle tissue remained low at all times, 
decreasing over the course of the scan, possibly due to the small amount of blood remaining 
in these tissues.  At the final time-point examined, 104 hours post-dose, 9.2% of the injected 
dose remained in the blood.    
The largest particles, with hydrated diameter of 8.8 µm, were sequestered primarily in 
the lungs after injection, likely due to their large size compared to the diameter of the 
capillary beds in this tissue, and only low amounts of particles remained in the circulation. 
Particles cleared from the lungs over the course of the study, with accumulation in the spleen 
and liver increasing over time.   Liver accumulation was the most significant for these larger 
particles compared to the other sizes examined, especially when viewed on a per gram basis.  
As with the 6.4 µm diameter particles, a dip in the amount of particles in the spleen and a 
corresponding increase in the blood occurred.  For these larger particles, this effect was more 
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dramatic, and happened earlier in the study (7 hours post-dose).  These particles were cleared 
from the blood to below their lower limit of quantification after the 7 hour time point (< 4.4 
% of the injected dose).   
 
3.2.5 Pharmacokinetics of Particle Clearance from Blood 
 Particle concentration in the blood was determined from blood drawn via cardiac 
puncture at each time-point.  Serial dilutions of particles in freshly drawn mouse blood 
allowed for the generation of standard curves which correlated fluorescent signal in whole 
blood to particle concentration.  The signal from blood harvested from dosed mice fell within 
the linear region of these plots in most cases, with late time-points falling below 
quantification limits (where the plot deviated from linearity) for the case of the 8.8 µm 
particles.  A plot of particle concentration in whole blood over time for the three particles is 
shown in Figure 3.6. 
 To evaluate the kinetics of clearance for the 3.8 and 6.4 µm diameter particles, we 
used a two compartment pharmacokinetic model, characterized by a bi-exponential decrease 
in particle concentration over time 21, with parameters fit by non-linear regression analysis 22.  
This model describes an initial (distribution) phase where the particles distribute from the 
plasma into various tissues, followed by a late (elimination) phase that describes the ultimate 
clearance of particles from the plasma.  For small molecules and nanoparticles the 
distribution is attributed to extravasation into tissue; because of their size, the distribution of 
our hydrogel microparticles may be due to physical entrapment in constricted capillaries (as 
in the lung) or tissues with low blood flow (such as the spleen) rather than by an 
extravasation process.   
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Both particles had similar pharmacokinetics of clearance, with much of the dose 
distributing to tissues rapidly after injection and slow elimination half-lives.  Elimination 
half-life (βt1/2) for 3.8 µm particles (59.55 h) was shorter than for the red blood cell- 
(RBC) sized 6.4 µm particles (85.49 h), suggesting that this size may crucial to the long 
circulation times of RBCs.  Additionally, the area under the curve (AUC), was more than 3 
times greater for the RBC sized particles than the smaller hydrogels (8.513 and 2.498 
mg*hr/mL, respectively), indicating that a greater amount of particles stayed in the 
circulation over time.   Parameters calculated with this model can be seen in Table 3.5.   
The circulation profile of the largest particles examined in this study (8.8 µm) was not 
analyzed with a pharmacokinetic model because these were rapidly cleared below the limits  
Particle Diameter (µm) 3.79 ± 0.17 6.39 ± 0.56 
A (mg/mL) 0.152 0.109 
B (mg/mL) 0.0268 0.0682 
α (hr-1) 0.765 1.076 
β (hr-1) 0.0116 0.00810 
αt1/2 (hr) 0.906 0.644 
βt1/2 (hr) 59.551 85.488 
VC (mL) 2.248 2.262 
AUC (mg*hr/mL) 2.498 8.513 
CLT (mL/hr) 0.160 0.0470 
Vdβ (mL) 12.684 5.727 
Table 3.5.  Pharacokinetic parameters for low modulus hydrogel PRINT 
particles with increasing diameters.  Parameters were determined from particle 
concentration in whole blood at times 0.2 -104 hours post-dose using a 
standard two-compartment model according to the equation C= Ae-αt +Be-βt 
where C is the concentration of particles in blood, t is time post-dose.    
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of quantification, leaving too few data points for such analysis.  These particles did not 
appear as if their clearance profile would fit well to a standard pharmacokinetic model due to 
the increase in particle concentration in blood at 3 and 7 hours, the explanation of which may 
require the application of more complicated  models23.  
 
3.3 Conclusions and Future Work 
 The above studies have shown the promise of HPA based hydrogels for PRINT 
applications where extremely low modulus particles are desired.  Hydrogels made from 
HP3A were fabricated over a physiologically relevant range of modulii by varying the 
amount of PEG4000DA crosslinker. Low modulus (E=6.5 kPa) RBC-like microparticles 
fabricated with HP3A demonstrated long elimination half-lives which we attribute, in part, to 
their deformability.  Using this material, we were able to fabricate particles which were 
larger (8.8 µm) and smaller (3.8 µm) than RBCs, and saw evidence that particles of both 
sizes avoided physical sequestration as a result of their ability to deform.   
 Further reduction of particle size to less than a micron with similarly low modulus 
should follow the above studies.  Reduction of particle size should allow for more facile 
avoidance of splenic and other filtration mechanisms, possibly leading to extended 
circulation times.  The HP3A monomer has a low vapor pressure compared to HEA and has 
very little evaporation when used in the PRINT process.  Initial attempts to fabricate particles 
from 200 nm molds with 1% PEG4000DA crosslinked HP3A appeared successful (Figure 
3.7).   
Much attention has been given to the potential of nanogels as pharmaceutical carriers 
due to their biocompatibility and potential for stimuli responsive cargo release2.  HPA 
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particles should show promise in this area, particularly for the encapsulation and release of 
macromolecular cargos, due to the high amount of swelling and the resultantly large pore 
size of these gels.  The inclusion of labile bonds into long-chain crosslinkers could facilitate 
cargo release from these gels.  For example, acetal groups are stable ar pH 7, but hydrolyze 
rapidly at acidic (pH =5) endosomal pH, resulting in cargo release in the endosome24.  
Disulfide-functionalized crosslinkers degrade in response to the presence of glutathione 
inside of cells, and may be a promising strategy for cargo release25.  Derivatives of the silane-
based, pH sensitive crosslinkers developed by Parrott, et al. in our laboratory may also be 
useful, especially due to the ease with which the degradation rate can be adjusted by 
changing the pendant groups on the silyl moiety26. 
 The ability of lightly crosslinked, charged hydrogels to incorporate 
biomacromolecules of the opposite charge should be a focus of future study.  In cases where 
the biomacromolecule and the hydrogel particle are oppositely charged, the components form 
a polyelectrolyte complex, with loading often proceeding throughout the gel rather than 
restricted to the surface2.   For example, cytochrome c, a cationic heme protein, was loaded 
efficiently into poly (acrylic acid)/PEG particles, with cargo release triggered by exposure to 
Ca2+ ions or acid27.   
For the fabrication of HPA hydrogels with high acid content, it may be desirable to 
synthesize a higher molecular weight, acid functional monomer.  The monomer used in the 
current study, 2-carboxyethyl acrylate, suffers from some of the same volatility-based 
limitations as HEA.  The extension of the PEG spacer in this monomer by one or two 
ethylene oxide units may allow for particles with higher acid content without any monomer 
evaporation.   
 98 
 
 
3.4. Materials and Methods  
3.4.1. Materials  
Acryloyl chloride (97%), diethylene glycol (99%), triethylene glycol (99%), 
tetraethylene glycol (99%), and 2-carboxyethyl acrylate (CEA, 97%) were purchased from 
Sigma-Aldrich and used as received.  Photoinitiators 2,2-diethoxyacetophenone (DEAP), and 
1-hydroxyl-cyclohexyl phenyl ketone (HCPK) were purchased from Aldrich and used as 
received.  Poly(ethylene glycol) diacrylate (PEG4oooDA) and methacryloxyethyl 
thiocarbamoyl rhodamine B (PolyFluor 570) were purchased from Polysciences, inc. and 
used as received.  Dylight 680 maleimide was purchased from Thermo Scientific.  All other 
reagents were purchased from Fisher and were used without further purification unless 
otherwise noted.       
 
3.4.2 Synthesis of Hydroxy PEG Acrylate Monomers 
 Mixtures of hydroxy PEG acrylate and hydroxy PEG diacrylate were obtained by 
reaction of di-, tri-, or tetraethylene glycol and acryloyl chloride in anhydrous 
dichloromethane under a nitrogen purge with triethylamine present as a scavenger for HCl 
evolved during the reaction.  In order to obtain a higher ratio of monoacrylate to the 
diacrylated product and a good yield, a 7:3 ratio of  di-, tri-, or tetraethylene glycol to 
acryloyl chloride was used28.  Addition of acryloyl chloride proceeded over 3 hours at room 
temperature, with stirring allowed to proceed for another 12-15 hours.  The ammonium 
chloride salts were removed via filtration.  The filtrate was washed several times with 
deionized water to extract the glycols and monoacrylates.  The aqueous phase was washed 
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several times with diethylether to extract the monoacrylate.  The ether washes were reduced 
by rotary evaporator in vacuo, and the product isolated via column chromatography.  The 
product was eluted using a mixture of hexane, ethyl acetate and methanol in a 6:3:1 ratio.  
Free radical inhibitor 4-Methoxy Phenol (MEHQ) was added to the product fraction at 500 
ppm of total acrylates prior to exhaustive vacuo rotoray evaporation to remove all of the 
residual solvent yielding a clear, colorless to pale yellow liquid.   The acrylic monomers are 
referred to as hydroxyl PEG acrylates, with the length of the PEG chain attached to the 
acrylic moiety denoted by number.  For example, HP4A refers to the tetraethylene glycol 
adduct, while HP2A refers to the diethylene glycol adduct.   
 
3.4.3 Purification of HPA Monomers 
 Normal column chromatographic purification techniques were sufficient to produce 
reasonably pure HPA monomers (>95% purity by NMR).  However, even trace impurities 
had measurable effects on the properties of the hydrogels fabricated with these monomers.  
As such, special care was taken to remove all possible impurities.   
First, the separation of the mono- and diacrylate products by column chromatography 
required careful attention.  It was necessary to take small volume fractions, especially 
between these two products, to ensure that no diacrylated byproduct remained to contaminate 
the HPA fractions.  Moderately overloading a TLC plate allowed for more sensitive detection 
of this impurity than NMR spectroscopy.   
Removal of solvent from the chromatographic fractions also proved somewhat 
problematic.  Residual solvent in the HPA monomers caused hydrogels made from these 
samples to be softer, and less tough than those made from “neat” monomers.  While this 
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effect was easily remedied by increasing the temperature and duration of the rotary 
evaporator, this tends to cause some of the monomer to polymerize.  The presence of 
polymer in the solvent free HPA monomer can easily be determined by a qualitatively 
noticeable increase in monomer viscosity.  Polymer formed in this way tends to act as a 
porogen in crosslinked hydrogels, changing the mechanical properties.  Polymerization can 
be avoided with the addition of a free-radical inhibitor at low concentration (250-500 ppm) 
prior to rotary evaporation.    
HPA monomers were stored in the freezer (-20 ºC) and were warmed to room 
temperature prior to opening, as the monomers appear to be somewhat hygroscopic.  It 
became apparent that, over time, diacrylate crosslinker was being generated in solution.  This 
was most readily apparent in particles made from older or improperly stored HPA, where the 
hydrated diameters were smaller than expected.  This was attributed to an ester hydrolysis-
based mechanism, as pre-particle mixtures containing an acidic co-monomer (2-carboxyethyl 
acrylate) which was capable of catalyzing ester hydrolysis showed this effect more rapidly.  
Proper storage of the monomer for up to 3 months (at -20 ºC in aliquots to prevent repeated 
exposure to the atmospheric moisture) resulted in reproducible particle diameters.   
 
3.4.4 Modulus Testing 
To measure the mechanical properties of crosslinked HPA hydrogels, macroscopic 
coupons of the prepolymer mixtures were polymerized via UV light in a Teflon mold.  
Approximately 650 µL of freshly prepared prepolymer mixture was pipette into a 2.5 x 2.5 
cm square mold.  The mold was placed in a low-intensity UV oven, and nitrogen purged for 
3 minutes prior to curing.  The low intensity oven was used to minimize the heat generated 
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from the UV light.  The coupons were cured for 5 minutes, allowed to cool for 3 minutes, 
then cured for an additional 3 minutes.  The cross-linked hydrogels were removed from the 
mold, weighed, and placed in pH 7.4 PBS buffer for 24 hours to fully hydrate.  The coupons 
were patted dry with paper towels and weighed again prior to sectioning into approximately 
10 mm wide strips with a razor blade for testing with an Instron 5556 Universal Testing 
Machine (Instron) with a strain rate of 5 mm/min.  Young’s modulus was determined from 
the initial slope of the resultant stress-strain curves.   
 
3.4.5 Particle Fabrication 
 Particles were fabricated using the PRINT (particle replication in non-wetting 
templates) process17,29.  PRINT molds for these studies were fabricated by Liquidia 
technologies and consisted of a thin layer of a patterned, photocured perfluoropolyether 
(PFPE) on top of a flexible poly(ethyleneterephthalate) (PET) backing.       
To fabricate particles, the pre-polymer mixture was spread onto a mold which was 
taped to a silicon wafer and chilled to 2-5°C on a custom built laminator platform.   The 
reduced temperature prevented evaporation of the pre-polymer solution prior to photo-curing.  
A PET sheet was laminated to the top of the mold and pre-polymer solution, wetting the total 
mold area.  The sheet was peeled away at the nip point of the laminator, leaving the wells of 
the mold filled while wicking away excess solution.  The filled mold was immediately 
transferred into a chilled (~5°C), nitrogen purged UV oven and cured with UV light 
(λ=365nm, 3 minutes, power ~ 20 mW/cm2). 
 Particles were transferred from the mold by laminating the filled, cured molds to a 
PET sheet which was coated with a thin film of luvitec (BASF).  The particle-filled mold and 
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luvitec coating were placed in contact and passed through the nip point of a laminator.  To 
increase the yield of harvested particles, a heated laminator was used for this step, with roll 
temperatures hot enough to allow the luvitec to flow and come into contact with the particles 
(typically >180 ºF).  Alternatively, it was possible in some cases to transfer the particles 
without added heat due to “sticky” adhesion of the particles to the luvitec film.   After 
cooling briefly, the mold was peeled away from the luvitec sheet at a steep angle, leaving the 
particles on the luvitec film in an ordered array.   
 Harvesting of the particles from the ordered array on luvitec into solution was 
accomplished by “bead harvesting”.  In this process, the particles on the harvesting film are 
passed through the vertical nip point formed by two rollers.  At the nip point, a bead of water 
dissolves the luvitec layer, suspending the particles in solution, as the rollers slowly draw the 
film down through the nip.  Streams of air are directed to either side of the bead of water to 
maintain it in the correct position to collect the particles.  The particle solution can then be 
collected with a pipette with a fine tip.   
 
3.4.6 Particle Harvesting and Purification 
The bead harvesting process leads to well stabilized particles, but leaves an 
abundance of dissolved luvitec in solution.  The particles were pelleted via centrifugation at 4 
ºC (12,000 rpm, 5-10 minutes depending on particle size) and the supernatant removed 
carefully so as not to disturb the pellet.  The pellet was resuspended in a solution of 0.1% 
poly(vinyl alcohol) in Dulbecco’s pH 7.4 PBS buffer (Fisher Scientific) and this procedure 
was repeated 2-3 times to remove excess luvitec and any soluble fraction of poly(HPA) or 
unreacted monomers.   
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It is worth noting that tangential flow filtration (TFF), which has been suggested to be 
a promising and gentle method for purifying particles without causing aggregation17, proved 
a poor choice for these particles.  In TFF filtration systems such as KrosFlo (Spectrum 
Laboratories, Inc.), particle solutions traveled tangentially to the membrane, effecting both 
diafiltration and concentration of particles while mediating particle loss due to adsorption to 
the membrane as a result of the indirect nature of the interaction. However, in this case, high 
pressures were required once the particle solution became concentrated, resulting in the mass 
fragmentation of the particles from the high shear stress.   Centrifugation was gentler, with 
little or no particle fragmentation, and yielded stable particle dispersions, perhaps because of 
the high water content of the particles or the stabilizing presence of the luvitec and the 
poly(vinyl alcohol).   
 
3.4.7 Particle Characterization 
 To accurately determine particle concentration, thermogravimetric  
analysis (TGA) was used.  To determine the weight of salts and polymer in the solution, 50 
µL of the particle solution was centrifuged exhaustively (14,000 RPM/20 minutes) to pellet 
the particles.  The supernatant (20 µL) was pipetted to a tared TGA pan and the weight was 
monitored on a Perkin Elmer Pyris 1 TGA under the following heating steps: 25-115 ºC by 
10 ºC/minute followed by a 10 minute hold to drive off the water in the solution. The dried 
sample provided the weight of salts and dissolved polymer in solution. In parallel, a 20 µL 
sample of the particle solution was analyzed under identical conditions, with the particle 
weight determined by subtracting the weight of salts and polymer in solution from this final 
weight.   
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 Particles dimensions were determined by analysis of images from a microscope 
mounted camera (Zeiss AxioCam MRm) using a 100x objective (Zeiss Axio Imager D.1M).  
Over 50 fully hydrated particles in pH 7.4 PBS buffer were measured for each case.  Zeta 
potentials for particles were measured on a nano ZS zetasizer (Malvern Instruments) in 
water.   
 
3.4.8 In vivo Studies 
 To track the pharmacokinetics and biodistribution of particles in mice, 20 mg 
particles/kg mouse weight was administered via a 2.0 mg/mL solution of particles in PBS 
with 0.1% poly(vinyl alcohol) via tail-vein injection to female BALB/c mice of 20-22g body 
weight.  Four mice were examined at each time-point, including points 0.2, 0.5, 1, 3, 7, 24, 
56, and 104 hours post injection.  At each time point examined, mice were sacrificed and 
tissues harvested.  Harvested tissues included the lungs, liver, kidneys, spleens, heart and a 
posterior leg (thigh) muscle.  Blood was collected via terminal cardiac puncture.  Control 
mice were undosed.   
 
3.4.9 Biodistribution 
The fluorescent signal from the particles in the tissues and blood was measured using 
an IVIS Lumina fluorescent imager (Caliper Life Sciences) with excitation at 675 nm and 
emission measured at 720 nm.    Blood was pipetted in 100µL aliquots to black 96 well plates 
for analysis on the IVIS Lumina imager, with blood measured in triplicate for each mouse.  
Harvested tissues were not perfused.  Tissues were weighed after imaging, and 
biodistribution was expressed as a function of fluorescent signal per gram of tissue weight.   
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3.4.10 Pharmacokinetics of Particle Clearance from Blood 
For determination of pharmacokinetic parameters including alpha and beta half-lives, 
a two-compartment model was fit to the data using nonlinear regression analysis.   The two 
compartment model, which was described in Chapter 2, assumes that particles are transported 
between the central and peripheral compartments with first-order kinetics and that particles 
are eliminated from the central compartment with first-order kinetics.  o Equation 3.1, was 
applied to the data where C is the concentration of the particle in the blood, and α and β are 
rate constants for the distribution and elimination processes, respectively.   Further details of 
the pharmacokinetic analysis can be found in Chapter 2, section 2.3.16. 
t tC Ae Be β−α −= +                                                      Equation 3.1 
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3.5 Figures 
 
 
 
Figure 3.1.  Synthetic scheme for hydroxyl PEG acrylates (HPAs).  The structure of the 
monoacrylated products are shown below the reaction scheme, along with the naming 
convention.   
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Figure 3.2.  Fluorescent images of the particles used for the in vivo studies.  The particles 
have hydrated diameters of (A) 3.79 ± 0.17 µm, (B) 6.39 ± 0.56 µm, and (C) 8.88 ± 0.47 µm.   
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Figure 3.3.  Biodistribution of extremely deformable particles of different sizes in mice over 
the course of several days.  These semi-log plots show the percent of fluorescent signal 
normalized per gram of tissue weight.  Four mice were examined per time-point, with error 
bars representing one standard deviation.   
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Figure 3.4.  Biodistribution of low modulus hydrogel particles of different sizes in mice in 
terms of total fluorescence signal (fluorescence efficiency) in each tissue.  Fluorescence in 
blood was measured in 100 µL aliquots and adjusted to account for the total blood volume of 
each mouse.  Four mice were measured per time point.  Error bars represent one standard 
deviation.   
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Figure 3.5.  A plot showing the change in particle concentration in blood over time for 
particles of different sizes.  Particles with a diameter of 6.4 µm, similar to that of mouse red 
blood cells, were cleared more slowly than both larger and smaller particles with identical 
mechanical properties and composition.  The concentration of the largest particles, with a 
diameter of 8.8 µm, fell to below the lower limits of quantification after 7 hours post-
injection.    
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Figure 3.6.  SEM images of 200 nm particles made from 1% PEG4000DA crosslinked HP3A.  
The particles are on a harvesting film after transfer from the mold.  A scratch in the 
harvesting film (top right corner of both images) illuminates the deformability of these 
particles where they were disturbed as the scratch was made.     
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Cationic Microgel Particles for Identification of Cancer Biomarkers 
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4.1 Introduction to miRNA as Cancer Biomarkers 
 Taken together, all forms of cancer were projected to account for more than 1,500 
deaths per day in the US  in 20101.  Although much progress has been made towards 
understanding cancer biology in the past decade, our progress towards early detection and 
screening for cancers has been considerably less successful2.  Early detection of cancer, an 
essential step towards improving treatment regimes, requires the discovery and development 
of sensitive and specific indicators, or biomarkers, of the disease.  The recent discovery of 
cancer cell dysregulation of microRNAs (miRNAs) has pushed them forward as potential 
biomarker predictors of cancers, as well as therapeutic targets.  These small (20-25 
nucleotides), endogenous, non-coding RNAs discovered in 1993 negatively regulate gene 
expression and govern cellular processes.  Aberrant expression of miRNA has been 
implicated in the pathogenesis of most human cancers2.  Several characteristics of miRNA 
point towards their use as tumor markers, including their stability, tissue specificity, and ease 
of detection.  As such, miRNAs are obvious and promising candidates as diagnostic and 
predictive indicators for cancer.   
 Identification of miRNA may be complicated by the presence of ribonucleases in the 
blood which act to decrease the concentration of available miRNA biomarkers in the 
circulation, thereby reducing the sensitivity and prognostic efficacy of such an assay3.  
Complexation with, or encapsulation of, these oligomeric nucleic acids before they are 
degraded in the circulation by polymers should protect them from nuclease-based 
degradation, allowing for more sensitive detection4,5.  The formation of polyelectrolyte 
complexes with oligonucleotides has been shown to protect from nuclease-based 
degradation6.  The capture and protection of miRNAs associated with cancers, followed by 
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recovery of these miRNAs for analysis, would be a compelling approach to the earlier, and 
less invasive, detection of miRNA associated cancers. A highly porous and deformable 
polycationic microgel should bind to and protect the negatively charged, and transiently 
available, miRNAs in the circulation.  Upon recovery of these microgels from the blood they 
could be isolated from nuclease-containing blood components via cell lysis.  Subsequent 
desorption of the bound miRNA should allow for identification of biomarkers at high 
sensitivity.         
Here we present a strategy for the identification of transiently available miRNA 
biomarkers from the circulation for the purpose of identifying biomarkers of cancer.  
Cationic red blood cell-mimicking hydrogel PRINT particles (CRBCMs) with low modulus 
should have extended circulation times as a result of high deformability7.  Surface 
modification of these CRBCMs via PEGylation with large (20 kDa) PEG yielded a core-shell 
structure with a slightly negative overall zeta potential and a highly porous, cationic core.  
These porous core particles demonstrated a generous capacity for binding to miRNAs and 
may be able to protect them from nuclease-based degradation.  Such a strategy may be able 
to capture and protect transiently available miRNA biomarkers for cancers, potentially 
providing for the discovery of novel biomarkers and for increased sensitivity for the 
detection of known miRNA biomarkers, thus potentiating early detection of the disease. 
 
4.2 Results and Discussion 
4.2.1 Low Modulus Cationic Hydrogels 
To test this theory, low modulus hydrogels were fabricated with the inclusion of 2-
aminoethyl methacrylate (AEM) to provide the gels with a positive charge (Table 4.1).  Bulk 
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samples of hydrogels composed primarily of 2-hydroxyethyl acrylate (HEA), with 5-20% 
AEM, 1% of DEAP photoinitiator, 0 or 10% of a nonreactive PEG porogen (PEG550dimethyl 
ether) and 2-10% of PEG4000DA crosslinker were polymerized in a Teflon mold via UV light 
in a nitrogen-purged UV oven.  The coupons were hydrated overnight in pH 7.4 PBS to 
mimic physiological conditions, and samples tested in an Instron tensometer with a strain rate 
of 5 mm/min to determine the Young’s modulus of the hydrogels.  Hydrogels containing 2-
4% of PEG4000DA crosslinker and 20% of the cationic monomer (AEM) possessed the levels 
of elasticity similar to that of red blood cells (15-26 kPa)8,9.  This level of deformability has 
been shown to promote long circulation times through avoidance of physical filtration in the 
capillary beds and elsewhere in the body7.    These studies suggest that it should be possible 
to tune the pore size through the addition of porogens or by alterations in the amount of 
crosslinker present in these gels.  Further, by varying the amount of positively charged 
monomer (AEM) the binding strength and release profiles for bound RNA cargos can be  
adjusted.    
 
4.2.2 Fabrication of Cationic Red Blood Cell Mimicking PRINT Particles  
RBC shaped particles were fabricated with the 4% crosslinker hydrogel described in 
Table 5.1 using 2 µm diameter, discoid PRINT molds for hydrated particles with 
PEG 4000 Diacrylate 10 5 5 5 4 2 
2-aminoethyl methacrylate 10 5 20 20 20 20 
2-hydroxyethyl acrylate 79 89 74 64 65 77 
PEG550DME - - - 10 - - 
Young’s modulus 55.3 ± 8.5 25.2 ± 6.4 33.6 ± 5.4 12.66 ± 4.5 15.6 ± 3.2 5.7 ± 2.7 
Table 4.1.  Young’s modulus values for cationic hydrogels with varied crosslink density, 
charge density, and amount of porogen added. 
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approximately 6 µm diameters. The fabrication method was similar to that used in Chapter 2 
for other HEA-based hydrogels, with chilled equipment mediating any monomer 
evaporation.  The cationic red blood cell mimics (CRBCMs) were harvested from the mold 
by freezing into a layer of 0.1% 22 kDa poly(vinyl alcohol) (PVOH) in water.  A high 
molecular weight stabilizer (PVOH) was used here to decrease penetration and binding of the 
PVOH to the particle interior.  The hydrated particles had a diameter of 6.2 µm and a zeta 
potential of 13.1 ± 3.41 mV in 10 µM kCl.  To give the particles a neutral or slightly negative 
charge while maintaining a cationic interior for binding to RNA, the CRBCMs were 
functionalized with PEG-NHS reagents of several lengths (Table 4.2).  Neutral or negative 
zeta potentials have been shown to decrease the rate of particle uptake, extending the 
circulation times of particles in vivo10. Longer PEG chains may be better suited to shield the 
cationic charge of the hydrogel particles while allowing miRNA to diffuse to the particle 
interior. A 20 kDa PEG gave the most negative zeta potential, and was used for surface 
functionalization of CRBCMs in the following studies.   
 
Surface Functionalization Reagent Zeta Potential (mV) 
None 13.10 ± 3.41 
5,000 g/mol PEG-NHS 2.99 ± 4..55 
20,000 g/mol PEG-NHS -3.37 ± 3.51 
30,000 g/mol PEG-NHS -1.83 ± 4.03 
35,000 g/mol PEG-NHS 0.74 ± 3.92 
Table 4.2.  Zeta potential of cationic red blood cell mimicking microgels with 
varying PEG chain length used for surface modification.   
 
4.2.3 Binding Capacity 
A DNA 20mer modified with a Cy3 dye (provided by the Sullenger lab, Duke 
University) was used as a model for miRNA in initial tests to determine the binding capacity 
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of CRBCMs.  PEGylated CRBCMs were incubated at 37º C for 4 hours on 1 µM Cy3 labeled 
DNA.  After washing (3x in DI water), fluorescence microscopy revealed a significant 
amount of fluorescence present in the Cy3 channel associated with the particles implying 
binding of the dye labeled DNA (Figure 4.1).    To determine the capacity of the CRBCMs 
to bind nucleic acids, ICP-MS was used to determine the amount of DNA by measuring the 
phosphorous present (from the DNA backbone) in a sample of particles.  CRBCMs that were 
surface functionalized with 20 kDa PEG to a neutral zeta potential and which were composed 
of 20% AEM were found to have bound 0.28 mg of DNA/mg particles.  
 
4.2.4 Binding and Release of miRNA from Cationic Microgels   
 As a first step in determining the capacity of the CRBCMs to bind to and protect 
miRNAs from ribonuclease (RNase) based degradation, we sought to bind miRNAs to the 
particles and affect their release via incubation with competing polyanions at high salt 
concentration.   MicroRNAs associated with prostate cancer were purchased from Sigma; 
miRNA 96 was associated with cancer recurrence after radical prostatectomy in a study of 79 
human patients11 and miRNA 100 is overexpressed in several prostate cancer cell lines and is 
believed to play a role in metastasis of this cancer12.  CRBCMs that had been surface 
functionalized with 20 kDa PEG were incubated with either miRNA 96 or miRNA 100 to 
load them with the RNA.  To release the bound miRNA, the CRBCMs were washed several 
times to remove unbound miRNA, then incubated at 37 ºC for 1 hour with 5mg /mL sodium 
heparin (Sigma) in 0.5 M Tris buffer.  The particles were spun down and the supernatant 
loaded onto a gel.  To provide a negative signal, with degraded RNA, a sample of each RNA 
was incubated with RiboShredder RNase cocktail.  The RNA was washed and resuspended in 
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loading buffer to run on the gel.  The gel (Figure 4.2) shows no signal from degraded 
miRNA, and a broad band associated with the miRNA released from the CRBCMs. Band 
broadening is likely due to the high salt content remaining in solution from the desorption 
conditions.  Future work will include an EtOH precipitation step to remove these salts before 
analysis.  We were unable to visualize any of the degraded RNA with ethidium bromide, 
likely due to the efficacy of degradation resulting in the inability of the dye to bind to the 
RNA fragments for increased fluorescence.     
 
4.3 Conclusions and Future Work 
The above experiments represent a promising beginning to this work, though many 
questions remain unanswered at this time.  Cationic hydrogels have been designed with a low 
modulus suitable for translation to long circulating microparticles.  Cationic red blood cell 
mimicking PRINT particles with a surface coating of PEG have demonstrated the capacity 
for binding and triggered release of miRNAs.  However, cross-link densities in CRBCMs 
may need to be adjusted to enable miRNAs to diffuse into and bind to the interior of the 
particles but still exclude the larger ribonucleases.   Challenge experiments should be carried 
out by exposure of the miRNA-loaded CRBCMs to ribonucleases (RiboShredder) to 
optimize the crosslink density so that the miRNAs are bound with high efficiency but are not 
degraded. While ribonucleases may be small enzymes, they are larger than the short (20-25 
nucleotides) miRNAs.  RNase A, for example, consists of 124 amino acids with a weight of 
approximately 13.7 kDa; significantly larger than the short miRNAs.  This point will be 
essential to the viability of CRBCMs for in vivo applications. 
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Identification and quantification of bound miRNAs will be essential for the discovery 
of novel biomarkers as well as in screening for known cancer-associated miRNAs.  The 
identity of isolated miRNAs can be confirmed via a sequencing reaction13,14.  Commercial 
assays for quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) should 
allow for the analysis of multiple miRNAs in small sample sizes15.  It should be possible to 
sequester and identify miRNAs from increasingly complex biological samples; from 
mixtures of two or more miRNAs (miRNA-100 and miRNA-96) to incubation of CRBCMs 
with PC-3 (prostate cancer) cells, which are known to overexpress miRNA-100, among many 
others.  The ultimate goal will be to inject CRBCMs into xenograft and GEM mouse models 
of cancers and to identify and quantify the bound nucleic acids to determine their utility as 
biomarkers for the associated cancers.  Computational and experimental approaches indicate 
that many more miRNAs are likely to be identified16-18.  By sequestering transiently available 
miRNA components of the secreted proteome of a cancer model, we may be able to identify 
biomarkers of disease with greater sensitivity or specificity than is currently possible. 
 The development of low modulus hydrogels with tunable properties opens the door 
on a number of possible therapeutic possibilities for deformable particles made from these 
gels.  The cationic gels described above may have multiple applications with very little 
modification to the particle matrix.  For example, such deformable particles may be capable 
of encapsulating a cationic drug for delivery to the spleen.  Similarly, these particles may be 
capable of sequestering and clearing extracellular DNA to mediate inflammation19.  Inclusion 
of a complementary RNA or DNA sequence to a crosslinking chain in similarly deformable 
particles could lead to highly specific screening methods for a single nucleic acid biomarker.   
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4.4 Materials and Methods 
4.4.1 Materials 
Photoinitiators 2,2-diethoxyacetophenone (DEAP), and 2-aminoethymethacrylate 
hydrochloride salt (AEM) were purchased from Sigma and used as received.  Poly(ethylene 
glycol) Diacrylate (4,000 g/mol) was purchased from Polysciences, Inc.  Commercially 
available 2-hydroxyethylacrylate (HEA, 96%, Aldrich) contains impurities such as acrylic 
acid, ethylene glycol and ethyleneglycol diacrylate (EGDA), and was purified prior to use 
according to the procedure set forth by Elif, et al 20, as described in Chapter 2 of this 
dissertation.  The miRNAs (mir-100 AACCCGUAGAUCCGAACUUGUG, and mir- 96 
UUUGGCACUAGCACAUUUUUGCU) were purchased from Sigma, with sequences 
identified with the miRBase database21.  RiboShredder RNase cocktail (Epicentre 
Biotechnologies) was used according to the manufacturer’s directions.  All other reagents 
were purchased from Fisher Scientific and were used as received unless otherwise noted.  
 The PRINT molds used in the above studies were provided by Liquidia Technologies, 
and were fabricated using the master templates described in Chapter 2.  
 
4.4.2 Modulus Testing 
To measure the mechanical properties of crosslinked cationic hydrogels, macroscopic 
coupons of the prepolymer mixtures were polymerized via UV light in a Teflon mold.  
Approximately 650 µL of freshly prepared prepolymer mixture was pipette into a 2.5 x 2.5 x 
0.5 cm square mold.  The mold was placed in a low-intensity UV oven, and nitrogen purged 
for 3 minutes prior to curing.  The low intensity oven was used to minimize the heat 
generated from the UV light.  The coupons were cured for 5 minutes, allowed to cool for 3 
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minutes, then cured for an additional 3 minutes.  The cross-linked hydrogels were removed 
from the mold, weighed, and placed in pH 7.4 PBS buffer for 24 hours to fully hydrate.  The 
coupons were patted dry with paper towels and weighed again prior to sectioning into 
approximately 10 mm wide strips with a razor blade for testing with an Instron 5556 
Universal Testing Machine (Instron) with a strain rate of 5 mm/min.  Young’s modulus was 
determined from the initial slope of the resultant stress-strain curves.   
  
4.4.2 Particle Fabrication 
The fabrication and harvesting of particles followed the procedures outlined in 
Chapter 2 for the fabrication of HEA-based PRINT particles.  Briefly, in low humidity 
(<30% relative humidity at 70 ºF) the pre-polymer mixture was spread onto a mold which 
was taped to a silicon wafer and chilled to 2-5°C on a custom built laminator platform.   The 
reduced temperature prevented evaporation of the pre-polymer solution prior to photo-curing.  
A PET sheet was laminated to the top of the mold and pre-polymer solution, wetting the total 
mold area.  The sheet was peeled away at the nip point of the laminator, leaving the wells of 
the mold filled while wicking away excess solution.  The filled mold was immediately 
transferred into a chilled (~5°C), nitrogen purged UV oven and cured with UV light 
(λ=365nm, 3 minutes, power ~ 20 mW/cm2).  The particles were transferred from the mold 
by the process of ice harvesting (described in chapter 2).  Briefly, the filled molds were 
placed face-down onto a thin layer of water with 0.1% PVOH on a sheet of PET.  For the 
cationic particles, a 22 kDa PVOH was used (Sigma).  This assembly was frozen on dry ice 
for 30 minutes, then the mold was peeled away rapidly, leaving the particles embedded in the 
ice layer.  Particles were then collected with the bead harvester described in Chapter 3.   
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4.4.3 Particle Purification 
 The particles were pelleted via centrifugation at 4 ºC (12,000 rpm, 4) and the 
supernatant removed carefully so as not to disturb the pellet.  The pellet was resuspended in a 
solution of 0.1% PVOH (22kDa) in Dulbecco’s pH 7.4 PBS buffer (Fisher Scientific) and 
this procedure was repeated 2-3 times to remove any soluble fraction or unreacted 
monomers.  Particles prepared for binding efficiency studies via ICP/MS were washed with 
millipore water rather than the stabilized buffer. The concentration of particles in solution 
was obtained via thervogravimetric analysis using a Perkin Elmer Pyris 1 TGA. 
 
4.4.4 Surface Modification  
To modify the surface of amine-containing particles with PEG, the particles were 
suspended in pH 7.4 PBS buffer.  N-hydroxy succinimidyl ether modified PEG was added in 
in excess (~1.5 molar equivalents compared to the total amines in the particles).  The mixture 
was incubated at room temperature for 4 hours with mixing on a shaker.  The particles were 
then washed with PBS by centrifugation and resuspension (3 times).  The PEGylation 
reaction was monitored by the change in zeta potential of the particles from positive to 
neutral or slightly negative.  
 The capacity of the CRBCMs to bind nucleic acids was quantified using a Varian 820 
ICP-MS to determine the amount of phosphorous in the sample.  Briefly, CRBCMs that were 
surface functionalized with 20 kDa PEG were incubated at 37ºC with 100 µM Cy3 labeled 
DNA 20mer for 1 hour.  The particles were washed with Millipore water (3x) via 
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centrifugation and resuspension.  This solution was submitted to UNC’s mass spec facility 
for analysis.    
 
4.4.6 Binding and Release of miRNA 
 CRBCMs that had been surface functionalized with 20 kDa PEG were incubated with 
either miRNA 96 or miRNA 100 (300 ng) at 37C for 1 hour then spun down and washed 
with DEPC water (2 times) to remove unassociated miRNA.  The CRBCMs were incubated 
at 37 ºC for 1 hour with 5mg /mL sodium heparin (Sigma) in 0.5 M Tris buffer to effect 
release of the bound RNA.  Particles were spun down and the supernatant loaded onto a 2.5% 
agarose gel.  A sample of each RNA was incubated with RiboShredder RNase cocktail for 10 
minutes, then phenol/chloroform extracted to remove the enzymes, and EtOH precipitated to 
collect the degraded RNA.  The RNA pellet was washed in 70% EtOH, repelleted and dried 
before resuspending in loading buffer to run on the gel.  
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4.5 Figures 
 
 
 
Figure 4.1.  Cationic hydrogel particles (A) Particles fluoresce in the green channel due 
to matrix bound fluorescein dye.  (B) Fluorescence in the red channel from adsorbed Cy3 
dye-conjugated DNA 20mer.  Particles were incubated at 37 ºC for one hour with 1 µM 
DNA, then washed 3 times to remove unassociated DNA.  Scale bars are 20 µm. 
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Figure 4.2.  Analysis of miRNAs bound to and released from CRBCM particles.  Lanes 
1-3 are miRNA 96 in increasing amounts (100, 200 and 300 ng).  Lane 4 is miRNA 96 
desorbed from CRBCs in high salt concentration, causing band broadening.  Lane 5 was 
loaded with miRNA 96 after degradation with and RNase cocktail.  Ethidium bromide 
was not sufficient to stain the degraded RNA.  Lanes 6-10 were identical to 1-5, 
respectively, but with miRNA 100 in place of miRNA 96.   
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5.1 Summary 
 Establishing the dependency of particle behavior in vivo on the characteristic of 
deformability has relevance for many different medical research foci, including rational 
particle design for drug delivery, medical imaging, and synthetic blood, as well as furthering 
our understanding of cancer metastasis.  Much attention has been directed towards the 
generation of particle design “maps” with the primary focus on the effect of changes in 
particle size and shape on their biodistribution in vivo, while particle modulus has largely 
been ignored. The particle replication in non-wetting templates (PRINT) technique allows for 
the fabrication of “calibration quality” particles through the tight control of particle size and 
shape afforded by the precision of the semiconductor industry-derived techniques used to 
fabricate PRINT master templates and molds.  By allowing us to specifically change particle 
modulus, while size and shape remain constant, or to change particle shape with 
deformability unchanged, we have been able to probe the specific biological effect of these 
independent parameters.  Having demonstrated the relevance of particle deformability, we 
have essentially added a novel parameter to the biodistribution maps sought by researchers in 
the above fields.  In addition to particle shape, size, charge, and surface chemistry we now 
see that the stiffness of the particle can drastically change in vivo behavior.     
Multiple applications for long-circulating particles which avoid liver uptake have 
been enabled by the unique circulation and biodistribution profile of deformable red blood 
cell mimicking microgel particles.  In initial studies, cationic versions of these particles 
showed the ability to sequester negatively charged RNAs through electrostatic complexation.  
These particles may be useful for the detection and discovery of miRNA biomarkers of 
disease. 
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5.1.1 Mechano-biological Mimicry of Red Blood Cells 
The addition of a non-functional monomer to hydrogel pre-particle formulations, such 
as an ether terminal short PEG chain, can increase hydrogel porosity while decreasing the 
stiffness.  Our initial efforts towards this strategy taught us several valuable lessons with 
regards to translating increased particle flexibility to altered in vivo behavior.  Simply 
increasing particle deformability did not guarantee measurable changes in biodistribution or 
clearance profiles.   It was determined that more sophisticated methods for in vitro evaluation 
of particle deformability would be necessary to ensure biologically relevant levels of particle 
flexibility were achieved.  We found that simple modifications to the commonly used PRINT 
particle formulations, consisting primarily of PEG triacrylates, yielded particles with poor 
properties for in vivo applications.  The biodistribution of particles suggested that particle 
fragmentation occurred in the case of the most deformable particles made with these 
formulations – a clearly undesirable result.  Analysis of bulk samples revealed that the elastic 
moduli of the materials used were on the order of 1 MPa and were somewhat brittle when 
hydrated.  In fact, these measurements were difficult to obtain due to the brittle nature of 
these bulk samples; the samples broke with very slight bending, and tended to crumble when 
placed in the clamps of the tensometer if more than minimal pressure was applied to hold the 
samples.  Further decreases in crosslink density for these, or similar, PEG di- or triacrylates, 
would yield a lower modulus material; however, a corresponding decrease in the material 
toughness would likely result in the advent of greater fragmentation.         
Lightly crosslinked hydrogels composed primarily of 2-hydroxyethyl acrylate (HEA) 
were found to have mechanical properties which were desirable for translation to deformable 
PRINT particles.  HEA hydrogels fabricated with 1-10% PEG4000DA were found to have 
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bulk elastic moduli on the order of tens of kPa, which was in the range of the modulus of red 
blood cells (RBCs) found in the literature (26 kPa) 1.  Further, hydrated HEA hydrogels were 
quite elastic, with yield strain on the order of 100% for this range.  A microfluidic system 
with constricted channels was designed to be a rigorous test of particle deformability for 
particles with size and shape reminiscent of RBCs.  These devices served as a successful in 
vitro method for examining red blood cell mimic (RBCM) particle deformability, as more 
highly crosslinked RBCMs clogged in the entrance to the channels while the more 
deformable (lower % crosslinker) particles were better able to navigate them.   
In the in vivo testing, the highly deformable 1% crosslinked RBCMs avoided 
filtration in the capillary beds in the lungs, leading to much slower clearance compared to 
particles which were stiffer.  Elimination half-life of the 1% RBCMs lengthened by a factor 
of 30, to 3.8 days, as a result of an approximately 8 fold decrease in elastic modulus 
compared to the 10% crosslinked RBCMs.  These results of the pharmacokinetic analysis 
from a fairly novel intravital microscopy method were confirmed via a more conventional 
blood-draw experiment.  The intravital method used for tracking particle clearance from the 
peripheral vasculature was thereby determined to be valid for the estimation of particle 
pharmacokinetics.  This intravital method should continue to be a crucial tool for future 
studies, as it significantly reduces the number of mice and amount of particles required for an 
initial examination of particle in vivo behavior.   
 
5.1.2 Pharmacokinetics and Biodistribution of Low Modulus Hydrogel Particles 
 Efforts to continue to map out the role of particle deformability in particles of varied 
size proceeded with the synthesis of novel acrylic monomers which were well suited to the 
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PRINT process.  We synthesized acrylates functionalized with hydroxyl terminal oligomeric 
PEG chains with 2, 3, and 4 repeat units.  Hydrogels synthesized with these hydroxyPEG 
acrylates (HPAs) had properties similar to HEA based hydrogels, including low modulus.  
By increasing the molecular weight of the monomer via an increase in the side chain (PEG) 
length, the in-mold evaporation seen with the lower molecular weight HEA monomer was 
avoided.  As surface PEGylation is in common use as a strategy to decrease particle 
opsonization, the increased PEG character of the hydrogel may make this monomer even 
more desirable for future particle studies in vivo.  HPA based hydrogels are well suited for 
PRINT applications where extremely low modulus particles are desired.   
Deformable HP3A hydrogel particles were fabricated over a range of moduli by 
varying the amount of PEG4000DA crosslinker. Low modulus (E=6.5 kPa) RBC-like 
microparticles fabricated with HP3A demonstrated long elimination half-lives similar to what 
was found with HEA based RBCMs of nearly identical modulus.  Using this material, we 
were able to fabricate particles which were larger (8.8 µm) and smaller (3.8 µm) than RBCs, 
and saw evidence that particles of both sizes avoided physical sequestration as a result of 
their ability to deform.   
 
5.1.3 Cationic Microgel Particles for Identification of Cancer Biomarkers 
 Cationic hydrogels with deformability similar to that of red blood cells were 
developed.  Cationic red blood cell mimicking PRINT particles (CRBCMs) made from these 
deformable cationic polymers displayed the ability to bind to miRNAs in solution.  Because 
the particles had been surface functionalized with a long chain PEG (20 kDa) to a negative 
overall zeta potential, it was clear that the miRNA had been internalized rather than surface 
 136 
 
bound, potentially affording protection from endogenous nucleases.  Initial tests using 
miRNAs associated with prostate cancer demonstrated the ability of the particles to tightly 
bind and responsively release the miRNAs. This strategy may enable the sequestration and 
identification of transiently available miRNA biomarkers of cancer.   
 
5.2 Future Directions 
5.2.1 Biodistribution Maps of Soft Particles 
 The discovery of deformability thresholds for RBC sized particles which allow for 
longer circulation times and altered biodistribution patterns opens up many opportunities for 
further study.  With PRINT, we can fabricate monodisperse particle populations of any size 
and shape for which we can fabricate master templates with monodisperse features.  Because 
master fabrication takes advantage of high-precision techniques first developed by the 
electronics and semi-conductor industries, an extremely high level of feature uniformity is 
possible for our master templates.  As such, PRINT particles can be viewed as “calibration 
quality” when it comes to probing the interaction of particles with cells and other biological 
systems because of the uniformity of particle size and shape.  Maps of biodistribution and 
pharmacokinetic behavior are highly desired for the field of nanomedicine, where rational 
particle design has the potential to greatly enhance the efficacy of a carried therapeutic.   
With HP3A hydrogels readily adaptable to smaller PRINT molds, an opportunity 
exists for plotting many points on these biodistribution maps with more highly deformable 
particles of different size and shape.   The work carried out thus far has focused on low 
aspect ratio (AR =0.25-0.33), deformable microparticles (Figure 5.1).  However, these 
studies could readily extend to hydrogel PRINT particles on both the micro- and nanoscale 
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which are spherical analogs (AR=1) or high aspect ratio particles (AR = 2 – 60)2-5 .  
Reduction of particle size to the typical range for nanoparticle therapeutics (100-200 nm) 
may be difficult due to the swelling of the hydrogels after molding, though master fabrication 
is constantly evolving and may produce a suitably small feature size in the future.  Currently, 
PRINT templates with the smallest dimension of 80 nm are available with aspect ratios from 
about 1 to over 605.   
 
5.2.2 Methods for Determination of Particle Modulus 
 The moduli of deformable PRINT particles have, to this point, been inferred from the 
measured properties of bulk materials.  Given that the bulk material has the same 
composition as particle, the mechanical properties should be very similar.  However, 
properties of a bulk material may differ from those occurring at an interface, such as the 
interface of the material with air or with sides of the PRINT molds6,7.   While these surface 
effects are minimal for the case of a macroscopic sample where the vast majority of the 
material exists away from an interface, they may become significant on the particle size 
scale.  The ratio of particle surface area to volume will increase as the size of the particle 
decreases, potentially making these surface effects relevant and changing the modulus of the 
particle with respect to that of the bulk material8.    
 Increasingly, attention has been given to the analysis of the mechanical properties of 
soft biological tissues, due in large part to the increase in the elasticity of cancer cells 
compared to benign cells9-11.  Significantly, metastatic cancer cells were found to be more 
than 70% softer than benign cells using AFM analysis, with elastic moduli on the order of 0.5 
kPa9.  Though a variety of methods exist for elastic analysis of cells10, atomic force 
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microscopy (AFM) may be the most readily accessible, most often used method, and most 
easily translatable to the analysis of particles.  The elastic modulus of the cells is determined 
by pushing on the cell surface with the tip on the end of an AFM cantilever (Figure 5.2).  
The force applied is correlated with the movement of the cantilever during this interaction 
allowing for a calculation of the elastic (Young’s) modulus of the cell12.  This method may 
be useful for the analysis of soft particles due to the precision with which low forces can be 
applied by AFM, and the wide availability of these instruments9. 
 The soft and slippery nature of hydrogels presents an area of possible difficulty in 
performing these measurements.  The immobilization of cells or particles for measurement 
on a substrate is typically done through chemical bonding of the particle to the surface of a 
glass slide through chemical modification of the surface.  Red blood cells, for example, can 
be attached to amine functionalized slides for AFM analysis by the application of 
glutaraldehyde solution which attaches the amines on the slide to amines on the membrane of 
the RBC1.  Similar methods for hydrogel particles may have the undesired side-effect of 
increasing the crosslink density of the hydrogel matrix on the surface, or in the bulk of the 
gel via diffusion of the reagent to the interior of the particle, thereby increasing the modulus 
of the particle.  It may be possible to immobilize the hydrogel particles via electrostatic 
interaction with a charged surface, for example, a polylysine coated slide will be positively 
charged due to the amine residues, and may serve to immobilize acid-functional particles.  
An alternate strategy involves the use of track etched membranes affixed to a substrate with 
appropriately sized pores.  Pores which are on the order of, or slightly larger than, the 
particles measured can serve to contain a hydrogel particle and keep it from moving while 
probing with the AFM cantilever13.   
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5.2.3 Hemoglobin Carriers for Oxygen Transport  
5.2.3.1 Introduction to Blood Substitutes  
 The need for the development of a safe and efficacious substitute for donated blood 
has been well demonstrated.  An ageing population and increase in the demand for selective 
surgery predicts a shortage of over four million units of donated blood by the year 2030 14.  
Research and development into a blood substitute was underway as early as the 1930’s, when 
Amberson et al. transfused animals with solutions of stroma free hemoglobin (Hb) 15.  While 
the unmodified Hb was found to be toxic, the modern search for a substitute for human blood 
was boosted by the outbreak of AIDS in the 1980’s and the lack of the corresponding 
screening techniques which have since come into practice`.    Donated blood has a short shelf 
life (42 days) and requires cold storage, both factors that make stockpiling blood supplies 
impractical if not impossible.  Concerns with storage, shelf-life, shortages, blood typing 
complications or delays, and infection by current and future pathogens are all motivations for 
the development of a safe and efficacious blood substitute.   
 
5.2.3.2 Encapsulation of Hemoglobin for Oxygen Transport 
 While whole blood carries out many functions in the body, including gas transport, 
clotting action and immunological defense, blood substitutes are most commonly designed 
only to replace lost blood volume and for oxygen delivery.  As such, “blood substitutes” are 
more properly called red cell substitutes or oxygen therapeutics.    Modification of Hb, the 
protein responsible for oxygen transport in RBCs, is the most common strategy employed 
towards the fabrication of an oxygen transporter.  Hb is a 68 kDa tetrameric protein with two 
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α and two β subunits, each with an iron containing heme, where each Hb tetramer is capable 
of binding four oxygen molecules.  Inside the erythrocyte, 2,3-DPG binds to Hb, causing a 
conformational change which decreases the oxygen affinity and allows for more ready 
release of oxygen to tissue.  Early isolations (1937) of Hb from human blood contained 
cytotoxin contaminated membrane stroma lipids which were found to have renal toxicity in 
animals 16.   Highly purified stroma-free hemoglobin was prepared and used in trials, but 
remained toxic to the kidneys 17.  Cell-free, the Hb tetramer degrades into α1β1 and α2β2 
dimers which show renal toxicity upon their rapid clearance by, and accumulation in, the 
kidneys.  These characteristics of renal toxicity and rapid splenic clearance of free Hb are the 
basis for the modification and encapsulation strategies employed by various proposed Hb 
based oxygen carriers (HBOCs) in the literature.   
 Strategies to avoid rapid clearance and toxic degradation products include 
modification of Hb by chemically crosslinking the subunits or tetramers14,18-22, using 
recombinant DNA technology to fuse subunits together, conjugation of PEG or other 
polymers to the protein surface, encapsulation into liposomal carriers23,24 and embedding in 
polymeric particles25,26.  While the above modifications have proven sufficient to mediate the 
toxicity of the free tetramer, the modified Hb products still suffer from one or more problems 
which have kept them from obtaining regulatory approval27. 
 The delicate nature of the PRINT process has allowed for the incorporation of 
sensitive biological cargos into PRINT particles, including RNA, pharmaceutical, and active 
proteins2,28.  To modify PRINT particles to carry and deliver oxygen, Hb and other allosteric 
effectors like 2,3-DPG and methemoglobin reductase can be included in the pre-particle 
formulation.   The primary anticipated challenges include the possible denaturation of some 
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of the encapsulated Hb by the particle making process, difficulty in encapsulating erythrocyte 
like amounts of Hb (up to 33% by weight) while retaining hydrogel strength and 
deformability, and leakage of Hb from the particles leading to renal toxicity.  While some 
amount of denaturation may be inevitable due to the UV curing process and the free radicals 
generated therein, the low temperature curing oven and laminator discussed in Chapter 2 may 
increase Hb stability.  Cargo encapsulation at high weight percentages may significantly alter 
the physical properties of the particle matrix material, requiring reexamination of the relative 
component ratios to obtain suitable material properties.   
Hemoglobin used for purposes of oxygen transport could be encapsulated inside of a 
hydrogel PRINT particle matrix.  Via co-encapsulation of 2,3-DPG, and other enzymes such 
at catalase, superoxide dismutase, methemoglobin reductase and carbonic anhydrase the 
cooperative oxygen binding behavior of Hb in a native erythrocyte may be immitated.  
Enzymatic activity was retained with co-encapsulation of Hb with catalase and Hb with 
carbonic anhydrase inside synthetic membranes 29.   The high surface area to volume ratio 
achieved through replication of the native RBC shape, and the inclusion of RBC enzymes 
should help to mimic the blood gas transport properties of RBCs.    These properties can be 
evaluated by measuring the the oxygen equilibrium curve (OEC), P50 and the cooperativity 
coefficient of the particles.  These measurements can be obtained with the use of a Hemox 
analyzer (TCS Scientific Corp., New Hope, PA).  The analyzer uses dual wavelength 
spectroscopy to measure the fraction of oxyhemoglobin and a Clark oxygen electrode to 
measure the partial pressure of oxygen.  An oxyhemoglobin dissociation curve will be 
generated.  The Adair equation, which models oxygen binding to the four binding sites of 
Hb, will be used to calculate the P50 and the cooperativity coefficient from the curve30. 
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Due to the renal toxicity of free hemoglobin, assays to determine the encapsulation 
efficiency of Hb in the particles and to quantify any release of free Hb will be crucial in 
determining the viability of these particles.   
 
5.2.4 Membranous Particles 
5.2.4.1 Layer-by-layer Membranes 
 While the deformable hydrogel particles discussed in this dissertation demonstrated 
biologically relevant deformability, they are structurally quite different from the cells they 
are meant to mimic.   Red blood cells are fluid-filled sacs contained by a complex membrane 
that has extreme flexibility originating from the membrane structure while our microgels are 
homogenous in structure.  These two structures should behave quite differently in flow 
conditions, despite sharing similar mechanical properties31,32.  The use of layer-by-layer 
(LbL) assembly on a sacrificial template particle has the potential to reproduce a similar 
structure to the cell membrane. These hollow membranes, called LbL capsules, are formed 
by the deposition of complementary polymers in alternating layers onto colloidal particles, 
followed by removal of the original particle template33.  Complementary layers are most 
often formed from the sequential deposition of contrastingly charged polymers, with 
electrostatic forces driving the assembly, although hydrogen bonding, hydrophobic 
interactions and even DNA base pair hybridization have been used to drive the LbL assembly 
process33.   The properties of these capsules are considered to be readily tunable according to 
variations in the number of layers, the assembly conditions (such as pH or salt concentration) 
and the layer composition.  hough little work has been done to maximize the elasticity of 
these capsules.  Recently, Doshi et al. employed this strategy towards the fabrication of red 
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blood cell inspired microparticles using spherical polystyrene and PLGA templates and a 
variety of polyelectrolyte layers13.     While these capsules were found to have a modulus an 
order of magnitude higher than that of red blood cells, dissolution of the template served to 
greatly reduce the modulus.   
The use of PRINT particle templates for the fabrication of such LbL capsules 
represents a promising route to the development of monodisperse particle populations of 
deformable LbL capsules.  Degradable or dissolvable materials such as PLGA34, proteins28 or 
degradable silyl-ether based monomers35 are promising templates for these capsules which 
have been used previously in the PRINT process. A current effort in LbL assembly is 
directed towards the formation of colloidally stable LbL capsules with diameters of 500 nm 
or less36.  As much work has been done in fabrication 200 nm PRINT particles, this 
represents an appealing goal.  
 
5.2.4.2 Hyaluronic Acid/Peptide Amphiphile Membranes 
The self-assembly of small and large molecules into membranes with hierarchical 
order represents a more complex option that may also better mimic the actual structure of a 
cell membrane.  Pioneered by the Stupp lab, hierarchically ordered membranes can form at 
an aqueous/aqueous interface with solutions of hyaluronic acid (HA) and positively charged 
peptide amphiphiles (PA)37.  Macroscopic sacs were formed from these solutions, with 
membrane formation forming several distinct, ordered domains.  These sacs were 
mechanically robust and were able to “heal” when damaged.  Additionally, it was found that 
they could be made permeable to proteins, which was novel for such robust membranes37.   
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To replicate these self-assembled HA/PA membrane structures on the micron size-
scale using PRINT, several strategies were employed.  Initial attempts involved filling a 
PRINT mold with an aqueous solution of HA, then freezing the HA filled mold to a thick 
layer of PA solution (both components supplied by the Stupp lab). The peptide amphiphile 
used in these studies consisted of an alkyl tail of 16 carbons attached to the peptide sequence 
V3A3K3.  Procedures laid out by Capito et al. were followed in terms of HA and PA solution 
concentrations and pH37, with membrane formation confirmed by the assembly of a 
macroscopic sac prior to application of the PRINT method.  A small amount of fluorescein 
isothiocyanate labeled HA was included in the HA solution to facilitate imaging.  The mold 
was peeled off the ice layer and the ice allowed to melt, with the intention of HA particles 
submerging into the melted PA to allow for membrane formation to succeed (Figure 5.3). 
This technique appeared promising initially, but closer inspection revealed the likely 
formation of unclosed sacs due to either evaporation of water from the HA solution or an 
incomplete submersion of the HA particles in the PA solution upon melting (Figure 5.4).   
As a material for the fabrication of PRINT particles, HA is not ideal due to processing 
concerns.  The HA solutions (96 kDa - 1.7 MDa) provided by the Stupp lab were quite 
viscous at concentrations higher than 5% for the lowest molecular weight, with the HA 
solution not completely de-wetting the mold surface (Figure 5.5).  The aqueous solutions 
showed rapid evaporation of water at these low concentrations, despite the high viscosity, 
making mold-filling difficult, although the use of low temperature equipment and humidity 
control may serve to mediate such evaporation in future experiments.  Attempts to lyophilize 
the HA-filled molds to yield porous HA scaffolds28 was unsuccessful in producing such 
particles, likely due to the limited solubility of HA in water leading to insufficient solids 
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content to support such structures.  Degrading before it melts, HA is not melt-processable38 
and could not be fabricated as solid particles.   
Despite the difficulties in translating this technology to the PRINT technique, such 
assembled membranous structures remain a promising goal.  The fabrication of such 
membranous particles may promote much more authentic, cell like in vivo behavior, enabling 
extremely long circulation times through improved avoidance of splenic accumulation.  Such 
long circulating particles could have applications in drug delivery, for the slow release of 
drugs, thrombotic applications, or for carrying hemoglobin and delivering oxygen.   
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5.3 Figures 
  
Figure 5.1.  A plot showing the diameter and modulus of low aspect ratio particles examined 
in this dissertation.  The grey oval indicates the particles which demonstrated longer 
circulation times as a result of avoidance of physical filtration mechanisms in the circulation.  
The green box indicates the combination of particle diameters and moduli which should be 
the target of future studies.   
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Figure 5.2.  A schematic representation of atomic force microscopy (AFM) being used to 
probe the mechanical properties of a PRINT particle.  A known force is applied by the AFM 
to the particle, causing a deformation in the particle.  The movement of the cantilever is 
tracked by the movement of a laser on a photodiode detector as it reflects from the top of the 
cantilever.   Deformations must be small relative to the thickness of the particle to avoid 
interference from the substrate.   
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Figure 5.3.  A schematic of the initial attempts at the fabrication of micron sized, self 
assembled HA/PA membranes.  (A) A PRINT mold (green) is filled with HA solution (red) 
and frozen before bringing into contact with a layer of PA solution (brown).  (B) The 
assembly is frozen on dry ice and, (C) the mold is peeled away, leaving the frozen HA 
particles on the PA ice surface.  (D) The solutions thaw and the HA drops into the PA 
solution where membrane self-assembly occurs, yielding hollow sacs. 
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Figure 5.4.  Membranes assembled from HA particles cast in 7x7µm cylinder PRINT molds 
and harvested to a solution of PA.  (A) The particles appeared to assemble into fully formed 
sacs which were reminiscent of red blood cells.  (B) Inspection with a confocal microscope 
showed that the sacs did not fully close, likely due to incomplete immersion of HA particles 
into the PA solution.  Scale bars are 20 µm.   
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Figure 5.5.  An image of sacs formed from assembly of HA and PA with a connecting scum 
layer resulting from incomplete de-wetting of the PRINT mold surface.  The bottom left of 
the image contains collapsed sacs trapped in this scum layer, while the upper right side has 
more holes in this membrane.  The scale bar represents 20 µm.   
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